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Abstract 
Background: Mendelian Susceptibility to Mycobacterial Disease (MSMD) is a primary 
immunodeficiency (PID) characterised by a predisposition to infection by weakly-pathogenic 
mycobacteria. In countries with a high prevalence of tuberculosis, individuals with MSMD are also 
prone to severe, persistent, unusual or recurrent infections by pathogenic Mycobacterium 
tuberculosis. Several MSMD-associated genes have been described, including IFNGR1, IFNGR2, 
IL12RB1, IL12B, STAT1, NEMO, ISG15, IRF8, TYK2, and CYBB, many resulting in a disruption of 
IL-12 and IFN-γ cytokine axis, which is essential for control of mycobacterial infections. This genetic 
heterogeneity results in many distinct disorders, which vary in their mode of inheritance and clinical 
presentation. An accurate molecular diagnosis, confirmed by immune functional studies, is essential 
to ensure that the patient receives optimal treatment and prophylaxis for infections. The aim of this 
study was to implement and optimise a set of immune phenotyping and functional validation tests for 
the key pathway, the IFN-γ and IL-12 cytokine axis, involved in MSMD, and to use these assays to 
assess immune function in a cohort of suspected MSMD patients.  
Methodology: Blood was collected from 17 participants with MSMD-like clinical phenotypes. DNA 
was extracted and PBMCs were isolated from the patients’ blood. Whole exome sequencing (WES) 
was performed and the resulting data was processed using an in-house bioinformatics pipeline, 
TAPER™. A set of flow cytometry and ELISA-based functional assays were implemented and 
optimised to assess the integrity of the IL-12-IFN-γ pathway. IFN-γR1 and IL-12Rβ1 expression were 
assessed by means of standard surface flow cytometry, and IFN-γ and IL-12 signalling was assessed 
by the detection of pSTAT1 and pSTAT4 respectively through intracellular phospho-specific flow 
cytometry. IFN-γ-induced IL-12 production as well as IL-12-induced IFN-γ production was also 
assessed by ELISA after 48-hour in vitro stimulation. The functional and genetic data were then 
reconciled in order to confirm the extent of functional impairment associated with each genetic variant. 
Results: Plausible disease-causing variants were identified through genetic investigations for 11 of 
the 17 participants. Variants in MSMD-associated genes were found in 8 of these patients, although 
only one of the identified variants, IFNGR1 (c.818del4), has been described before. Variants in genes 
not previously associated with MSMD were also found, including variants in IKZF1, NOD2, IRAK1, 
IKBKB, and NFKB2. All the functional assays were optimised and the combination of the three assays 
for the assessment of the integrity of the IL-12-IFN-γ pathway was successful in identifying immune 
deficits in essentially all of the participants included in this study.  
Conclusions: The current study led to the implementation of functional immune readouts that allowed 
for the evaluation of the functional impact of both novel and previously described genetic variants on 
the IL-12-IFN-γ pathway. The results generated from the functional assays were highly variable and 
often defects within the same gene lead to different phenotypes, which emphasises the importance 
of in vitro functional confirmation of all PIDs. Hence it would be beneficial to apply these assays 
routinely for patients with suspected PID relating to mycobacterial susceptibility. A molecular 
diagnosis with confirmed functional impairment paves the way for targeted treatment and improved 
disease management options for these patients. 
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Opsomming 
Agtergrond: Mendeliese vatbaarheid vir mikobakteriële siektes (MSMD) is ‘n primêre immuundefek 
(PID) wat deur vatbaarheid tot infeksie deur minder-patogeniese mikobakterieë gekenmerk word. In 
lande met ‘n hoë voorkoms van tuberkulose, het hierdie individue ‘n hoër waarskynlikheid om ernstige, 
ongewone, aanhoudende of herhalende infeksies met die patogeniese Mycobacterium tuberculosis 
te kry. Verskeie gene wat met MSMD geassosieer word is reeds beskryf, onder andere IFNGR1, 
IFNGR2, IL12RB1, IL12B, STAT1, NEMO, ISG15, IRF8, TYK2 en CYBB. Hierdie gene lei almal tot 
die ontwrigting van die IL-12-IFN-γ sitokien padweë wat noodsaaklik is vir die beheer van 
mikobakteriële infeksies. Hierdie genetiese diversiteit lei tot verskeie unieke versteurings wat verskil 
in die manier van oorerflikheid en kliniese voorkoms. ‘n Akkurate molekulêre diagnose, wat bevestig 
is deur funksionele studies, is daarom belangrik om te verseker dat die pasiënt optimale behandeling 
en profilakse vir infeksies ontvang. Die doel van hierdie studie was om ‘n stel immuun-fenotipering en 
funksionele validering toetse te implementeer en optimaliseer vir die MSMD kenmerkende sitokien 
padweë van IL-12 en IFN-γ. 
Metodes: Bloedmonsters van 17 pasiënte met ‘n kenmerkende MSMD kliniese fenotipe is vir DNS 
ekstraksie en PBMC isolasie geneem. Volledige-eksoom-volgordebepaling (WES) is op pasiënt DNS 
uitgevoer en die data is deur ‘n binne-huis bioinformatika pyplyn, TAPER™, verwerk. ‘n Stel 
vloeisitometrie en ELISA-gebaseerde funksionele toetse was geïmplementeer en geöptimaliseer om 
the integriteit van die IL-12 en IFN-γ padweë te ondersoek. IFN-γR1 en IL-12Rβ1 uitdrukking is deur 
middel van standard vloeisitometrie bepaal, en IFN-γ en IL-12 sein-oordrag is bepaal deur ondersoek 
van pSTAT1 en pSTAT4 deur middel van fosfo-spesifieke vloeisitometrie. IFN-γ-geïnduseerde-IL-12-
produksie, asook IL-12-geïnduseerde-IFN-γ-produksie, is deur ELISA bepaal na 48 uur in vitro 
stimulasie met die onderskeie sitokiene. Funksionele en genetiese data was versoen om MSMD te 
bevestig of uit te sluit as die betrokke PID. 
Resultate: Moontlike patogeniese genetiese variante is geïdentifiseer in 11 van die 17 pasiënte. 
Variante in MSMD-veroorsakende gene is in 8 van hierdie pasiënte gevind, maar slegs een van hierde 
variante, IFNGR1 (c.818del4), is al voorheen beskryf. Variante is ook in gene gevind wat nog nie 
voorheen met MSMD geassosieer is nie, insluitend IKZF1, NOD2, IRAK1, IKBKB en NFKB2. Die 
funksionele toetse was suksesvol geöptimaliseer en die kombinasie van hierdie toetse vir die 
integriteit van die IL-12 en IFN-γ padweë het immuundefekte in die meerderheid van die pasiënte 
geïdentifiseer. 
Gevolgtrekkings: Hierdie studie het gelei tot die implementering van funksionele 
immuunassesseringstoetse wat dit moonlik maak om die impak van beide nuwe en vooraf-beskryfde 
genetiese variante op die IL-12 en IFN-γ padweë te bepaal. Die resultate van die funksionele toetse 
het gewissel en dikwels het variante in dieselfde geen tot verskillende fenotipes gelei. Dít beklemtoon 
die noodsaaklikheid van in vitro funksionele bevestiging van alle PIDs. Dit sal voordelig wees om 
hierdie toetse op ‘n roetine wyse aan te wend vir pasiënte wat vermoedelik ‘n PID het wat verwant is 
aan tuberkulose-vatbaarheid. ‘n Molekulêre diagnose sal lei tot beter behandelingopsies vir hierdie 
pasiënte, omdat die molekulêre meganisme van die individu se siekte toegelig is.   
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Chapter 1  Introduction 
Primary immunodeficiencies (PIDs) are genetically inherited disorders caused by defects in one 
or more elements of the immune system. There is very little reporting of PIDs in Africa and it is 
suspected that they may be a lot more common than previously thought (Modell et al. 2016). The 
under-reporting of PIDs from socially and economically disadvantaged communities is of special 
concern and increased awareness is needed in order to diagnose, treat and prevent devastating 
childhood infections due to immune deficits in these communities (Eley and Esser 2014). 
South Africa is among the countries with the highest burden of tuberculosis (TB) (WHO 2016) 
and PIDs that relate specifically to susceptibility to mycobacterial infection, such as Mendelian 
Susceptibility to Mycobacterial Disease (MSMD) is of particular importance. Being an area of 
high endemicity, children with MSMD are at further increased risk for acquiring severe, recurrent, 
unusual and persistent TB infections (Esser et al. 2016). 
In countries with high TB burden, it is essential to identify individuals with MSMD early since they 
are at risk for developing potentially devastating TB infections, including early BCG (Bacillus 
Calmette–Guérin)-dissemination if they are not diagnosed timeously. It is possible that MSMD 
and other PIDs relating to TB susceptibility are more common in South Africa than previously 
believed due to these PIDs being overshadowed by the massive Human Immunodeficiency Virus 
(HIV)-TB co-epidemics. It is therefore important to find a more rational immunological approach 
for the screening and diagnosis of MSMD. 
Currently, the most reliable way to diagnose MSMD and other PIDs relating to TB susceptibility 
is through Whole Exome Sequencing (WES). After a plausible disease-causing variant has been 
identified through WES, patient immune cells should be studied in vitro in order to confirm the 
functional manifestation of the identified variant (Gallo et al. 2016; Casanova et al. 2013). 
In this study, a set of functional immune screening tests relating to the Interleukin-12-Interferon-
gamma (IL-12-IFN-γ) pathway, which is essential for the control of mycobacteria, were 
implemented and optimised to aid in the diagnosis of MSMD and related PIDs in our setting. 
These assays were then used to assess the integrity of the IL-12-IFN-γ pathway in 17 suspected 
MSMD patients.  
A validated functional screen for MSMD would allow for confirmation of functional manifestations 
of known and novel genetic signatures of this condition. Effective and accurate diagnosis of this 
condition is important in the broader context of PIDs in general in that these assays could provide 
a resource for screening for PIDs that overlap, especially at the level of cytokine gene function 
and related immunological signalling cascades.  
Reliable functional screening tests to aid in the diagnosis of PIDs relating to TB are essential to 
ensure that the affected individuals receive the correct treatment and long-term care.  
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Chapter 2  Literature Review 
2.1. Primary Immunodeficiencies 
PIDs are genetically inherited, non-communicable heterogeneous disorders caused by defects 
in different elements of the immune system. PIDs are generally characterised by severe, 
persistent, unusual and/or recurrent infections usually presenting in infancy and early childhood. 
These infections often involve microorganisms that rarely cause disease in healthy people. PIDs 
consist of a group of more than 350 genetically determined mono-genetic conditions that have 
an identified molecular basis (Picard et al. 2018). The pattern, frequency and severity of 
infections depend on the underlying immunological defect as well as geographical and social 
determinants (Modell et al. 2016; Eley and Esser 2014).  
PIDs can present in many different ways, apart from unusual infections. Particular organ 
problems (e.g. diseases involving the skin, heart, facial development and skeletal system) may 
be present in certain conditions. Others may predispose to the development of tumours or 
autoimmune disease, where the immune system reacts to the body’s own tissues. The type of 
infections, as well as the additional features can provide clues as to the exact nature of the 
immune defect (Al-Mousa and Al-Saud 2017; Bonilla et al. 2015; Routes et al. 2014; Arkwright 
and Gennery 2011). A summary of general warning signs for PID are listed in Table 2.1. 
In most countries, PID screening is not routinely performed on individuals at birth (or any other 
stage of life), therefore PIDs are usually only detected after the affected individual has 
experienced severe or recurrent infections. A study from Bousfiha et al. (2013) has revealed that 
PIDs are a lot more common than previously estimated and that about 1-2% of the population 
worldwide are affected by some form of PID.  
Awareness of PIDs among healthcare professionals, patients and the general public remains a 
challenge and there is a pressing need to improve awareness in order to ensure early diagnosis, 
treatment and management of these conditions and ultimately reduce the associated morbidity 
and mortality (Picard et al. 2018; Chapel et al. 2014). 
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Table 2.1: Summary of PID warning signs. Adapted from de Vries et al. (2012) & van den Berg et al. 
(2017). 
Findings Suggestive of Immunodeficiency 
Persistent lymphopaenia 
Severe, Persistent, Unusual and Recurrent (SPUR) infections 
• Eight ear infections, two sinus infections per year, two episodes of pneumonia within one year 
or chronic suppurative chest infection/lesion 
• Rare or unusual complications, for example, complicated varicella or vaccination complication 
• Infections caused by unexpected or opportunistic microorganisms 
Dependence on or refractory to antibiotic therapy 
• Need for intravenous antibiotics to clear infection 
• Two or more deep-seated infections (e.g. sepsis, meningitis, pneumonia) 
Organisms 
• Less virulent or opportunistic causative agent 
• Persistent oral thrush or cutaneous candidiasis (especially in children older than four months) 
• Neisseria meningitidis meningitis. 
Constitutional symptoms 
• Failure to thrive 
• Persistent, extensive, atypical dermatitis or erythroderma 
• Chronic diarrhoea 
Clinical examination 
• Lymph nodes and tonsils may be absent in severe PID 
• Evidence of chronic ear infection; Evidence of bronchiectasis 
Family History 
• Diagnosed PID in the family or familial occurrence of similar symptoms; Unexplained sudden 
death in infancy 
• Consanguinity 
• Autoimmunity or malignancy in several family members 
Age and Gender 
• Severe Combined Immunodeficiency (SCID) presents in early infancy 
• Profound antibody deficiency usually presents in first year of life 
• Severe immunodeficiencies more commonly affect boys 
Unexplained fever or autoimmunity 
 
2.1.1. Types of Primary Immunodeficiencies 
The International Union of Immunological Sciences (IUIS) PID expert committee has proposed a 
PID classification system, which facilitates clinical research and comparative studies worldwide. 
It is updated every other year to include new disorders or disease-causing genes (Picard et al. 
2018; Bousfiha et al. 2015; Ochs and Hagin 2014). Table 2.2 shows the global prevalence of the 
different types of PID, as reported by physicians in 2016 (Modell et al. 2016). 
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Table 2.2: Physician reported prevalence of primary immunodeficiencies globally. Adapted from 
Modell et al. (2016) 
Type of Primary Immunodeficiency n % 
Combined immunodeficiency 4 762 5.3 
Well-Defined Syndromes with Combined Immunodeficiency 11 597 12.9 
Predominantly Antibody Deficiencies 47 548 53.0 
Diseases of Immune Dysregulation 2 633 2.9 
Congenital Defects of Phagocyte number, function or both 4 654 5.2 
Defects in Innate Immunity 954 1.1 
Autoinflammatory Disorders 6 402 7.1 
Complement Deficiencies 4 948 5.5 
Unspecified or Other Deficiencies (Phenocopies of PID) 6 136 6.8 
Total 89 634 100 
 
Primary immunodeficiencies are broadly characterised into nine distinct groups (Picard et al. 
2018; Al-Herz et al. 2015; Ochs and Hagin 2014; Routes et al. 2014):  
(1) Combined immunodeficiency, which includes severe combined immunodeficiency (SCID) 
and other combined immunodeficiencies with less profound effects. This mainly includes defects 
in signalling pathways, abnormal development of T and B cells and insufficient DNA repair;  
(2) Combined immunodeficiency with associated/syndromic features, which refers to 
disorders of combined immunodeficiency associated with characteristic features that may 
present prior to immune defects for instance Wiskott-Aldrich (WAS), DiGeorge, hyper 
Immunoglobulin (Ig) E syndromes, etc.;  
(3) Antibody deficiency, which results in reduction in one or more serum immunoglobulin 
isotypes and a profound decrease in B cell numbers, for example common variable 
immunodeficiency (CVID) and CD40/CD40L deficiency;  
(4) Immune dysregulation, which includes a wide range of disorders such as immune deficiency 
associated with faulty regulatory T cell development (e.g. Immune deficiency associated with 
faulty regulatory T cell development [IPEX] syndrome) or other defects affecting lymphocyte 
proliferation or the cytotoxic or apoptotic functions of lymphocytes;  
(5) Defects of phagocyte number and/or function, which includes defects that lead to 
abnormal differentiation of myeloid cells, decreased neutrophil mobility due to abnormal 
adherence to endothelium, defects in respiratory oxidative burst, and defects in macrophage and 
lymphocyte signalling pathways;  
(6) Defects in innate immunity, which is due to defects in pathways involved with germline 
encoded receptors [e.g. Toll-like receptors (TLRs)], this usually results in lack of cytokine 
production and overall lack of response in innate immune cells, examples include defects in 
Interleukin-1 receptor-associated kinase 4 (IRAK4) and Myeloid differentiation primary response 
88 (MyD88) which impairs TLR3 signalling;  
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(7) Autoinflammatory disorders, which are associated with recurring fevers and other 
inflammation-associated features. These disorders can be due to inflammasome defects (e.g. 
overproduction of pro-inflammatory cytokine such as IL-1β) or non-inflammasome related defects 
(e.g. deficiency of IL-1 receptor antagonist);  
(8) Complement deficiency, which refers to defects in the classic, alternative and/or lectin 
complement regulatory pathways. This results in a broad range of clinical phenotypes, which 
ranges from susceptibility to encapsulated bacteria to autoimmunity;  
(9) Phenocopies of primary immunodeficiency disease, which includes conditions that 
resemble PID but lack causative germline mutations, for instance autoantibody production 
against various cytokines.  
2.1.2. Diagnosis of Primary Immunodeficiencies 
Underdiagnoses and diagnostic delay contribute to mortality and morbidity associated with PIDs. 
Identification of the cause of the PID at the molecular level as well as the associated disease 
mechanisms could enable earlier protective interventions and targeted treatment. Identifying 
defects as early as possible is also essential in order to minimise administration of certain 
treatments and procedures, for instance an X-ray will exacerbate the condition of patients with 
PIDs associated with ‘unstable DNA (Stray-Pedersen et al. 2017; Routes et al. 2014). Precise 
diagnosis is necessary, not only to ensure that the patient receives defect-specific treatment and 
care, but also so that the affected family members can receive genetic counselling and/or pre-
natal screening for future children (Chapel et al. 2014). 
While recurrent, persistent and unusual infections are the most common presentation of PID, 
other clinical and laboratory findings can be equally informative for diagnosis. The first step 
toward a PID diagnosis involves a thorough analysis of a suspected patient’s medical history. 
Birth route, vaccination and infection history, response to antibiotic therapy, etc. are all to be 
considered when investigating a PID (Ochs and Hagin 2014; Madkaikar et al. 2013). Complete 
physical examination, with attention to dysmorphic features, evaluation of lymphoid tissue, 
rashes, warts, and thrush should also be performed. The medical history and physical 
examinations should direct further investigations, such as screening of different components of 
the immune system by means of laboratory testing (Ochs and Hagin 2014). 
Several laboratory tests can be performed if a patient is suspected of having a PID. These may 
include, but are not limited to, full blood count, differential leukocyte subset counts (enumeration 
of granulocytes, lymphocytes, monocytes), lymphocyte subset count (enumeration of T cells 
[total CD3+, CD4+ and CD8+ subsets], B cells and Natural Killer [NK] cells), neutrophil burst 
assay, immunoglobulin isotypes/subclasses, and total complement assessment. These initial 
laboratory tests can give an indication as to which type of immune defect, based on the World 
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Health Organisation (WHO)/IUIS classification format, the patient might have (Picard et al. 2018; 
Al-Herz et al. 2015; Bonilla et al. 2015; Madkaikar et al. 2013). Sometimes, however, the baseline 
laboratory tests do not reveal an obvious immune defect. In such cases molecular testing, such 
as sequencing of specific genes, WES and chromosomal microarrays, can provide valuable 
information. Molecular testing is discussed further in section 2.3.2. More detailed information on 
the routine laboratory methods used for the evaluation of immunodeficiencies of both adaptive 
and innate immunity can be found in Table 2.3 (Chapel et al. 2014; Ochs and Hagin 2014).  
Table 2.3: Evaluation of Immunodeficiencies of Adaptive and Innate Immunity. Adapted from Ochs 
and Hagin (2014). 
System Quantitative evaluation Qualitative evaluation 
Adaptive Immunity 
B cells and antibody 
production 
o Flow cytometry to enumerate 
and characterise B cells. 
o Serum Immunoglobulin isotype 
levels (IgG, IgA, IgM, IgE). 
o Specific Antibody levels (to 
vaccines). 
o B cell flow-based 
immunophenotyping to evaluate B 
cell development and maturation. 
o Antibody responses to booster 
immunisation. 
o Antibody responses to neoantigens. 
T cells o Flow cytometry to enumerate 
and characterise T cell 
subsets. 
o T cell flow-based 
immunophenotyping to evaluate T 
cell development and maturation. 
o Mitogen and antigen proliferation 
assays. 
o Anti-CD3 proliferation assay. 
Innate Immunity 
Complement system 
 
o Levels of individual 
complement component 
(usually ordered after abnormal 
pathway activity). 
o CD50 (classical pathway activity). 
o AH50 (alternative pathway activity). 
o Lectin pathway activity. 
o Function of individual complement. 
Phagocytic system o Blood cell count and 
differential. 
o Examination of stained blood 
smear. 
o Flow cytometry for adhesion 
molecules. 
o Bone marrow biopsy. 
o Measurement of oxidase function 
(nitroblue tetrazolium test or 
equivalent). 
NK cells 
 
o Flow cytometry to enumerate 
NK cells. 
o Target cell lysis. 
TLRs  o Expression of degranulation surface 
marker. 
o Cytokine production in response to 
different TLR antagonists. 
Abbreviations: Ig, Immunoglobulin; AH50, complement, alternative pathway; CD50, total haemolytic 
complement assay; NK, natural killer; TLR, Toll-like receptor. 
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2.1.3. Treatment of Primary Immunodeficiencies 
Most PIDs are lifelong conditions and there is a great need to detect these defects as early as 
possible in order to refer individuals to specialised care centres or to initiate therapies that can 
be continued in an open-ended fashion. Early diagnosis and therapy is the best approach to 
prevent significant disease-associated morbidity. (Oliveira and Fleisher 2010; Immune Deficiency 
Foundation 2009). 
Different PIDs present with varying degrees of susceptibility to pathogenic organisms, depending 
on the specific disorder as well as other environmental factors. Many PIDs have defining 
characteristics which can guide the diagnostic and treatment approach. Where PIDs are 
associated with decreased immunoglobulin isotypes (Ig), such as IgA deficiency or IgG subclass 
deficiency, immunoglobulin replacement therapy is a preferred treatment option (Bonilla et al. 
2015; Chapel et al. 2014). PIDs associated with SCID or  severe immune dysregulation, including 
lymphoproliferation and syndromes with autoimmunity, aggressive chemotherapy followed by 
hematopoietic stem cell transplantation (HSCT) is recommended as soon as possible in order to 
prevent demise of the patient (Eley and Esser 2014; Routes et al. 2014). Phagocytic defects are 
often treatable with IFN-γ and antimicrobials, although in some cases HSCT has been performed 
successfully. Prophylactic anti-microbials and anti-fungal agents are often prescribed for PID 
patients in order to prevent future infection, and often this is the only way to manage PIDs for 
which no other treatment is available or effective (Bonilla et al. 2015; Chapel et al. 2014; Immune 
Deficiency Foundation 2009). 
More recently, gene therapy, which ‘edits’ the patient’s DNA and replaces a faulty gene with a 
functional one, is being assessed for use in children for which HSCT is not available (generally 
due a lack of a matched donor for HSCT). Gene therapy is not currently used as a routine 
treatment approach, although it has been performed successfully, in clinical trials, on several 
patients mostly SCID, chronic granulomatous disease (CGD) and WAS patients, and they 
generally no longer require therapy or prophylaxis. A small number of patients who have received 
gene therapy developed leukaemia-like disorders as a result of random mutations introduced into 
the host due to the viral vector used for gene therapy. To minimise this mutagenic effect of the 
vectors, new improved self-inactivating viral vectors have been developed and are currently 
being used in clinical trials and have thus far proven much safer than the original vectors (Ghosh 
and Gaspar 2017; Modell et al. 2016; Chapel et al. 2014; Immune Deficiency Foundation 2009). 
Gene therapy holds great promise for the future treatment of PIDs with defined molecular 
diagnoses. 
The role of vaccination in PID has been greatly debated. Vaccines, specifically inactivated 
vaccines rather than live vaccines in most cases, are beneficial in some PIDs (e.g. neutrophil 
defects, complement deficiency, other antibody failure PIDs) and will contribute to prevention of 
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severe infections. On the other hand, vaccination can also be detrimental in certain PIDs (e.g. 
SCID, CGD, T-cell defects). BCG dissemination, also referred to as BCGosis, due to vaccination 
can compromise HSCT in these patients. It is recommended that vaccination be delayed in all 
children with suspected PID until the nature of their condition has been elucidated (Principi and 
Esposito 2014). 
Specialist PID care is often unavailable in less developed regions of the world, even once a 
diagnosis is made. Governments in such countries often do not fund life-long immunoglobulin 
replacement or HSCT. Management of PID patients is a financial and technical challenge for 
developing countries (Chapel et al. 2014).  
2.1.4. Prevalence of Primary Immunodeficiency in South Africa 
There is very little reporting of PIDs in Africa. In the 2016 Jeffrey Modell Foundation (JMF) global 
survey, 1 237 patients with PIDs out of a global total of 83 743 were from Africa (Table 2.4) 
(Modell et al. 2016). This low under-reported prevalence of 1.5% contrasts with Africa’s 
contribution of approximately 15% to the total global population. Speculation based on population 
size and world-wide prevalence data, suggests that from 58 000 to as many as 902 000 PID 
cases should be reported from Africa (Bousfiha et al. 2013). In South Africa, assuming the 
prevalence of PID is similar to that in well-resourced settings, the total number of people with 
PIDs should range between 3 000 and 46 000. However, in total fewer than 400 PID cases have 
been reported in South Africa (Esser et al. 2016; Naidoo et al. 2010). The patients in the South 
African National PID Registry reflect similar deficiencies to those in European and USA data, with 
the majority being antibody deficiencies. The under-reporting of PIDs from disadvantaged 
communities is of special concern. As infections are common in childhood in such communities, 
an increased level of awareness is needed to investigate those infections that may be caused by 
an immune deficit (Eley and Esser 2014). 
Table 2.4: The number of patients followed, diagnosed and referred with primary immunodeficiency 
globally compared to in Africa in 2015. Adapted from Modell et al. (2016) 
 Globally (2015) Africa (2015) 
Patients evaluated and followed  157 454 1 627 
Patients diagnosed with Primary immunodeficiencies  83 743 1 237 
Patients referred 81 339 2 260 
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2.2. Tuberculosis  
In 1882, Robert Koch discovered and described Mycobacterium tuberculosis (M.tb), the 
causative agent of TB. M.tb is an obligate intracellular pathogenic bacterium that primarily infects 
the lungs or other parts of the respiratory system (Keshavjee and Farmer 2012). It has been 
theorised that the M.tb complex, which consists of a group of closely related Mycobacterium 
species, originated in Africa and co-evolved, migrated and expanded with their human hosts. 
This theory of the co-expansion of M.tb and modern humans is supported by the similarities in 
geographical locations of branching and divergence events that were found after comparing M.tb 
phylogeny and human mitochondrial genomes (Comas et al. 2013; Blouin et al. 2012; Hershberg 
et al. 2008; Wirth et al. 2008). 
Currently, TB is the worldwide leading cause of death due to a single infectious agent (Fogel 
2015; Tiruviluamala and Reichman 2002). It is estimated that approximately one third of the 
global population is infected with TB. In 2016, there was an estimated 1.3 million deaths globally 
due to TB and an additional 374 000 deaths due to HIV-TB co-infection. The WHO reported an 
estimated TB incidence of 10.4 million cases worldwide in 2016. South Africa is one of 14 
countries listed by the WHO with the highest burden of TB, HIV-TB co-infections and also multi-
drug resistant (MDR)-TB cases. Figure 2.1 illustrates the estimated global incidence of TB, as 
recorded in 2016. South Africa has a TB incidence of 258 000 cases per year and an additional 
19 000 incidence cases of MDR-TB.  The high TB incidence is also associated with high rates of 
mortality in both TB mono- and HIV-TB co-infection (CIA World Factbook 2018; World Health 
Organization 2017). 
 
Figure 2.1: Estimated TB incidence worldwide in 2016 (World Health Organization 2017). South 
Africa, with a TB incidence of 258 000 cases a year, is one of the 14 countries in the world with the highest 
TB incidence. 
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2.2.1. Host Immune Response to Mycobacterial Infection  
M.tb enters the host via the respiratory tract through the inhalation of contaminated droplets. The 
preferred target cell is the alveolar macrophage. Once the organism has infected alveolar 
macrophages there are 4 potential outcomes: (1) The initial host immune response is effective in 
killing the organism, which means that there is no chance that the individual will develop TB; (2) 
The bacterium can multiply effectively in the lung macrophages, which will lead to clinical disease 
known as pulmonary or primary TB; (3) The bacterium becomes dormant and does not cause 
any clinical disease, this is known as latent TB infection; (4) Dormant or latent M.tb can start to 
multiply again to cause clinical disease similar to (2), this is often referred to as ‘reactivation’ of 
TB (O’Garra et al. 2013; Schluger and Rom 1998). 
Generally, the M.tb bacterium can be controlled by the immune response in healthy people. An 
effective immune response consists of both the innate and adaptive immune components. The 
innate immune response refers to the initial immune response carried out by host immune cells 
upon first contact with the pathogen. The adaptive immune response, on the other hand, is 
dependent on prior contact with the pathogen’s antigens or immunogenic components and is 
initiated after the initial innate responses. The adaptive immune response is more specifically 
directed against the particular invading pathogen, due to the antigen-epitope specificity of 
adaptive immune cells. The antigen specificity allows for more effective control and/or elimination 
of the pathogen from the host than innate immunity, which operates on a broader pathogen 
pattern recognition principle (Jasenosky et al. 2015; Lerner et al. 2015; O’Garra et al. 2013; 
Vankayalapati and Barnes 2009). Figure 2.2 summarises the general innate and adaptive 
immune responses to pathogens. Figure 2.3 illustrates the cellular immune response to TB. 
Innate Immunity 
Two out of three people that are exposed to TB, do not develop active TB disease, suggesting 
that the innate immune responses of most healthy individuals is capable of preventing M.tb 
infection without the need for an adaptive, T or B cell mediated response (Lerner et al. 2015; 
Gupta et al. 2012; Vankayalapati and Barnes 2009). A short summary of the effector mechanisms 
of the major innate immune cells is summarised in Table 2.5. 
Table 2.5: Effector mechanisms of the major innate immune cells. Adapted from Gupta et al. (2012) 
 Effector mechanism(s) 
Neutrophils Degranulation 
Production of reactive oxygen species 
Macrophages Phagocytosis 
Production of reactive nitrogen intermediates and nitic oxide 
NK cells Cytolysis of infected cells/intracellular bacteria 
Activation of macrophages via IFN-γ 
Complement system Membrane attack complex, opsonisation and phagocytosis by macrophages 
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Figure 2.2: The innate and adaptive immune response to a pathogen. Innate immune responses are 
initiated on first contact with a pathogen and leads to a general inflammatory response through the 
production of various mediators. The innate immune cells play an important role in activating adaptive 
immune responses, which are more specific and is mediated by various adaptive immune cell subsets. 
 
 
Figure 2.3. The cellular immune response to M. tb (O’Garra et al. 2013). (1) After initial infection with 
M.tb, (1a) alveolar macrophages, (1b) neutrophils and (1c) dendritic cells (DCs) can become infected, 
which leads to production of antimicrobial peptides and cytokines and subsequent apoptosis or necrosis. 
Infected cells can also be taken up by DCs, which then (2) migrate to the lymph nodes under the influence 
of IL-12 and various chemokines to initiate differentiation of naïve T cells into TH1 cells. (3) TH1 cells migrate 
back to the site of infection and produce IFN-γ which leads to (4) macrophage activation, 
cytokine/chemokine production as well as the induction of (5) microbicidal factors to enhance bacterial 
control. 
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When M.tb is inhaled, it passes along the respiratory mucosa of the airway, which forms the first 
line of defence against M.tb. The respiratory mucosa consists of a layer of epithelial cells that 
forms a barrier against invasion. Below the epithelial cells is a layer of connective tissues and 
immune cells such as lymphocytes and macrophages. Airway epithelial cells (AECs) can 
recognise pathogen associated molecular patterns (PAMPs) present on the surfaces of M.tb. 
After exposure to M.tb AECs can present antigens to mucosal associated invariant T cells 
(MAITs) and stimulate them to produce IFN-γ, tumour necrosis factor (TNF)-α and granzyme, 
which all contribute to the clearance of M.tb. MAITs respond very rapidly to infection and activate 
macrophages (Lerner et al. 2015; Harriff et al. 2012; Gold et al. 2010). AECs also influence the 
composition of the airway surface liquid (ASL), which contains mucus, immunoglobulin A and 
other innate immune factors such as anti-microbial peptides (Lerner et al. 2015; Harriff et al. 
2012; Li et al. 2012; Middleton et al. 2003) that aid in the defence against pathogens.  
M.tb that manages to pass through the upper airways are delivered to the alveoli, which consist 
of a lining of epithelial cells as well as other immune cells such as neutrophils, dendritic cells 
(DCs) and alveolar macrophages (AMs) (Lerner et al. 2015). Similar to AECs, alveolar epithelia 
can also produce anti-microbial molecules (Rivas-Santiago et al. 2005) as well as pulmonary 
surfactant, which cause agglutination (Ferguson et al. 1999) and enhanced phagocytosis 
(Gaynor et al. 1995) by macrophages upon binding to M.tb. 
AMs are the primary tissue resident phagocytic cells involved in the initial immune response to 
M.tb. M.tb infected AMs can elicit signals that lead to the killing of the infected cells through the 
induction of apoptotic responses. Unfortunately, M.tb has developed ways to circumvent the 
apoptotic-driven immune responses of AMs and can often survive and proliferate in AMs (Lavalett 
et al. 2017; Queval et al. 2017; Srivastava et al. 2014). 
DCs, also among the first cell types to encounter M.tb, have various receptors on their surfaces 
to detect PAMPs and they are very efficient phagocytes. After the uptake of M.tb into the cell, 
DCs in the alveoli will mature and migrate to the draining lymph nodes to present antigens to T 
cells; therefore, DCs are an important link between the innate and adaptive immune systems 
(Lerner et al. 2015; Marino et al. 2004).  
In individuals with active TB, M.tb often infects neutrophils in the airways (O’Garra et al. 2013; 
Eum et al. 2010). Neutrophils are professional phagocytes and have been described to play 
conflicting roles in the pathology of TB, dependent on the host factors, pathogen virulence factors 
and the stage of the disease. It has been observed that neutrophils can both favour (Denis 1991) 
or restrict (Brown et al. 1987) the growth of M.tb. M.tb infected neutrophils can be phagocytosed 
by macrophages, leading to improved killing of the bacterium. Another major role of neutrophils, 
apart from phagocytosis, is the production of chemokines and pro-inflammatory cytokines which 
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lead to the activation and recruitment of other immune cells (Lerner et al. 2015; Riedel and 
Kaufmann 1997). 
NK cells are the primary mediators for the innate immune response against TB, and mediate the 
production of effector molecules and cytokines that will aid in an effective immune response 
(Lerner et al. 2015; Li et al. 2012). NK cells are recruited to the site of infection early on and are 
very effective at eliciting an immune response against M.tb. NK cells can lyse macrophages 
(Vankayalapati and Barnes 2009) that are infected and also produce IFN-γ to further activate 
macrophages and expand T cell populations for the adaptive immune response (Lerner et al. 
2015). 
There is evidence that M.tb activates all three pathways of the complement system (classical, 
lectin and alternative), which enhances the inflammatory response and increases phagocytic 
uptake of the bacteria by AMs (Lerner et al. 2015; Gupta et al. 2012).  
The innate response to TB requires a wide range of cell types to protect the host and the natural 
physical barriers and anti-microbial substances are just as important as the immune cells for 
defending the host against infection (Lerner et al. 2015; O’Garra et al. 2013). If the innate immune 
response is ineffective at killing M.tb, it will likely disseminate, and the host’s adaptive immune 
response will become essential for control of the infection. 
Adaptive Immunity 
The adaptive immune response is mediated mainly by lymphocytes. Adaptive immunity can be 
divided into two distinct categories, namely the humoral response, which is mediated mainly by 
B cells, and the cell-mediated response, which is mediated by T cells (Gupta et al. 2012; 
Vankayalapati and Barnes 2009). Regarding the adaptive response to TB, T cell-mediated 
immunity has been described to play the most vital role in the elimination of M.tb (Vankayalapati 
and Barnes 2009), however, more recent studies have shown that the humoral immune response 
(B cells) also play an important role in TB infection (Kozakiewicz et al. 2013; O’Garra et al. 2013). 
The effector mechanisms of the adaptive immune system are summarised in Table 2.6. 
Table 2.6: Effector mechanisms of the major adaptive immune cells. Adapted from Gupta et al. (2012) 
 Effector mechanism(s) 
CD4+ T cells Cytolysis of infected cells/intracellular bacteria 
Activation of macrophages through IFN-γ and TNF-α 
CD8+ T cells Cytolysis of infected cells/intracellular bacteria 
Activation of macrophages through IFN-γ 
B cells Opsonisation and phagocytosis by macrophages 
Modulation of T cell responses  
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Cell-mediated immunity 
DCs and macrophages, which can act as both phagocytes and antigen presenting cells (APCs), 
produce IL-12 and IL-23 during the innate immune response which drives the inflammatory 
response and the initiation of the cell-mediated adaptive immunity (Cooper et al. 2007; Losana 
et al. 2002). APCs (primarily DCs) migrate to the draining lymph nodes where they can induce 
the activation of naïve T cells by providing antigen-specific stimulus as well as additional signals 
required for the development of effector T cells (Cooper 2009). IL-12, produced during the innate 
immune response, has been shown to promote the migration of DCs to the lymph nodes (Khader 
et al. 2006; Demangel et al. 2002).  
APCs (primarily DCs in the initial induction of effector T cells) induce the proliferation and 
differentiation of predominantly T lymphocyte helper subset 1 (TH1) type effector cells. Mature 
M.tb-specific TH1 (CD4+) cells then migrate to the primary site of infection to mediate the immune 
response to M.tb (Jasenosky et al. 2015; Cooper 2009). CD4+ T cell effector subtypes produce 
a range of essential cytokines, including IL-2, IFN-γ, and TNF-α, which play roles in activation of 
phagocytes (Darrah et al. 2007). IFN-γ is the main cytokine involved in the activation of 
macrophages and monocytes, which allows them to control infection by phagocytosis or by 
secreting products that can directly kill M.tb. 
For IFN-γ production by CD4+ cells, the crucial need for IL-12 and IL-23, produced by mainly by 
DCs and macrophages, has been demonstrated extensively (O’Garra et al. 2013; Cooper et al. 
2007; van de Vosse and Ottenhoff 2006; Khader et al. 2005; Losana et al. 2002). Decreased 
CD4+T cells, for instance in lymphopaenic HIV patients, has been linked to increased 
susceptibility to TB (Cooper 2009; North and Jung 2004; Orme et al. 1993). CD8+ T cells also 
contribute to immunity against M.tb by secreting IFN-γ, however CD8+ cells are unable to fully 
compensate for a lack of CD4+ cells (North and Jung 2004; Flynn and Chan 2001). 
The IL-12 and IFN-γ cytokine pathways and their importance in immunity against M.tb is 
discussed in more detail in section 2.3. 
In an attempt to contain the infection, granulomas, consisting of AMs, T cells and DCs are often 
formed to surround the bacterium to prevent further spread of the pathogen. Additional T and B 
lymphocytes are recruited if necessary to surround these structures in order to contain the 
bacteria and damaged tissues. Granuloma formation is considered to be a hallmark of TB and it 
signifies both infection by M.tb as well as an induction of a host immune response against the 
pathogen (Martinot 2017; Lerner et al. 2015; O’Garra et al. 2013; Gupta et al. 2012; Volkman et 
al. 2010). Granuloma-mediated immune cells function similarly to other immune cells and 
produce various cytokines, including IL-12 and IFN-γ, which aids in containment of the infection. 
Macrophage effector functions, including phagolysosome fusion and the deployment of reactive 
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oxygen/nitrogen species, all apply pressure on M.tb to engage in rigorous responses that arrest 
bacterial growth (Martinot 2017). 
Humoral immunity  
Upon exposure to pathogens, it known that CD4+ T cells can shape B cell responses, including 
expansion, class switching, somatic hypermutation, affinity maturation of antibodies, the 
development of memory B cells and antibody-producing plasma cells, as well as cytokine 
production (Chan et al. 2014; Vinuesa et al. 2005). B cell activity is often dependent on T cell 
responses; however, B cells can also modulate T cell immunity due to their ability to present 
antigens to naïve T cells in the lymph nodes (Lund and Randall 2010; Gray et al. 2007). This 
capability of B cells to present antigens to T cells have been demonstrated in a model system 
lacking other APCs (Liu et al. 1995; Kurt-Jones et al. 1988). 
B cells can also modulate the activity of T cells through the production of a wide range of 
cytokines, which are either constitutively expressed or induced upon interaction with antigens or 
T cells (Harris et al. 2000; Mosmann 2000). In a TH1 environment, B cells are primed to produce 
IFN-γ, IL-12, TNF, IL-10 and IL-6, which in turn promotes T cell driven immunity (Mauri and 
Bosma 2012; Lund and Randall 2010; Harris et al. 2005; Mosmann 2000).  
Antibodies, produced by specialised B cells, can bind to M.tb antigens to form immune 
complexes, which can bind to Fcγ receptor (FcγR) to enhance the priming of T cells (Chan et al. 
2014; Nimmerjahn and Ravetch 2008). Studies have shown that in mice that lack FcγRIIB, an 
inhibitor of FcγR, higher frequencies of IFN-γ producing CD4+ T cells were observed (Chan et 
al. 2014; Maglione et al. 2008). 
BCG vaccination and tuberculosis 
BCG is an attenuated live strain of M.bovis that was initially developed to prevent the 
development of TB disease. Vaccination with BCG has been shown to be highly effective at 
preventing TB-meningitis (TBM) and disseminated extra-pulmonary TB; however, the efficacy 
thereof for preventing pulmonary TB varies greatly between children, youth, adults and the 
elderly. Some studies have reported 80% efficacy of BCG, whereas others have reported 0% 
efficacy (Kaufmann et al. 2010; Colditz et al. 1994). Regardless of its variable efficacy, BCG is 
one of the most widely administered vaccines around the world (Moliva et al. 2017; Trunz et al. 
2006). 
BCG mediates immunity by inducing the development of antigen-specific memory T cells which 
allows a quick immune response following subsequent infection with M.tb (Henao-Tamayo et al. 
2014; Shen et al. 2002). This is most likely the reason that BCG is able to protect against 
disseminated TB and TBM, however, it is not entirely clear why this mechanism fails to prevent 
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the development of pulmonary TB, although it is speculated that the pulmonary immune response 
is driven by innate rather than T cell mediated immunity (Moliva et al. 2017; Connor et al. 2010). 
2.2.2. Diagnosis of TB 
Due to the non-specific classical clinical phenotype of TB, which overlaps with other diseases 
such as lung cancer, pneumonia, and sarcoidosis, laboratory tests are essential for the diagnosis 
of active TB disease (O’Garra et al. 2013). 
The classical workflow for the laboratory detection of TB infection generally starts with 
assessment of the presence of acid-fast mycobacteria through microscopic examination of 
patient sputum, i.e. the smear test. The smear test, however, cannot distinguish between M.tb 
and other mycobacteria and is also known to have variable sensitivity. Due to the difficulty of 
obtaining sputum samples from paediatric patients, and the lower sensitivity of the smear test in 
these patients, bacterial culture is the preferred method for diagnosis of mycobacterial infections 
for all patients, paediatric and adult (Brent et al. 2017; O’Garra et al. 2013).  
Culturing of patient samples for the identification of M.tb can take up to six weeks. Invasive 
procedures, such as bronchoscopy or biopsy, are often necessary (in 30-50% of cases) for 
successful culture of M.tb. Positive bacterial cultures are then identified as either M.tb complex 
(MTBC) or non-MTBC by means of commercial identification kits. After identification of MTBC or 
non-MTBC, the bacteria undergo further drug-susceptibility testing such as the Hain Genotype® 
line probe assay, which can detect resistance to the most common first-line anti-TB drugs 
isoniazid and rifampicin (Brent et al. 2017; O’Garra et al. 2013). 
Due to the long turn-over time of microbial cultures, the WHO endorses the Xpert MTB/RIF 
automated molecular polymerase chain reaction (PCR) based test, which can rapidly detect the 
presence of M.tb and rifampicin resistance genes. Rifampicin is the most common first-line TB 
drug. The Xpert MTB/RIF assay has decreased sensitivity compared to the culture ‘gold standard’ 
and it is therefore recommended that both are performed (Brent et al. 2017). 
More recently, assays that detect TB infection based on in vitro evaluation of T cell immunity 
have been developed. These IFN-γ release assays (IGRAs) detect IFN-γ secretion by leukocytes 
in response to TB antigens, most commonly early secrete antigenic target-6 (ESAT-6) and culture 
filtrate protein 10 (CFP-10). Commercially available IGRAs include the T-SPOT® TB test (Oxford 
Immunotec, Oxford, UK), with an enzyme-linked immunospot (ELISpot) assay used to detect 
individual IFN-γ-producing T cells, and the QuantiFERON®-TB (QFT) test (Cellestis, Ltd, 
Australia) with an enzyme-linked immunoassay (ELISA) that measures IFN-γ concentration in 
blood plasma (El Azbaoui et al. 2016; Kobashi et al. 2009). 
Although the QFT test was developed to be used as a TB test for adults, the utility of this test has 
been tested previously in children by El Azbaoui et al. (2016), Ge et al. (2014) and Howley et al. 
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(2015), and has been shown to be reliable. The QFT IGRA is not affected by BCG vaccination, 
unlike the tuberculin skin test (TST) which may give inaccurate results due to BCG-driven 
immune responses (Riazi et al. 2012). 
2.2.3. Primary Immunodeficiencies relating to TB Susceptibility 
South Africa has the second highest TB incidence in the world and contributes to about 80% of 
the total estimated new TB cases (World Health Organization 2017). Due to the high prevalence 
of TB in South Africa, the BCG vaccine is customarily administered at birth and although it is 
aimed at reducing the risk for severe or disseminated TB in childhood, it presents an early life 
threat for children with immune deficits. The dissemination of BCG in HIV negative infants is 
usually suggestive of an underlying genetic immune defect (Esser et al. 2016; Eley and Esser 
2014). 
Individuals with PID are, in general, susceptible to multiple infections although some PIDs have 
been found to confer specific predisposition to infections by mycobacteria. Examples of such 
PIDs, that have been documented in the South African PID Registry, include the prototypic TB 
susceptibility PID viz. Mendelian Susceptibility to Mycobacterial Disease (MSMD) as well as 
CGD, Hyper IgM syndrome, SCID and CVID (Esser et al. 2015, 2016; Haverkamp et al. 2014).  
In high TB prevalence regions, individuals with PIDs are continuously exposed to TB and will 
most likely present with TB at some point in time if not already before any other particular PID-
defining infection. Very little is known about the frequency, complications and recurrence of TB 
in PID patients in regions with high TB endemicity. Hence, there are no current guidelines for the 
prevention and management of TB in PID patients with excessive exposure to TB. There are also 
no reports in the literature on prevention, screening and individualised treatment of PID patients 
in TB endemic regions (Esser et al. 2016; Eley and Esser 2014). 
2.3. Mendelian Susceptibility to Mycobacterial Disease 
MSMD is the prototype PID relating to mycobacterial susceptibility. MSMD is characterised by 
selective predisposition to infection by weakly virulent mycobacteria, e.g. BCG vaccines and 
environmental mycobacteria. This MSMD designation however does not account for all the 
clinical features observed in patients, as affected individuals are also prone to infection by 
Salmonella, Candida and other intra-macrophagic bacteria, parasites and fungi. In regions with 
high prevalence of TB it has been reported that these patients can present with very severe, 
persistent, unusual or recurrent M.tb infection. The patients generally display no other major 
abnormalities as evidenced by normal haematological profiling (Apt et al. 2017; Esser et al. 2016; 
Naranbhai 2016; Boisson-dupuis et al. 2015; Bustamante et al. 2014; Merchant et al. 2013; 
Boisson-Dupuis et al. 2011; Cooke et al. 2006; Caragol and Casanova 2003). 
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To date, ten MSMD disease-causing genes have been described. Of these, eight are autosomal 
(IFNGR1, IFNGR2, STAT1, IL12B, IL12RB1, TYK2, ISG15 and IRF8) and two are X-linked 
(NEMO and CYBB). These MSMD causing genes have all been associated with a disruption in 
IFN-γ and IL-12 immunity, which has been shown to be essential in the control of mycobacterial 
infections (Masserot et al. 2017; Naranbhai 2016; Boisson-dupuis et al. 2015; O’Garra et al. 
2013; Caragol and Casanova 2003). The allelic heterogeneity of these ten genes results in at 
least 19 distinct genetic disorders, which vary in their mode of inheritance and clinical 
presentation. Although it has high levels of allelic heterogeneity, MSMD displays physiological 
homogeneity, since all associated defects ultimately impair IFN-γ immunity by either hindering 
the production of IFN-γ or by causing abnormal responses to IFN-γ signalling (Casanova 2015; 
Bustamante et al. 2011; Al-Muhsen and Casanova 2008). The IFN-γ-IL-12 pathway and the 
MSMD-associated mutations within this pathway are illustrated in Figure 2.4. 
Mutations in IL12B, IL12RB1, STAT1 and IFNGR1 have been described in patients with multiple 
episodes of TB or disseminated TB (Chapgier et al. 2006; Ozbek et al. 2005; Caragol et al. 2003; 
Picard et al. 2002; Jouanguy et al. 1997). 
MSMD was initially classified as a phagocyte defect (Al-Herz et al. 2015; Ramirez-Alejo and 
Santos-Argumedo 2014), but according to the 2018 IUIS Criteria, it is now classified as a defect 
in innate or intrinsic immunity (Picard et al. 2018).  
 
 
Figure 2.4: Cells producing and responding to IFN-γ. The IFN-γ-IL-12 pathway is involved in the host 
response to infection with mycobacteria and Salmonella. Macrophages and dendritic cells (DCs) secrete 
IL-12 (and IL-23) which bind to their receptors on T lymphocytes and NK cells, inducing the production of 
IFN-γ. IL-12 production is enhanced by a CD40-triggered, NEMO/NFκB-dependent pathway. Proteins for 
which mutations in the corresponding genes have been identified and associated with MSMD are indicated 
in blue. Mutations in IFNGR1, IFNGR2, CYBB, STAT1 and IRF8 impair the action of IFN-γ while mutations 
in IL12B, IL12RB1, ISG15, NEMO and IRF8 impair IFN-γ production (Adapted from Bustamante et al. 
2014). TYK2 is not indicated in this figure but is involved in IL-12/23 signalling as it provides a docking site 
for STAT4 (See Figure 2.5). 
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2.3.1. Mutations associated with MSMD 
Mutations associated with MSMD either impair the production of IFN-γ or the action thereof. Both 
IL-12 and IFN-γ and their associated signalling pathways are essential for an effective immune 
response to mycobacteria. A defect in any of the receptor components or in any of the 
downstream signalling components can result in impairment or collapse of the IFN-γ-IL-12 
pathway, leading to an insufficient or total lack of an immune response against mycobacteria. 
Mutations in different parts of a gene will have different effects, for example a mutation in a 
receptor gene may lead to either increased or decreased receptor expression with variable 
functionality. An illustration of the IL-12 and IFN-γ receptors and the associated signalling 
components can be seen in Figure 2.5 (Haverkamp et al. 2014). 
 
Figure 2.5: IL-12 and IFN-γ signalling. (A) The IL-12 receptor consists of two subunits, IL-12Rβ1 and IL-
12Rβ2. Co-expression of both subunits are required to generate high affinity for IL-12. Signal transduction 
through IL-12R firstly induces phosphorylation of JAK2 and TYK2, which in turn activates and 
phosphorylates STAT4. STAT4 forms a homodimer, which translocates to the nucleus where it activates 
the transcription of IL-12 responsive genes, including IFN-γ. (B) The IFN-γR consists of the ligand binding 
subunit (IFN-γR1) and the signal transducing subunit (IFN-γR2). After IFN-γ binds to IFN-γR1, it associates 
with IFN-γR2. Receptor assembly leads to phosphorylation of JAK1 and JAK2, which leads to the 
recruitment and subsequent phosphorylation of STAT1 molecules. STAT1 homodimers (also known as 
GAF, gamma-activating factor) then translocate to the nucleus to activate a wide range of IFN-γ response 
genes. Adapted from Haverkamp et al. (2014). 
IFNGR1 and IFNGR2 
Complete IFN-γ receptor ligand-binding chain (IFN-γR1) deficiency was the first described 
genetic aetiology of MSMD. Mutations in IFN-γ receptor signalling chain (IFN-γR2) were 
subsequently found to be associated with MSMD (Casanova and Abel 2002). Recessive 
mutations in either IFNGR1 or IFNGR2 can result in a complete lack of IFN-γ receptor (IFN-γR) 
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expression on cell surfaces, leading to a lack of cellular responses to IFN-γ. In all forms of 
complete IFN-γR deficiency, elevated levels of IFN-γ can be detected in circulating blood (Apt et 
al. 2017; Fraser et al. 2003; Casanova and Abel 2002).  
Partial IFN-γR deficiencies have also been reported. This means that the IFN-γR is being 
expressed at lower than normal levels and has reduced affinity for IFN-γ or the signalling 
response to IFN-γ is impaired (Apt et al. 2017; Fraser et al. 2003; Casanova and Abel 2002). 
Partial dominant IFN-γR1 deficiencies occur where truncated IFN-γR is capable of binding IFN-γ 
but cannot transduce IFN-γ-triggered signals due to a lack of intracellular binding sites (Casanova 
and Abel 2002). 
STAT1 defects 
Signal transducer and activator of transcription (STAT) 1 is an essential transducer of IFN-γ 
signals and mediates signalling either as STAT1 homodimers, designated as gamma-activating 
factor (GAF), or STAT1/STAT2/p48 trimers, also known as interferon-stimulated gamma factor 3 
(ISGF3). Not all mutations in STAT1 necessarily result in mycobacterial disease, although in 
some cases it can lead to loss of STAT1 function, resulting in clinical phenotypes that are very 
similar to IFN-γR deficiency (Apt et al. 2017; Ramirez-Alejo and Santos-Argumedo 2014; Sharfe 
et al. 2014). 
IL12B 
The IL12B gene encodes for the p40 subunit of IL-12, which is a potent IFN-γ inducing cytokine 
that is secreted mainly by monocytes (or resident macrophages) and DCs. In the case of an 
IL12B mutation resulting in a complete deficiency of IL-12p40, neither monocytes nor DCs are 
capable of producing functional IL-12. In some cases, the impaired IFN-γ secretion can be 
compensated for by administering exogenous recombinant IL-12 to affected individuals 
(Casanova and Abel 2002; Picard et al. 2002).  
IL-12RB1 
Autosomal recessive IL12RB1 mutations, which result in lack of expression of the IL-12β1 
receptor subunit on lymphocytes, are the most commonly reported aetiology of MSMD. T cells 
and NK cells from these patients do not respond effectively to IL-12 and as a result produce no 
to very low levels of IFN-γ. Individuals with this defect usually present early in life and generally 
display broad resistance to other infectious agents, apart from mycobacteria and Salmonella. A 
IL12RB1 gene defect was the first of the MSMD-associated genes to be associated with TB 
(Altare et al. 2001). IL-12Rβ1 deficiencies also need to be considered in cases where 
salmonellosis, particularly cases of extra-intestinal non-typhoidal salmonellosis, is the only 
clinical presentation (Alinejad Dizaj et al. 2018; Boisson-Dupuis et al. 2011; de Beaucoudrey et 
al. 2011). 
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NEMO 
NEMO, also known as inhibitor of nuclear factor kappa-B kinase subunit gamma (IKK-γ), 
encoded by the IKBKG gene, forms an integral path of Nuclear factor kappa B (NFκB) signalling, 
which is crucial for the transmission of information between immune cells through CD40/CD40L. 
A defect in NEMO leads to impaired NK cell activity, hyper IgM as well as impaired IL-12 and 
IFN-γ production. The impaired IL-12 and IFN-γ production is due to a lack of cross-talk between 
monocytes and lymphocytes. Approximately 6% of all NEMO mutations are MSMD cases 
(Neehus et al. 2017; Braue et al. 2015; Haverkamp et al. 2014). 
CYBB 
CYBB, which encodes for gp91phox, is an IFN-γ inducible component of the oxidative burst that is 
a feature of all phagocytes. Patients with mutations in CYBB often lack a normal respiratory burst 
response. An effective respiratory burst, driven by Reactive Oxygen Species (ROS) is crucial for 
protective immunity against mycobacteria (Haverkamp et al. 2014; Bustamante et al. 2011; Al-
Muhsen and Casanova 2008). 
TYK2 
TYK2 is a tyrosine kinase that phosphorylates multiple cytokine receptors. It provides docking 
sites for STAT4 as part of the IL-12 and IL-23 signalling cascade. Mutations reported in TYK2 
lead to defects in IL-12/23 signalling causing an imbalance between the TH1 and T lymphocyte 
helper subset 2 (TH2) immune responses. Not all cases of TYK2 defects are associated with 
MSMD phenotypes (Haverkamp et al. 2014). 
IRF8 
Interferon Regulatory Factor 8 (IRF8) is an IFN-α/β inducible transcription factor that regulates 
the differentiation of phagocytes and macrophages. It also plays important roles in the cross-talk 
between TLRs and IFN-γ signalling pathways, and in IFN-γ-induced production of IL-12 and TNF. 
Reported defects in IRF8 caused mild forms of MSMD, due to extremely low numbers of IL-12 
producing DCs (Haverkamp et al. 2014; Lee et al. 2011). 
ISG15 
ISG15 is the most recent MSMD-associated gene to be described. Interferon-Stimulated gene 
(ISG) is an IFN-α/β inducible intracellular protein that is present in secretory granules of 
granulocytes. ISG15 tags intracellular proteins for degradation, similar to ubiquitin. Additionally, 
secreted ISG15 acts synergistically with IL-12 to induce IFN-γ production by NK and T cells. 
Reported defects in ISG15 resembled the phenotypes observed in IL12B/IL12RB1 deficiency 
(Haverkamp et al. 2014). 
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2.3.2. Diagnosis of MSMD 
It is important to diagnose MSMD patients based on their specific molecular defect as it has a 
major impact on their clinical outcomes and responses to anti-bacterial/TB therapy. It is estimated 
that about half of MSMD patients lack a defined genetic aetiology (Cottle 2011). Delayed 
diagnosis can hinder the proper treatment for the affected patients. It is recommended that 
patients with suspected MSMD should undergo molecular testing in order to accurately diagnose 
their particular immune deficit (Parvaneh et al. 2015; Wang et al. 2012).  
Molecular investigations are generally only pursued after the initial laboratory screening, as 
discussed in section 2.1.2, i.e. full blood count, leukocyte differential count, lymphocyte subsets, 
oxidative burst screen, total complement screen and enumeration of antibody classes/isotypes.  
Diagnosis at the molecular level is desirable in most cases of PID (including MSMD) in order to 
(i) establish a clear, definitive diagnosis, (ii) permit accurate genetic counselling, (iii) allow 
planning of future pregnancies or their potential outcomes, (iv) better define genotypic/phenotypic 
associations, and (v) identify candidate patients for gene-specific therapies (Bonilla et al. 2015). 
Genetic testing for PIDs 
There are several target gene sequencing panels available for PIDs, which can assess several 
targeted genes of interest. However, there are no gene panels that are specific to MSMD 
available in South Africa, and shipping samples from suspected MSMD patients to countries that 
do offer such gene panels is only feasible in selected cases, for instance if the family can afford 
the tests and if it is possible to collect enough sample (sputum or blood) required for the tests. 
More generalised PID panels can be performed in certain private pathology laboratories, but at 
high cost and with the caveat that only well-described mutations will be screened. Targeted gene 
panels only sequence very specific regions of genes that have been implicated in a disease 
phenotype, therefore they are unable to detect novel, de novo mutations that could also result in 
the disease phenotype (Stray-Pedersen et al. 2017; van den Berg et al. 2017; Esser et al. 2016).  
Currently, the most effective way of diagnosing rare genetic defects is by means of WES of 
patient DNA. With WES, only the exome or protein-coding regions of the genome is sequenced. 
Although the exome only makes up approximately 2% of the genome, it contains more that 85% 
of genetic alterations associated with human disease. Due to the feasibility and relative cost-
effectiveness, WES has become the new first-line approach to identify disease-causing 
mutations in individuals with Mendelian disorders (Gallo et al. 2016; Naranbhai 2016; Casanova 
et al. 2013). WES-identified genetic variants are usually validated by traditional Sanger 
sequencing. 
WES provides rapid molecular diagnosis and improves the diagnostic yield, which is particularly 
useful in a clinically and genetically heterogenous disorder such as MSMD (Stray-Pedersen et 
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al. 2017). Analysis of exome data, although very time-consuming and complex (Glanzmann et 
al. 2016), can identify probable disease causing genetic variants. However, the identification of 
a genetic variant does not necessarily imply dysfunctionality of the associated protein; it is 
therefore also important to do in vitro functional assessment to confirm any suspected disorder 
(Gallo et al. 2016). 
Functional Assessment in suspected PID cases 
Functional assessment of the immune system is often more affordable than extensive genomic 
analysis, but in most cases, it is only used after a defect has been identified by molecular 
investigations, such that a particular pathway involving the candidate defective component can 
be assessed (Abraham and Aubert 2016; Gallo et al. 2016). 
Functional assays are performed to ascertain the impact of variants identified by WES. Functional 
analysis may include: lymphocyte proliferation assays, assessment of NK cell mediated lysis of 
target cells, detection of expression of various cell proteins on cell surfaces (e.g. cytokine 
receptors or First Apoptosis Signal [FAS] death receptors), and measurement of cytokine 
production upon TLR stimulation. Assays to detect protein transcription or expression can be 
done through real-time PCR (qPCR), flow cytometry or Western blot (Gallo et al. 2016). 
Flow cytometry in MSMD diagnosis 
Flow cytometry has many different applications in many different fields of research and can be 
used on almost all cellular sources (body fluid, tissue, bone marrow, blood), which makes it an 
ideal tool for screening, diagnosis or functional assessment of PIDs. Flow cytometry is the 
preferred method for many routine immune investigations, including immune cell subset 
enumeration, phenotyping and functional profiling. It is also the preferred method for investigating 
disease-specific immune defects (Abraham and Aubert 2016). 
In patients with MSMD, flow cytometry has been used to assess the expression of IFN-γR and 
IL-12R subunits on the surfaces of immune cells (de Vor et al. 2016; Robinson 2015; Holland 
2007; Caragol and Casanova 2003; Caragol et al. 2003). Additionally, flow cytometry is also used 
to detect intracellular production of IFN-γ and IL-12 (de Vor et al. 2016; Losana et al. 2002).  
Assessment of signalling pathways, by detecting phosphorylation of signalling proteins, has been 
performed since 1980 by detection of radioisotope-labelled proteins and electrophoresis. Since 
the 1990s, Western blot has been the most popular tool for studying proteome-wide 
phosphorylation events. (Bonilla et al. 2008). 
More recently, phospho-specific flow cytometry, more commonly referred to as phospho-flow or 
Phosflow, has been implemented to detect intracellular phosphorylated proteins. During 
Phosflow, blood-cells are stimulated with cytokines or antigens which will activate signalling 
pathways, resulting in phosphorylation of signalling proteins such STAT or Extracellular signal-
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regulated kinases (ERK). After stimulation, cells are stained with fluorochrome-conjugated anti-
phospho-protein (e.g. anti-pSTAT or anti-pERK) antibodies that bind to the phosphorylated 
protein of interest. Stained samples are then analysed by a flow cytometer. In contrast to Western 
blot, which indicates only the presence or absence of the phosphoprotein in the proteome (entire 
set of proteins expressed by all cells), Phosflow can quantify the degree of phosphorylation in 
single cells by comparing the fold-increase in phospho-protein detection in stimulated cells 
compared to unstimulated cells (Davies et al. 2016; Bonilla et al. 2008).  
2.3.3. Treatment of MSMD 
Treatment of MSMD patients need to be targeted to the specific disease-causing genetic defect 
and clinical presentation. Generally, established infections are treated with the appropriate 
antimicrobials and prophylactic antimicrobials are administered, even in periods of disease 
remission (Caragol and Casanova 2003). 
MSMD patients with causative mutations identified in genes that result in insufficient IFN-γ 
production, which include IL12B, IL12RB1, NEMO/IKBKG, IRF8, ISG15, as well as partial IFN-
γR defects, may benefit significantly from treatment with recombinant exogenous IFN-γ. 
Recombinant IFN-γ therapy has been shown to have less severe side effects than recombinant 
IL-12 therapy, which was previously used for patients with defects in IL12B. Long-term IFN-γ 
treatment has been deemed safe and well tolerated in both adult and paediatric patients 
(Haverkamp et al. 2014; Holland 2000). 
For MSMD patients with defects in proteins that are essential for IFN-γ signalling, which impairs 
the action of IFN-γ, such as IFNGR1, IFNGR2, STAT1, TYK2 and CYBB, HSCT is the only 
curative treatment option (Haverkamp et al. 2014; Caragol and Casanova 2003; Dorman and 
Holland 2000; Holland 2000). 
Gene therapy is another potentially appropriate solution for MSMD patients, however this field is 
still in its early stages and is generally only recommended in severe cases of PID where HSCT 
is not available. Gene therapy has been successfully performed in vitro, where IL-12Rβ1 
expression, together with IFN-γ production, was restored in cell-lines that had defects in 
IL12RB1. There are no known successful cases of in vivo gene therapy for MSMD, although 
research is ongoing (Haverkamp et al. 2014; Routes et al. 2014).  
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2.3.4. Towards a rational immunological approach to MSMD screening 
and diagnosis 
In countries with high TB burden, it is essential to identify individuals with MSMD since they could 
acquire early potentially devastating TB infections if they are not diagnosed timeously. It is 
possible that MSMD and other PIDs relating to TB susceptibility are a lot more common in South 
Africa than previously believed due to these PIDs being overshadowed by the massive HIV-TB 
co-epidemics. It is therefore important to find a more rational immunological approach to 
screening/diagnosis of MSMD. 
In suspected MSMD cases (either pre- or post-molecular investigation), IGRAs, such as the QFT 
test can be used as a broad initial screen to assess the integrity of the IFN-γ pathway. If the QFT 
test result is negative for a patient that has or ever had a culture positive TB result, it is a clear 
indication that the patient’s immune cells cannot produce IFN-γ in response to TB antigens. An 
indeterminate QFT result, where the positive control failed to induce an IFN-γ response, can 
indicate an even more severe IFN-γ deficit due to lack of response to not only TB antigens but 
also to the mitogen. 
The IGRAs can then be followed by flow cytometry-based techniques to assess IL-12R and 
IFN-γR expression. ELISA or Luminex can be used to measure basal plasma levels of IFN-γ, 
which is often higher in cases of IFN-γ-signalling defects, as well as induced IL-12 and IFN-γ 
production. Finally, flow cytometry or western blot can be used to measure downstream signalling 
molecules (e.g. STAT1 and STAT4) to assess the integrity of the IFN-γ and IL-12 signalling 
pathways. 
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Study Rationale 
South Africa is among the countries with the highest burden of TB and has the third highest 
incidence in the world. These incidence rates have increased by over 400% in the last 15 years 
(World Health Organization 2017). PIDs that relate specifically to susceptibility to mycobacterial 
infection, such as MSMD are of special importance in South Africa. It is estimated that about 15-
20% of TB cases in high burden areas are observed among children (Esser et al. 2015). Being 
an area of high endemicity, children with MSMD are at risk for acquiring potentially devastating 
and recurrent TB infections and post-vaccination BCGosis. 
In the Tygerberg Academic Hospital (TBH) setting (Located in Bellville, South Africa) between 10 
and 20 unusual TB infections in children are flagged as potential MSMD each year. These 
children often present with severe, persistent, unusual and recurrent TB or acquire TB-like 
diseases from weakly virulent strains of Mycobacteria (for example the BCG vaccine or other 
environmental strains of mycobacteria). 
Currently the most reliable diagnostic technique available for the diagnosis of MSMD and closely 
related PIDs is WES. Although WES is reliable, it is very time consuming to process and interpret 
the massive data sets that are generated (Glanzmann et al. 2016; Naranbhai 2016). Even after 
a candidate genetic variant suspected to be the involved in causing the disease phenotype has 
been identified by WES, functional validation tests still need to be done in order to confirm the 
manifestation of the genetic defect in the patients’ immune cells. More affordable and rapid 
diagnostic tests are required for PIDs such as MSMD, especially in countries like South Africa 
with a high endemicity of TB.  
The goal of this study was to implement and optimise a set of functional screening tests that will 
aid in the diagnosis of MSMD in South Africa, a high TB burden setting. These assays were then 
used to investigate immune functionality in 17 suspected MSMD cases. Having a validated 
functional screen for MSMD would allow for confirmation of functional manifestations of known 
genetic signatures of this condition. Effective and accurate diagnosis of this condition is important 
in the broader context of PIDs in general in that the development of such a testing algorithm 
could provide a resource for screening for other PIDs that overlap, especially at the level of 
cytokine gene function and related signalling cascades. Reliable functional screening tests aiding 
in the diagnosis of PIDs in children are essential in order to ensure that the affected individuals 
receive the correct treatment and care.  
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Aims and Objectives 
The aim of this study was to implement and optimise immune phenotyping and functional 
validation tests for the key genes/pathways involved in MSMD. This was primarily focussed on 
the IFN-γ and IL-12 cytokine axis pathways. 
The objectives of the study included: 
I. Implementation and optimisation of flow cytometry-based assays to: 
a. Evaluate surface expression of key cytokine receptors (IFN-γR1 and IL-12Rβ1) 
on the surfaces of lymphocytes, monocytes and NK cells (Standard surface flow 
cytometry). 
b. Evaluate IFN-γ and IL-12 signalling by measuring intracellular phosphorylated 
STAT proteins, STAT1 and STAT4, in lymphocytes, monocytes and NK cells upon 
stimulation with IFN-γ or IL-12 respectively (Phosflow). 
II. Implementation and optimisation of a secreted cytokine assay to determine the levels of 
in vitro IFN-γ-induced IL-12 production and IL-12-induced IFN-γ production after 48-
hours. Assay readout was through IFN-γ and IL-12 ELISAs. 
III. Comparing the functional and genetic (WES) data for 17 suspected MSMD patients to 
ascertain the impact of the genetic defect on the IFN-γ and IL-12 pathways. 
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Chapter 3  Methodology 
3.1. Participant recruitment and initial investigations 
The research documented in this thesis formed part of a larger genetic study by the collaborative 
Primary Immunodeficiency Diseases Genetics (PIDDGEN) Research group, within the 
Departments of Molecular Biology and Human Genetics and Pathology at Stellenbosch 
University. PIDDGEN aims to identify genes and gene variants contributing to susceptibility to 
TB in individuals with suspected PIDs. This study was approved by the Health Research Ethics 
Committee (HREC), Faculty of Medicine and Health Sciences at Stellenbosch University 
(N13/05/075; PI: Dr Craig Kinnear). 
The study was based at the TBH Paediatric immunology clinic and National Health Laboratory 
Service (NHLS) Immunology Unit. The patients came from all over the Western Cape as they are 
often referred to TBH by physicians from other hospitals. Patients were recruited over a period 
of 24 months spanning the period June 2016 to June 2018. 
Immunology consultant and NHLS Immunology Unit head, Prof. Monika Esser, aided in the 
identification of children with suspected PID with mycobacterial associations. Reported suspect 
cases were reviewed based on standard clinical examination criteria and routine laboratory 
results, and either excluded or included into the study. All patients were assessed by a 
paediatrician in consultation with the Immunology Unit; relevant family histories were recorded 
and PID diagnosis was evaluated according to internationally recognised warning signs and PID 
category diagnosis was made according to the 2017 IUIS criteria (Picard et al. 2018). 
Patients and their parents or guardians were required to give comprehensive informed consent 
in order to be included in the study (Appendix A). All patients and their families received pre-test 
genetic counselling, as well as further genetic counselling depending on outcome of genetic 
analyses.  
Routine Laboratory Tests  
All suspected PID patients (including those in this study) undergo standard clinical examination 
and a set of routine laboratory tests at TBH or at their referral medical facility. These routine 
laboratory tests include: conventional TB testing by means of GeneXpert® and/or bacterial culture 
followed by acid fast bacteria (AFB) identification and further drug susceptibility testing (e.g. Hain 
test); full blood counts (FBC) and differentials (neutrophil, lymphocyte, monocyte and eosinophil 
subset enumeration); lymphocyte subset enumeration (T and B lymphocytes and NK cells); and 
levels of specific-immunoglobulin classes (total IgG, IgM, IgA).  
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Inclusion/Exclusion Criteria 
Patients showing clinical and/or immunological evidence for a mycobacterial-associated PID 
during routine immunology assessment, including possible disseminated BCG infection or 
infection with other atypical mycobacteria or Salmonella, as well as patients presenting with 
recurrent, persistent and unusual TB were included in the study. Patients that were positive for 
HIV infection or had other acquired causes for immunodeficiency, such as immunosuppressive 
therapy, were excluded from the study.  
Patients that form part of the larger PIDDGEN study cohort, that were flagged as potential MSMD 
cases before the start of this study were also included, although only if the patient was able to 
return for a follow-up visit to TBH for blood collection and additional routine tests (if not already 
performed during a previous visit). 
3.1.1. Sample collection and processing 
Following consent, approximately 15 to 20 mL of blood was collected by venepuncture into 
Ethylenediaminetetraacetic acid (EDTA) BD Vacutainer tubes (BD Vacutainer, CA, USA) as well 
as 1 mL into each of the four QuantiFERON TB Gold Plus® Tubes (Qiagen, Hilden, Germany) for 
each patient. Samples were also collected from consenting family members where appropriate, 
i.e. where a family member has the same clinical presentation or family history of PID. Blood 
samples were collected in the Paediatric Immunology clinic (ward C3A, TBH) or, in certain cases, 
in the other wards where patients were hospitalised (TBH or another nearby hospital). In cases 
where it was not possible to collect sufficient blood at a single visit, additional blood was collected 
at a follow-up visit. 
Blood was also collected from 10 self-reported healthy adult laboratory volunteers (age range: 
22 - 45) to serve as non-PID controls for this study. Participants signed informed consent forms 
(Appendix B) and the collection of blood from volunteers was ethically approved by the HREC, 
Faculty of Medicine and Health Sciences at Stellenbosch University (N10/08/249; PI: Prof Eileen 
Hoal). Control blood was only used for PBMC isolation and not for DNA extraction or subsequent 
genetic analysis. 
PBMC Isolation and Cryopreservation 
Peripheral blood mononuclear cells (PBMCs) were isolated from patient and control whole blood 
within 4 hours of collection by means of the Ficoll-gradient method, adapted from Boyum (1976). 
Patient whole blood was centrifuged at 2000 relative centrifugal force (RCF) for 10 minutes using 
the Rotanta 46R (Hettich Zentrifugen, Tuttlingen, Germany) centrifuge, thereafter the top plasma 
layer was collected and stored in 1 mL aliquots at -80°C. An equal amount of complete Roswell 
Park Memorial Institute medium (RPMI-1640 with AQmedia™, with L-alanyl-glutamine, sodium 
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bicarbonate, 1% Penicillin-Streptomycin; Sigma-Aldrich®, MO, USA) was then added to the 
remaining volume of whole blood and mixed thoroughly. The diluted blood was then layered 
carefully onto a 10 mL layer of Ficoll Histopaque-1077 (Sigma-Aldrich®, MO, USA) and 
centrifuged at 1500 RCF, with the lowest settings for acceleration and brakes, for 30 minutes. 
The PBMC interface was then carefully pipetted into a new tube containing 10 mL complete 
RPMI. The PBMC-RPMI solution was centrifuged at 1200 RCF for 12 minutes, also with the 
lowest settings for acceleration and brakes, and the resulting supernatant was discarded in one 
swift movement and the pellet was dislodged by flicking the tube. The PBMCs were resuspended 
in complete RPMI containing 10% heat-inactivated Foetal Bovine Serum (FBS; Sigma-Aldrich®, 
MO, USA) and a cell count was performed using a 1:1 dilution of cell suspension to Trypan blue 
on a TC20™ cell counter (Bio-Rad Laboratories, CA, USA) to determine cell concentration and 
viability. The cell-suspension was then centrifuged at 1000 RCF for 10 minutes, acceleration and 
brake settings at maximum, and the resulting supernatant was discarded, and pellet dislodged. 
Freezing medium [made up from 40% complete RPMI, 10% Dimethyl sulfoxide (DMSO; Sigma-
Aldrich®, MO, USA) and 50% FBS] was added in a dropwise manner whilst gently shaking the 
tube, on ice, so that the final cell concentration was 1-3 million cells per mL. The PBMCs in 
freezing medium were aliquoted into 1 mL cryovials, which were placed in a Mr Frosty (Thermo 
Fisher Scientific™, California, USA) at -80°C overnight. The PBMCs were transferred to liquid 
nitrogen for longer-term storage within 2 days.  
DNA Extraction 
DNA was extracted from 5-10 mL of blood, depending on availability. DNA extractions were 
performed by collaborators at the Department of Molecular Biology and Human Genetics, 
Stellenbosch University, within 48 hours of blood collection. DNA was extracted using the 
Nucleon BACC3 kit (Amersham Biosciences, Buckinghamshire, UK) according to manufacturers’ 
instructions. 
3.1.2. Genetic Analyses 
WES, Sanger Sequencing as well as sequence analysis and annotations was performed by 
collaborators Drs Brigitte Glanzmann, Marlo Möller, and Craig Kinnear at the Department of 
Molecular Biology and Human Genetics at Stellenbosch University, Tygerberg Medical Campus.  
Whole exome capture and sequencing 
Library preparation for sequencing was carried out using the Ion AmpliSeq™ Exome RDY and 
the Ion Xpress™ Barcode Adaptors 1-16 Kit (Life Technologies, CA, USA). The DNA template for 
sequencing was prepared on the Ion Chef system using the Ion PI™ Hi-Q™ Chef Kit and the 
Ion™ Chip Kit v3. Sequencing was performed on an Ion Proton™ (Thermo Fisher Scientific™, 
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CA, USA) at the Central Analytical Facility (CAF) at Stellenbosch University, Stellenbosch, South 
Africa. 
Read mapping, variant detection and annotation 
Sequences were aligned to the human reference genome, hg19 using Torrent mapping 
alignment (TMA; version 5.2.1) in the ion-analysis workflow on the Torrent Suite (version 5.2.1) 
(Thermo Fisher Scientific™, California, USA). Base quality score recalibration, indel realignment 
and variant calling were performed using the variantCaller (version 5.2.1.1) plugin on the Torrent 
Suite and variant annotation was performed. Variant prioritisation was performed using TAPERTM 
(Tool for Automated selection and Prioritisation for Efficient Retrieval of sequence variants), a 
custom-designed in-house method, and variants in a homozygous recessive state or compound 
heterozygous state were prioritised as potential candidate variants (Glanzmann et al. 2016). In 
brief, TAPERTM 1) submits variant called format (.vcf) files to an online variant caller, 2) removes 
all synonymous and non-frameshift variants, 3) removes all variants with a frequency of greater 
than 1%, if present in the 1000 Genomes Project or Exome Sequencing Project 6500, 4) removes 
all variants with negative Genomic Evolutionary Rate Prediction (GERP) +++ scores, 5) removes 
all variants with Functional Analysis Through Hidden Markov Models (FATHMM) scores greater 
than 0.1, 6 and lastly 6) identifies associated disorders for prioritised genes. 
Various in-silico prediction tools were used to estimate the likelihood of pathogenicity of the 
identified variants. Sorting intolerant from tolerant (SIFT) (Kumar et al. 2009), PolyPhen 
(Adzhubei et al. 2010), MutationTaster (Schwarz et al. 2014) and Combined Annotation 
Dependant Depletion (CADD) Scores (Kircher et al. 2014) were all used. Thereafter The 
American College of Medical Genetics and Genomics (ACMG) criteria (Green et al. 2013) and 
the newer Sherloc criteria, which is a refined version of the ACMG criteria, (Nykamp et al. 2017) 
were used to make a final call on the pathogenicity of each variant. A brief description of each of 
the in-silico tools used can be found in Appendix C, which also illustrates the various 
combinations of variables used to determine the pathogenicity, as suggested by the 
ACMG/Sherloc criteria. 
Sanger Sequencing 
A fragment containing each of the candidate variants was PCR-amplified from genomic DNA 
from the patient and the relevant family members. Each amplicon was bi-directionally sequenced 
using the BigDye® Terminator v3.1 Cycle Sequencing Kit (Perkin-Elmer, Applied Biosystems 
Inc., CA, USA.), followed by electrophoresis on an ABI 3130XL Genetic Analyzer (Perkin-Elmer, 
Applied Biosystems Inc., CA, USA). All automated DNA sequencing reactions were performed 
at CAF at Stellenbosch University, Stellenbosch, South Africa. The Primers used for PCR/Sanger 
sequencing can be found in Appendix D. 
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3.1.3. QuantiFERON TB Gold Plus® Test 
The QFT Gold Plus® test is an IGRA available as a commercialised TB diagnostic test, but it is 
not yet routinely used in South Africa. The test involves the collection of patient blood into four 
specialised tubes labelled NIL, TB1, TB2 and Mitogen. This test is used to establish 
responsiveness of patient cells to M.tb antigens (Kobashi et al. 2009; Mazurek et al. 2005). 
The TB1 and TB2 tubes contain M.tb-specific antigens, ESAT-6 and CFP-10, that elicits a cell-
mediated immune response in CD4+ helper T lymphocytes (TB1) and CD8+ cytotoxic T 
lymphocytes (TB2), respectively. Patient T lymphocytes respond to the TB antigens and produce 
IFN-γ. The NIL tube contains no antigen and detects the background or baseline IFN-γ 
production. The mitogen tube serves as a positive control (El Azbaoui et al. 2016; Kobashi et al. 
2009).  
QFT-plus was only performed on a subset of 8 patients due to the others patients not being able 
to return to the clinic solely for the QFT-plus test. In-house QFT-plus was performed on 5 of the 
8 patients. In-house QFT-plus could only be performed when there was sufficient reagents and 
expertise available on the day. For the other 3 patients, samples were collected in QFT-plus 
tubes and then outsourced to a private pathology laboratory, PathCare, for incubation and 
analysis.  
Sample collection and incubation 
Blood was collected and incubated according to manufacturer’s instructions. After blood 
collection, the tubes were inverted several times to ensure that the inner surface of the tubes are 
coated with blood so that the antigens dissolved into the blood. Tubes were then incubated 
upright for 16-24 hours at 37˚C (no CO2 required). Following incubation, tubes were centrifuged 
for 15 minutes at 2000 RCF and the resulting plasma was harvested with a pipette and aliquoted 
into 1.5 mL tubes for storage at -20˚C. 
QuantiFERON TB Gold Plus® ELISA  
The QFT-plus IFN-γ ELISA was performed according to the manufacturers’ recommended 
protocol (Qiagen® 2015). In brief, 50 µL of test plasma samples as well as 50 µL of each of the 
IFN-γ ELISA standards (4.0 international units [IU]/mL, 1.0 IU/mL, 0.25 IU/mL, and 0.0 IU/mL; 
where 1 IU = 0.5 ng) were added to respective wells containing 50 µL IFN-γ ELISA conjugate 
and incubated at room temperature for 2 hours. Thereafter the wells were washed 6 times with 
at least 400 µL of wash buffer using the ImmunoWash™ 1575 microplate washer (Bio-Rad 
Laboratories, CA, USA). Enzyme substrate (100 µL) solution was then added to each well and 
after 30 minutes incubation at room temperature 50 µL of enzyme stopping solution was added. 
The optical density (OD) of each well was measured, using the iMark™ microplate reader (Bio-
Rad Laboratories, CA, USA), at 450nm with a 650nm reference filter. The OD results were 
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analysed manually, with MS Excel 365, to determine the IFN-γ concentration in each well as well 
as to calculate the overall test results.  
Interpretation of Test 
QFT-plus ELISA test results were judged based on Centers for Disease Control and Prevention 
(CDC) guidelines (Kobashi et al. 2009; Mazurek et al. 2005). The test result was considered 
positive if the IFN-γ level in the sample (minus the background IFN-γ level in the NIL tube), after 
stimulation with the TB antigens, was ≥0.35 IU/mL, regardless the result for the positive control 
well. The test was considered negative if the IFN-γ level in the sample (minus the background 
IFN-γ level in the NIL tube) was either <0.35 IU/mL, regardless of and the positive control well, 
or ≥0.35 IU/mL, if the positive control well had an IFN-γ level of ≥0.5 IU/mL. The test result was 
recorded as indeterminate if the IFN-γ was <0.5 IU/mL in the positive control well. Figure 3.1 
shows a simplified QFT-plus interpretation flowchart.  
 
 
Figure 3.1: Interpretation of the QuantiFERON TB Gold Plus® test. Adapted from QFT-plus product 
insert (Qiagen® 2015). 
 
The QFT-plus test is intended for use as a TB diagnostic test and therefore a positive result would 
imply that TB infection is very likely, and a negative result implies that TB infection is unlikely in 
a patient. If a QFT-plus result is reported as indeterminate, it is usually due to either a high 
background in the NIL tube or a low response in the positive control, Mitogen, tube. 
Indeterminate results, which are generally due to technical factors resulting from incorrect sample 
handling and processing, may provide information on the immune status of the individual, 
especially in cases where the patient currently had or previously had culture or GeneXpert® 
confirmed TB. A defective IFN-γ production pathway could produce an indeterminate result due 
to lack of induction of IFN-γ following mitogenic Phytohaemagglutinin (PHA) stimulation 
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3.2. Evaluation of the IL-12–IFN-γ pathway by flow cytometry 
Two separate flow cytometry-based assays were implemented and optimised for this study. The 
expression of cytokine receptors on cell surfaces was assessed by means of standard surface 
marker flow cytometry and the cytokine signalling, which is mediated through these cytokine 
receptors, was assessed by means of an intracellular Phosflow assay. 
Surface flow cytometry – Cytokine receptor detection 
Surface expression of IFN-γR1 (CD119) and IL-12Rβ1 (CD212) on lymphocyte subsets, NK cells 
and monocytes was evaluated by standard surface flow cytometry, whereby cells were stained 
with fluorochrome-conjugated antibodies and the fluorescence data acquired by a flow cytometer. 
Detection of IFN-γR1 and IL-12Rβ1 has previously been used to confirm several cases of MSMD 
(Esteve-Solé et al. 2018; Neehus et al. 2017; Kong et al. 2013; de Beaucoudrey et al. 2011; 
Fieschi 2004). 
Phosflow – Assessment of cytokine signalling 
IFN-γ and IL-12 signalling was assessed by measuring the intracellular phosphorylation of the 
respective cytokine receptor-associated signal transducer molecules STAT1 and STAT4. This 
was achieved by an intracellular flow cytometric-based phosphorylation assay – Phosflow – 
where, after PBMC stimulation with either IFN-γ or IL-12, levels of phosphorylated STAT1 and 
STAT4 (pSTAT1 and pSTAT4) were measured intracellularly by detecting the bound phospho-
specific fluorochrome-conjugated antibodies. The Phosflow protocol differs significantly from 
standard surface flow cytometry and involves brief stimulation of the cells, followed by fixation 
and permeabilisation prior to staining and acquisition of fluorescent data on a flow cytometer. 
Detection of pSTAT1 and pSTAT4 has also previously been used to assess IFN-γ and IL-12 
signalling in several MSMD cases (Esteve-Solé et al. 2018; Kong et al. 2013; van de Vosse et 
al. 2009). 
3.2.1. Panel Design 
Two nine-colour staining panels were designed, designated as the Receptor Panel and the 
Signalling/Phosflow Panel, for each of the two flow cytometric assays. The two panels shared 
the following fluorochrome-conjugated antibodies: Fixable viability stain 575V (FVS575V), which 
is a fixable amine-reactive viability marker; CD3-Fluorescein isothiocyanate (FITC); CD4-
Allophycocyanin (APC); CD8-Phycoerythrin-Cyanin5 (PE-Cy5); CD14-Phycoerythrin-Cyanin7 
(PE-Cy7) and; CD56-Brilliant Violet 510 (BV510). The Receptor Panel also contained: CD19-
Brilliant Blue 700 (BB700); CD119-Phycoerythrin (PE) and; CD212-Brilliant Violet 421 (BV421). 
The Signalling Panel contained: CD20(Intracellular)-Peridinin-chlorophyll protein-Cyanin5.5 
(PerCP-Cy5.5); pSTAT1-BV421; and pSTAT4-PE. All antibodies used in this study were 
Stellenbosch University  https://scholar.sun.ac.za
35 
 
procured from BD (BD Biosciences, CA, USA). Table 3.1 shows a summary of the clone, isotype 
and reactivity information of the monoclonal antibodies (mAbs) that were used in this study.  
Table 3.1: Clone, isotype and reactivity information on the monoclonal antibodies used to in this 
study. For the monoclonal antibodies shared across both panels, specific clones known to be compatible 
with the Phosflow protocol were chosen. 
 Target mAb Fluorochrome Clone Isotype Reactivity 
BD 
Catalogue 
number 
U
s
e
d
 i
n
 b
o
th
 t
h
e
 R
e
c
e
p
to
r 
a
n
d
 
S
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n
a
ll
in
g
 P
a
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e
ls
 
Dead cells 
FVS575V 
(a dye, not 
a mAb) 
Intracellular amine 
reactive dye with 
emission detectable 
in 605/40BP filter 
N/A N/A Mammalian 565694 
T cells CD3 FITC UCHT1 
Mouse 
IgG1, ĸ 
Human 561806 
T helper cells CD4 APC SK3 
Mouse 
IgG1, ĸ 
Human 565994 
T cytotoxic 
cells 
CD8 PE-Cy5 HIT8a 
Mouse 
IgG1, ĸ 
Human 561946 
Monocytes CD14 PE-Cy7 M5E2 
Mouse 
IgG2, ĸ 
Human 560919 
NK cells CD56 BV510 R19-760 
Mouse 
IgG1, ĸ 
Human 744218 
E
x
c
lu
s
iv
e
 t
o
 
R
e
c
e
p
to
r 
P
a
n
e
l 
B cells CD19 BB700 HIB19 
Mouse 
IgG1, ĸ 
Human 566397 
IFN-γR1  CD119 PE GIR-208 
Mouse 
IgG1, ĸ 
Human 558934 
IL-12Rβ1 CD212 BV421 
2.4E6 (2-
4E6) 
Mouse 
IgG1, ĸ 
Human 744202 
E
x
c
lu
s
iv
e
 t
o
 
S
ig
n
a
ll
in
g
 P
a
n
e
l B cells 
CD20 
(I/C)* 
PerCP-Cy5.5 H1 (FB1) 
Mouse 
IgG2a, 
ĸ 
Human 560907 
Phosphorylated 
STAT1 
pSTAT1 BV421 4a 
Mouse 
IgG2a, 
ĸ 
Human 566238 
Phosphorylated 
STAT4 
pSTAT4 PE 
38/p-
Stat4 
Mouse 
IgG2a, 
ĸ 
Human 558249 
N/A – Not Applicable 
* CD20(I/C) is an intracellular B cell marker. This is used instead of CD19 in the Signalling panel, due to most 
commercially available CD19 clones being incompatible with the Phosflow protocol. 
mAb: Monoclonal antibody 
 
3.2.2. Implementation of flow cytometry panels 
Sample preparation 
Cryopreserved PBMCs were thawed rapidly to preserve the viability of the cells (Hønge et al. 
2017). For the thawing process, cryovials containing PBMCs were transferred, on dry ice, from 
liquid nitrogen storage to a 37ﹾC bead bath. The cells were left in the bead bath for 1-2 minutes 
or until vial contents had liquefied. Complete RPMI medium containing 10% FBS (pre-warmed to 
37ﹾC) was added in a dropwise manner into the cryovial so that the final volume is double that of 
the cell suspension. The PBMCs were transferred to a 50-mL BD FALCON® tube (Corning 
Science, NY, USA) and the cryovial was rinsed twice with the pre-warmed complete RPMI (10% 
FBS). The cell suspension was then centrifuged at 1200 RCF for 10 minutes. The supernatant 
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was discarded, and pellet dislodged by gently flicking the tube. The PBMC pellet was washed 
twice, each time by adding 10 mL complete RPMI with 10% FBS followed by centrifugation at 
1200 RCF, and the resulting supernatant was discarded. The PBMC pellet was then 
resuspended with desired volume of complete RPMI with 10% FBS. The number of cells and 
their viability was determined using a 1:1 dilution of the cell suspension and trypan blue and the 
TC20™ cell counter. 
For immediate staining of PBMCs, a total of between 5x105 and 1x106 cells, depending on 
availability, were transferred to 5-mL BD Falcon™ polystyrene round-bottom tubes (BD 
Biosciences, MA, USA), where they were once again centrifuged, and the supernatant discarded. 
The PBMCs were then ‘washed’ with staining media (Phosphate buffered saline [PBS; Sigma-
Aldrich®, MO, USA] with 2% FBS), i.e. 10 mL staining media was added, followed by another 10-
minute centrifugation and discarding of the resultant supernatant. The PBMCs were then stained 
with the appropriate volumes of antibody. 
For processing of PBMCs for the signalling panel, an overnight (approximately 18 hours) resting 
period was required after thawing in order for cells to be able to respond optimally to the short-
term cytokine stimulation of the Phosflow protocol. Resting of PBMCs also reduce the basal 
levels of phosphorylation (Uzel et al. 2001). Therefore, after thawing and washing, PBMCs were 
resuspended in complete RMPI with 10% FBS and then transferred to 5-mL BD FALCON® 
polypropylene round-bottom tubes (Corning Science, NY, USA) and placed in an incubator with 
5% CO2 to rest overnight. 
Polypropylene tubes, instead of the conventional polystyrene tubes were required for overnight 
incubation to prevent attachment of monocytes to tube walls. Although EDTA or other specialised 
solutions can be used to detach the cells from the tube walls, it was discovered during the 
optimisation experiments that these solutions impaired the ability of the cells to optimally respond 
to stimuli. 
Instrument set-up 
Flow cytometric data acquisition was performed on a BD LSRII (BD Biosciences, CA, USA) using 
BD FACSDiva™ software at the BD Flow Cytometry training centre-CAF at Stellenbosch 
University, Tygerberg Medical Campus. This flow cytometer is equipped with Blue (488 nm), 
Violet (405 nm) and Red (633 nm) lasers and emission filters for PE-Cy7 (Long-pass filter [LP]: 
735, Band-pass filter [BP]: 780/60), PerCP-Cy5.5/BB700 (LP: 685, BP 695/40), PE-Cy-5 (LP: 
635, BP 670/14), PE (LP: 550, BP 575/26), FITC (LP: 505, BP 530/30), BV605 (LP: 505, BP 
605/40), BV510 (LP: 505, BP 525/50), BV421 (LP: -, BP 440/40), APC (LP: -, BP 660/20), and 
others (which are not relevant for this study).  
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The cytometer was calibrated with BD cytometer setup and tracking (CS&T) beads (BD 
Biosciences, CA, USA) on each day that an experiment was performed in order to verify that the 
fluidics and optics systems of the instrument were performing optimally.  
Voltage set-up 
For the Receptor panel, a cryopreserved, unstained PBMC sample was used to adjust the 
instrument’s voltages to standardise the light scatter [forward scatter (FSC) and side scatter 
(SSC)]. The unstained PBMC sample was also used to adjust the robust standard deviation (rSD) 
of each fluorescent parameter so that it was equivalent to 2.5 or more times the rSD of the 
electronic noise (rSDEN). 
Similarly, a cryopreserved, rested, unstained PBMC sample that had undergone fixation and 
permeabilisation was used to set the voltages for the Signalling/Phosflow panel. 
Monoclonal antibody titrations 
Antibody titrations were performed to determine the optimal antibody volumes to be used that 
would provide optimal discrimination between positive and negative populations. The signal-to-
noise ratio, calculated by dividing the median fluorescence intensity (MFI) of the positive 
population by that of the negative population, was used to determine the ability to distinguish 
between positive and negative populations (Figure 3.2). To be able to make accurate 
measurements of fluorescence, it is important to maximise the signal while reducing the noise.  
Some noise is unavoidable which comes from the cells (autofluorescence), and the inherent 
noise in the system. Titration helps minimise noise due to non-specific binding of the antibodies 
to low-affinity targets (Cossarizza et al. 2017). 
 
Figure 3.2: Signal-to-noise ratio calculation. The Signal-to-noise ratio is calculated by dividing the MFI 
of the positive cells with the MFI of the negative cells. The higher the signal-to-noise ratio, the easier it is 
to discriminate between positive and negative populations. The stain index, also shown in the figure, refers 
to the relative ‘brightness’ of a particular fluorochrome compared to a negative (unstained) control. 
 
When an antibody is titrated, it needs to be done under the same conditions in which it will be 
used during the experiment. For this study PBMCs were cryopreserved, thawed and stained in 
the exact same way for titrations and experiments. Only the antibodies from the Receptor panel, 
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which includes the antibodies that are shared between the two panels, were titrated under 
standard surface staining conditions. The antibodies that are exclusive to the Signalling panel 
were not titrated and were used at manufacturer recommended concentrations throughout. 
For the antibody titration experiments, cryopreserved PBMCs were thawed and then stained with 
decreasing concentrations of fluorochrome-conjugated antibodies. Where the manufacturers’ 
recommended staining dilution was 1:20, cells were stained with a doubling dilution series of 
1:10, 1:20, 1:40, 1:80 and 1:160. Likewise, where the recommended staining dilution was 1:5, 
cells were stained with a dilution series of 1:2.5, 1:5, 1:10, 1:20 and 1:40. The cells were stained 
with 50 µL of the appropriate dilution for 30 minutes, away from direct light. After staining, the 
cells were washed twice by adding 1mL staining buffer, which consists of PBS (Sigma-Aldrich®, 
MO, USA) and 2% FBS, and centrifuging for 10 minutes at 1200 RCF. The supernatant was 
discarded after each wash and the pellet was resuspended in 200 µL for acquisition on the flow 
cytometer. For titration of CD212 (IL-12Rβ1), cells were first incubated with 5µg/ mL PHA (Sigma-
Aldrich®, MO, USA) for 24 hours at 37°C with 5% CO2 to upregulate CD212 expression (de 
Beaucoudrey et al. 2011; Fieschi 2004). Table 3.2 shows the optimal titrated staining dilutions 
for the antibodies, as determined by the titration experiments. 
Table 3.2: Optimal titrated staining dilutions for each of the antibodies in this study, as determined 
by the titration experiments. 
Monoclonal 
Antibody Fluorochrome 
Manufacturer 
recommended 
staining dilution factor 
Titrated staining 
dilution factor 
FVS575V 
Intracellular amine reactive dye with emission 
detectable in 605/40BP filter 
1:1000 1:2000 
CD3 FITC 1:5 1:20 
CD4 APC 1:20 1:160 
CD8 PE-Cy5 1:5 1:40 
CD14 PE-Cy7 1:20 1:40 
CD56 BV510 N/A** 1:20 
CD19 BB700 1:20 1:160 
CD119 PE 1:20 1:20 
CD212 BV421 N/A** 1:20 
CD20 (I/C)* PerCP-Cy5.5 1:10 - 
pSTAT1 BV421 1:20 - 
pSTAT4 PE 1:5 - 
*CD20(I/C) is an intracellular B cell marker. This is used instead of CD19 in the Signalling panel, due to CD19 being 
incompatible with the Phosflow protocol 
**CD56-BV510 and CD212-BV421 are BD Optibuild reagents and do not have specified recommended staining 
dilutions 
 
Compensation for spectral overlap  
Spectral overlap occurs when the fluorescence of one fluorochrome ‘spills’ into an adjacent 
detector, for example the fluorescence emitted by the fluorochrome PE is often detected in the 
FITC detector. In order to compensate for spectral overlap between fluorochromes, the 
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Photomultiplier tubes’ (PMT) voltage settings of the cytometer are adjusted for each detector to 
ensure that all fluorescence detected in each of the detectors belongs only to the fluorochrome 
of its designated detector (Cossarizza et al. 2017; Roederer 2001). 
A representation of the spectral overlap that occurs for the fluorochromes used in for the Receptor 
flow cytometry panel can be seen in Figure 3.3. These images were generated using the BD 
Fluorescence Spectrum Viewer online tool (BD Biosciences 2018  http://www.bdbiosciences.com 
/us/s/spectrumviewer).  
Anti-mouse Ig, kappa (ĸ) chain and Negative Control Compensation Particles (BD CompBeads; 
BD Biosciences, CA, USA) were used for setting up the compensation for each panel. For each 
fluorochrome in a panel, one drop of BD CompBeads anti-mouse Ig and one drop of the BD 
CompBeads negative control were added to 100 µL staining buffer.  
For the Receptor panel, the optimal staining concentration, determined by the titration 
experiment, for each fluorochrome-conjugated antibody was added to the compensation beads 
and then incubated for 30 minutes at room temperature away from direct light. After staining, the 
beads were washed with staining buffer and resuspended in 500 µL staining buffer for acquisition. 
FVS575V is an amine-reactive viability dye and does not bind to BD CompBeads, therefore 
thawed PBMCs, with between 50% and 80% viability, as determined by the TC20™ cell counter, 
were used for FVS575V compensation set-up.  
For the Signalling panel, the BD CompBeads and the negative control beads were incubated with 
the BD Cytofix™ (BD Biosciences, CA, USA) buffer for 10 minutes at 37˚C, and thereafter 
permeablised with the permeabilisation buffer. The beads were then stained for 60 minutes at 
room temperature away from direct light. After staining the beads were washed with staining 
buffer and resuspended in 500 µL staining buffer for acquisition. FVS575V was compensated for 
in the same way as mentioned above for the Receptor panel. 
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Figure 3.3: Spectral overlap between fluorochromes used in this study. The absorption (dotted lines) 
and emission spectrum (solid lines with coloured graphs) for each of the fluorochromes in this study are 
shown for the blue 488nm, violet 405nm and red 633nm lasers. The rectangles on each of the spectra 
represent the band-pass filters of the flow cytometer that determine which parts of the spectrum can be 
detected in each of the filters. It is evident that there is significant overlap of some fluorochromes into the 
detectors of adjacent fluorochromes. The observed spill-over needs to be compensated for before multi-
colour staining experiments can be performed. 
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Fluorescence Minus One Controls for gating 
Fluorescence minus one (FMO) analyses was performed in order to establish accurate 
discrimination between positive and negative (background) marker expression. For the FMO 
controls, PBMCs from a healthy volunteer were stained with all of the fluorochrome-conjugated 
antibodies in the panel minus the one fluorochrome-conjugated antibody of interest.  
Designated population gates, defining populations with specific scatter or fluorescence 
characteristics, were created in order to identify and examine the various cell sub-populations 
based on the expression of various surface markers. FMO controls were then used to place or 
adjust positive vs. negative discriminator regions. The full gating strategy is described in the next 
section. FMOs were only performed for the 2 cytokine receptors, CD119-PE, CD212-BV421. The 
use of unstained control samples was sufficient for setting up accurate gates and regions for the 
other fluorochrome-conjugated antibodies in this study, due to them having well-described and 
very distinct positive and negative populations. An example of the FMO controls for CD119 on 
monocytes and CD212 on lymphocytes are shown in Figure 3.4.  
 
Figure 3.4: Fluorescence Minus One (FMO) gating control for CD119 and CD212. Histograms showing 
the fluorescence intensity for CD119 (on FSC vs. SSC monocytes) and CD212 (on FSC vs. SSC 
lymphocytes) for PBMCs stained without either CD119 or CD212 (i.e. FMO controls) compared to fully 
stained samples. FMO controls allow for the establishment of gates that allow accurate discrimination 
between positive and negative populations. 
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3.2.3. Acquisition and gating 
After the cytometer had been set up optimally for each of the two respective panels, antibody 
cocktails containing the optimal titrated volumes of each antibody in a panel were prepared and 
then used to stain the thawed PBMC samples. 
Acquisition parameters 
Samples were acquired on the BD LSR II using a medium flow rate. BD FACSDiva™ software 
was used for acquisition. There was no defined gating strategy for acquisition, apart from the 
FSC vs. SSC lymphocyte-defined gate. The FSC vs SSC lymphocyte gate was used as an 
acquisition “stopping gate” i.e. once there was a specified number of events recorded within the 
gate, no further data was acquired. All events, not just the ones within the stopping gate, were 
stored in Flow Cytometry Standard data files (.fcs) for further analysis. A total of 50 000 events, 
within the FSC vs. SSC lymphocyte gate, were acquired for the Receptor panel. For the Signalling 
panel, a total of 100 000 events, also within the FSC vs. SSC lymphocyte gate were acquired. 
Gating strategy 
FlowJo® software was used for post-acquisition gating and analysis. The gating strategy for the 
Receptor and the Signalling panel were overall very similar. A ‘Time’ gate, with SSC vs. Time, 
was created first in order to confirm that data acquisition was stable over time. The live cells were 
then gated (i.e. the FVS575V negative population) thereafter an FSC vs. SSC dot-plot was used 
to distinguish between the overall lymphocyte and monocyte subsets. The FSC vs. SSC dot-plots 
generated by the Receptor and Signalling panel differ significantly due to the effect that the harsh 
Phosflow protocol has on the cells. 
From the FSC vs. SSC lymphocyte population, doublets were excluded by using an SSC-Area 
vs. SSC-Height gate. Various lymphocyte sub-populations were then identified based on the 
expression of CD56 (NK cells), CD3 (T lymphocytes) or CD19/CD20 (B lymphocytes). The CD3+ 
T lymphocytes were then further characterised by the expression of CD4 (T helper cells) or CD8 
(Cytotoxic T cells). From the FSC vs. SSC monocyte population, CD14+ cells were gated using 
an SSC-Height vs. CD14 dot-plot. Doublet exclusion was not performed for the monocyte 
populations due to their larger size and propensity to adhere to one another.  
For the Receptor panel, CD119 expression was assessed for the FSC vs. SSC monocyte 
population as well as the CD14+ monocyte population. CD212 expression was assessed for all 
of the lymphocyte sub-populations. CD119-, CD119+, CD212- and CD212+ regions were created 
for each of the abovementioned cell subpopulations by means of FMO controls. Similarly, for the 
Signalling panel, pSTAT1 was assessed for the FSC vs. SSC monocyte population and the 
CD14+ populations, while pSTAT4 was assessed for all lymphocyte sub-populations.  
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The gating strategy was slightly adjusted in PHA stimulated samples due to the induced changes 
in lymphocyte morphology. The lymphocyte gates were therefore adjusted to include activated 
lymphocytes that have increased size and granularity compared to cells that were not stimulated 
with PHA.  
A graphical example of the gating strategy for the Receptor panel and the Signalling panel is 
shown in Figures 3.5 and 3.6 respectively.  
 
Figure 3.5: Gating Strategy for Receptor panel. CD119 expression is measured for all lymphocyte and 
monocyte subsets. CD119 expression in FSC vs. SSC monocytes as well as in CD14+ monocyte 
populations are shown in the figure as examples. CD212 expression is assessed for all lymphocyte and 
monocyte subsets. CD212 expression in CD56+ and CD3+CD4-CD8- subsets are shown in the figure as 
an example. Bisector gates for CD119 and CD212 were created according to FMO controls. 
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Figure 3.6: Gating Strategy for the Signalling panel. Gating strategy for the Signalling panel differs from 
the Receptor panel due to the effect of the Phosflow protocol on the cells. In the figure, detection of pSTAT1 
in FSC vs. SSC monocytes and in CD14+ monocytes are shown for IFN-γ stimulated (blue) and 
unstimulated (red) samples. Detection of pSTAT4 in CD56+ and CD3+CD4-CD8- subsets are shown for 
IL-12 stimulated (blue) and unstimulated (red) samples.  
 
3.2.4. Optimisation of flow cytometry panels 
Several optimisation steps were required to set up both the Receptor and Signalling panels. The 
optimisation findings are described in Chapter 4; however, the fully optimised protocols are 
described below in section 3.2.5. 
Receptor  
PHA stimulation and its effect on CD212 and CD119 expression 
According to de Beaucoudrey et al. (2011) and Fieschi et al. (2004), PBMCs should be stimulated 
with PHA for 72 hours and co-cultured with IL-2 for optimal upregulation of CD212 expression on 
the surfaces of lymphocytes. In order to simplify the workflow for this study, patient PBMCs were 
not incubated for extended periods and no co-culture with IL-2 was performed. The simplified 
assays were compared to the abovementioned previously published assays to determine 
whether the simplification of the assays significantly impact on the results. 
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Stimulation of cells with PHA alone is known to upregulate the expression of CD212 on 
lymphocytes, however, the effect of PHA on CD119 expression has not been reported. In order 
to determine the effect of PHA on the expression of CD119 and CD212 on lymphocytes in our 
setting, thawed PBMCs were incubated with PHA (5 µg/mL) for 0, 24 and 48 hours at 37˚C and 
5% CO2 and then stained with an antibody cocktail from the Receptor panel for 30 minutes.  
The fold change in CD212 expression (Δ𝐶𝐷212 =  
𝐶𝐷212 𝑀𝐹𝐼 𝑓𝑢𝑙𝑙𝑦 𝑠𝑡𝑎𝑖𝑛𝑒𝑑 𝑠𝑎𝑚𝑝𝑙𝑒
𝐶𝐷212 𝑀𝐹𝐼 𝑢𝑛𝑠𝑡𝑎𝑖𝑛𝑒𝑑 𝑠𝑎𝑚𝑝𝑙𝑒
) was calculated for 
both the PHA stimulated and unstimulated samples and used to determine the effect of PHA on 
CD212. The percentage of CD119 expression on FSC vs. SSC monocytes and CD14+ 
monocytes were assessed for the PHA stimulated and unstimulated samples to determine the 
effect of PHA on CD119. 
Phosflow 
Permeabilisation buffers 
Two separate permeabilisation buffers namely BD Phosflow™ Perm Buffer III and BD 
Phosflow™ Perm Buffer IV (BD Biosciences, CA, USA) were evaluated to determine which would 
provide the best detection of pSTAT1 and pSTAT4 whilst resulting in minimal destruction of 
surface epitopes. 
To test the effect of each permeabilisation buffer on each of the surface markers, thawed PBMCs 
were fixed with BD Cytofix™ buffer (BD Biosciences, CA, USA) and then permeablised with 
either Perm III (30 minutes on ice) or Perm IV (1X) (20 minutes at room temperature) prior to 
staining with each of the respective surface marker fluorochrome-conjugated antibodies. Perm 
IV (1X) is prepared by diluting the Perm IV (10X) stock solution with PBS. 
To determine which permeabilisation buffer allowed optimal detection of pSTAT1 and pSTAT4, 
thawed PBMCs were either stimulated for 15 minutes with IFN-γ (100 ng/mL) and IL-12 (100 
ng/mL) or left unstimulated. The cells were then fixed with BD Cytofix™ and permeablised with 
Perm III and Perm IV (1X) respectively. The cells were then stained with both pSTAT1-BV421 
and pSTAT4-PE. The fold change (
𝑀𝐹𝐼 𝑠𝑡𝑖𝑚𝑢𝑙𝑎𝑡𝑒𝑑 𝑠𝑎𝑚𝑝𝑙𝑒
𝑀𝐹𝐼 𝑢𝑛𝑠𝑡𝑖𝑚𝑢𝑙𝑎𝑡𝑒𝑑 𝑠𝑎𝑚𝑝𝑙𝑒
) in pSTAT1 and pSTAT4 was calculated 
to determine which buffer was best suited. 
PHA stimulation and pSTAT4 detection 
Uzel et al. (2001), one of the first groups to describe pSTAT4 detection by means of Phosflow, 
activated PBMCs with PHA and IL-2 prior to IL-12 stimulation. In this study, however, PBMCs 
were stimulated with 5 µg/mL PHA, without IL-2, for 24 hours in order to assess the impact of 
PHA on pSTAT4 detection.  
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Cytokine dosage effect of pSTAT detection 
To determine the optimal concentrations of cytokines to be used for stimulation, the Phosflow 
protocol was performed using varying concentrations of IFN-γ and IL-12. Stimulation with IFN-γ 
or IL-12 at concentrations of 10, 50, 100, 150 and 200 ng/mL was assessed. 
The effect of stimulation time was not investigated in this study, since several sources have 
reported that 15 minute cytokine stimulation is optimal for both pSTAT1 and pSTAT4 detection 
(Esteve-Solé et al. 2018; Depner et al. 2016; Pertovaara et al. 2016; Uzel et al. 2001; Yao et al. 
1999). 
3.2.5. Optimised protocols 
Receptor Panel 
Cryopreserved PBMCs were thawed and washed with RPMI with 10% FBS, as described in 
section 3.2.2, and then split into two separate 5 mL round-bottom polypropylene tubes with each 
then containing at least 2.5 x 105 cells. One of the tubes was left unstimulated, for CD119 
detection, and 5 µg/mL PHA was added to the other, for upregulation of CD212. Both tubes were 
placed into a 37˚C, 5% CO2 incubator for 24 hours. After the incubation period, the PBMCs were 
washed twice, first with complete RPMI with 10% FBS and then with staining buffer.  
Cells were then stained with the viability marker, FVS575V, for 10 minutes at room temperature 
and then washed with staining buffer. Thereafter each tube was stained for 30 minutes at room 
temperature with 50 µL of an antibody cocktail containing all antibodies from the Receptor Panel, 
as listed in Table 3.1, with the optimal staining dilution for each antibody as listed in Table 3.2. 
After staining, the cells were washed with staining buffer and then resuspended in 200 µL staining 
buffer. The tubes were thoroughly vortexed before the sample was acquired immediately within 
2 hours on the BD LSR II at the BD CAF Flow Cytometry Centre.  
Signalling Panel 
Similar to the Receptor Panel, cryopreserved PBMCs were thawed and washed with RPMI with 
10% FBS, as described in section 3.2.2, and then split into three separate 5-mL round-bottom 
polypropylene tubes, labelled unstimulated, IFN-γ stimulated, and IL-12 stimulated, with each 
containing at least 5 x 105 cells. PHA (5 µg/mL) was added to only one of the tubes – IL-12 
stimulated – to upregulate CD212 expression, allowing for optimal pSTAT4 detection. All three 
tubes were then placed into a 37˚C, 5% CO2 incubator overnight (approximately 18 hours). After 
the incubation period, the PBMCs were washed with complete RPMI with 10% FBS.  
After the overnight incubation, the cells were stained with the fixable viability marker, FVS575V, 
for 10 minutes at room temperature and then washed with complete RPMI with 10% FBS. Tubes 
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were then stimulated with 500 µL of either complete RPMI with 10% FBS (unstimulated), 100 
ng/mL human recombinant IFN-γ (IFN-γ stimulated) or 100 ng/mL human recombinant IL-12 
(PHA pre-stimulated IL-12 stimulated tube) for 15 minutes at 37˚C, 5% CO2.  
Immediately after stimulation, an equal volume of BD Cytofix™ was added, and the cells were 
placed in a 37˚C bead-bath for 10 minutes in order to fix the cells. The cells were then centrifuged 
for 10 minutes at 2300 RCF, and the supernatant discarded. The tubes were then vortexed 
vigorously to resuspend the cells completely. To permeablise the cells, 1 mL Perm IV (1X), made 
from a 1:10 dilution of Perm IV (10X) in PBS, was added and incubated for 20 minutes at room 
temperature. After permeabilisation, cells were washed twice by adding at least 2 mL staining 
buffer and then centrifuging for 10 minutes at 2300 RCF.  
Thereafter, each tube was stained for 60 minutes at room temperature with 50 µL of an antibody 
cocktail containing all antibodies from the Signalling Panel, as listed in table 3.1, with the optimal 
staining dilution for each antibody as listed in Table 3.2. After staining, the cells were washed 
with staining buffer and then resuspended in 200 µL staining buffer. The tubes were thoroughly 
vortexed before being acquired on the BD LSR II at the BD CAF Flow Cytometry Centre.  
3.2.6. Processing of control and patient PBMCs and analysis of flow 
cytometry data 
Using control PBMCs to establish a baseline 
For each panel, 10 controls, which were all assumed healthy, non-PID adult laboratory 
volunteers, were processed using the optimal protocol described above in 3.2.5 to establish a 
‘normal’ baseline range that patient samples could be compared to. For the Receptor panel, the 
frequency (%) of CD119 and CD212 expression for each of the parent populations were 
measured as well as the density (MFI) of expression on each cell subset. For the Signalling panel, 
the fold change in pSTAT detection between the cytokine stimulated and unstimulated samples 
for each patient was determined for both pSTAT1 and pSTAT4.  
Data acquired from the LSR II using the BD FACSDiva™ software was exported as .fcs files and 
further analysed in FlowJo®. Raw cytometry data generated using FlowJo® was exported into 
MS Excel format and then GraphPad Prism (version 7) was used for further analysis of 
percentage expression and fold change in MFI data. Descriptive statistics of receptor expression, 
for both CD119 and CD212, and fold change in pSTAT detection were generated for each of the 
various cell subtypes. Non-parametric spearman correlation tests were performed to determine 
whether receptor expression correlated with fold change in pSTAT detection. The data for all cell 
subsets were combined for the correlation analyses. 
Stellenbosch University  https://scholar.sun.ac.za
48 
 
Processing of patient samples 
Patient PBMCs were processed, similarly to the controls, using the optimised protocol for each 
of the respective flow cytometric assays. Functional work was also performed on family members’ 
PBMCs for comparison in cases where the family member had or was suspected of having the 
same variant as the patient. 
Data acquired from the LSR II using the BD FACSDiva™ software was exported as .fcs files and 
further analysed in FlowJo®. Percentage and MFI data was exported from FlowJo® to MS Excel 
format. Thereafter, patient data was compared to a 90% reference interval obtained from 
controls’ data, i.e. for each patient, it was assessed whether the patient data falls within the 5th 
to 95th percentile of the control, or reference, data. 
3.3. Detection of Induced Cytokine Production 
3.3.1. Cytokine stimulation 
The levels of IL-12-induced IFN-γ production and IFN-γ-induced IL-12 production was measured 
in vitro after 48-hour stimulation of PBMCs. This assay was derived from the ‘gold standard’ 
method, developed by Feinberg et al. (2004) for the study of the integrity of the IFN-γ pathway. 
The Feinberg et al. method involved the measurement of IL-12p40, IL12p70 and IFN-γ after 
stimulation of whole blood or PBMCs with BCG with or without recombinant IL-12p70 or IFN-γ. 
Dorman and Holland (1998) used a similar method where they stimulated PBMCs with PHA, 
rather than BCG, and IL-12 to describe a defect in the  IFN-γ signal-transducing chain in a patient 
with a mutation in IFN-γR2. 
For this assay, cryopreserved PBMCs were activated with 5 µg/mL PHA, similar to Dorman and 
Holland (1998), with or without recombinant human IFN-γ or IL-12p70 (BD Biosciences, CA, 
USA), in order to assess the integrity of the IFN-γ-IL-12 pathway as proposed by Feinberg et al. 
(2004).  
Cryopreserved PBMCs were rapidly thawed, washed with complete RPMI containing 10% FBS 
and a cell count was performed and recorded as described in 3.3.2. Four wells in a 24-well cell 
culture plate (Corning Incorporated, NY, USA) were prepared for each patient or control PBMC 
sample: (i) no activation, (ii) PHA activation (5 µg/mL), (iii) PHA activation and IL-12 stimulation 
(20 ng/mL), and (iv) PHA activation and IFN-γ stimulation (50 ng/mL). Between 150 000 and 
500 000 cells were added per well, depending on availability of input material. The exact number 
of cells added into each was recorded in order to adjust cytokine concentrations to represent 
cytokine production per 105 cells (as indicated in ELISA analysis section 3.3.2). The components 
of each well are also listed in Table 3.3. The plate was then incubated for 48 hours at 37°C in an 
incubator with 5% CO2. After the incubation period, the total contents of each well were 
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transferred to a 1.5 mL tube and centrifuged at 2500 RCF for 10 minutes. The supernatants were 
then transferred to 1.5 mL safe-lock tubes for storage at -80°C until ELISA analysis. 
Table 3.3: Composition of the four wells prepared for each sample in the cytokine-induced cytokine 
production assay. The first well contained only cells and media, this serves as a negative control; The 
second well contained cells, media and PHA, this serves as a second control, for PHA stimulation; The 
third well contained cells, media, PHA and IL-12; The fourth well contained cells, media, PHA and IFN-γ. 
Well number/name 
1 2 3 4 
No activation PHA PHA + IL-12 PHA + IFN-γ 
Cells (PBMC in suspension) + + + + 
PHA (5ug/ml final concentration) - + + + 
IL-12 (20ng/ml final concentration)  - - + - 
IFN-γ (50ng/ml final concentration) - - - + 
Media + + + + 
Total volume 1 mL 1 mL 1 mL 1 mL 
 
Ten healthy control PBMCs, the exact same controls used for the flow cytometry assays, were 
processed and the results were recorded in order to establish a ‘normal’ baseline that could be 
used for comparison to patients. Thereafter the cytokine-induced cytokine production assay was 
performed on PBMCs for all patients as well as for their family members’ where appropriate. 
3.3.2. Cytokine detection 
ELISAs 
A human IFN-γ Quantikine® ELISA kit as well as a high-sensitivity human IL-12p70 Quantikine® 
HS ELISA kit (R&D Systems, MN, USA) were used to measure the levels of IFN-γ and IL-12p70 
for each patient in each of the 4 wells from the abovementioned activation and cytokine 
stimulation assay. In addition to the cell culture supernatants from the 48-hour activation and 
cytokine stimulation assay, IFN-γ levels, but not IL-12p70 levels, present in plasma samples 
harvested from whole blood during PBMC isolation (3.1.1) will also be analysed by means of 
ELISA. 
The manufacturers’ recommended protocol for each assay was followed. Before analysis by 
ELISA, samples were thawed to room temperature and centrifuged at 13 000 RCF for 15 minutes 
to remove particulate material from the cell culture supernatants or plasma. Briefly, sample cell-
culture supernatant or standard was added to a well in a 96-well plate containing assay diluent 
and incubated for 2 (IFN-γ) or 3 (IL-12) hours at room temperature. The standards for the IFN-γ 
ELISA were 1000 pg/mL, 500 pg/mL, 250 pg/mL, 125 pg/mL, 62.5 pg/mL, 31.3 pg/mL and 15.6 
pg/mL. The standards for the IL-12p70 ELISA were 40 pg/mL, 20 pg/mL, 10 pg/mL, 5 pg/mL, 
2.5 pg/mL, 1.25 pg/mL and 0.625 pg/mL. After the incubation, each well was washed thoroughly, 
using the Bio-Rad ImmunoWash™ 1575 microplate washer, with the respective wash buffer and 
then the human IFN-γ or IL-12p70 conjugate was added to each well and incubated for 2 hours, 
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followed by another washing step. Substrate solution was then added to each well and after an 
incubation period of 30 minutes (IFN-γ) or 1 hour (IFN-γ) the stop solution was added – prior to 
adding the stopping solution for the IL-12p70 ELISA, an amplifier solution, which allows the 
detection low concentrations of IL-12p70, is added and allowed to incubate for another hour. 
The optical density (OD) of each well was determined within 30 minutes of adding the stop 
solution. OD was measured using the Bio-Rad iMark™ Microplate Reader at 450 nm (570 nm 
correction wavelength) for the IFN-γ ELISA and at 490 nm (670 correction wavelength) for the 
IL-12p70 HS ELISA. 
ELISA Analysis 
Duplicate OD readings were averaged for each standard, control or sample, and the average OD 
of the zero/blank standard was subtracted. A standard curve was generated by plotting the mean 
absorbance for each standard on the y-axis against the concentration on the x-axis. Examples 
of the standard curves generated for the IFN-γ and HS IL-12p70 ELISAs are illustrated in Figures 
3.7 and 3.8, respectively. Quantification of cytokine levels requires comparison with the standard 
curve that was generated, for each ELISA assay, from a non-linear regression model generated 
in MS Excel 365 (Microsoft, USA). 
Concentrations of each cytokine were expressed as pg/mL cytokine produced by the equivalent 
of 105 PBMCs: 
[𝑐𝑦𝑡𝑜𝑘𝑖𝑛𝑒 𝑝𝑟𝑜𝑑𝑢𝑐𝑒𝑑 𝑝𝑒𝑟 105 𝑐𝑒𝑙𝑙𝑠 (𝑝𝑔/𝑚𝐿)  =  
𝑡𝑜𝑡𝑎𝑙 𝑐𝑦𝑡𝑜𝑘𝑖𝑛𝑒 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 (𝑝𝑔/𝑚𝐿) 𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑑 𝑏𝑦 𝐸𝐿𝐼𝑆𝐴
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑝𝑒𝑟 𝑤𝑒𝑙𝑙
 ×  105] 
  
Figure 3.7: Example of standard curve generated for the IFN-γ ELISA using MS Excel 365. 
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Figure 3.8: Example of standard curve generated for the IL-12p70 HS ELISA using MS Excel 365. 
 
3.4. Statistical Analysis 
Data was exported from FlowJo® into Microsoft Excel files and statistical analysis was performed 
using the GraphPad Prism Software for Windows (Version 7.0, GraphPad, CA USA). Normality 
of the data was determined through the D’Agostino-Pearson test. Non-parametric data was not 
normalised. Medians and Interquartile ranges (IQRs) were used to describe the non-parametric 
data. Kruskal Wallis 1-way ANOVA was used, followed by Dunn’s multiple comparison post-test 
to compare the patient and control data for each cell subtype in each assay. Results were 
considered significant when the p-value was less than 0.05 (p<0.05). Spearman’s rank 
correlation analysis was performed to determine whether there are significant correlations 
between cytokine receptor expression and cytokine receptor-related signalling.  
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Chapter 4  Results 
This chapter consists of three sections. The first section (4.1) describes the participants and their 
associated genetic findings. The second section (4.2) describes the optimisation of the flow 
cytometry-based assays. The last section (4.3) describes the results obtained from the flow 
cytometry-based assays as well as the ELISA-based cytokine assays for both the healthy control 
samples and the suspected MSMD patients. 
4.1. Participants 
Sixteen patients with suspected PID with mycobacterial associations were included in this study. 
One additional TB unexposed patient with recurrent Salmonella infections, an infection which has 
previously been described in MSMD patients, was also included in this study. The patients were 
assigned random identifiers (PID01 to PID17).  
4.1.1. Case Reports and Routine Laboratory findings 
Of the 17 patients included in this study, 10 (59%) patients had multiple TB episodes, and 12 
(71%) had disseminated or extrapulmonary TB. Non-tuberculous mycobacterial infections were 
confirmed in only 1 case, PID01 (M.avium), although suspected in PID09 as well. All participants 
received BCG vaccination as infants, although only 1 (PID09) presented with suspected 
BCGosis. None of the participants were HIV exposed. All of the participants were HIV negative 
and none had a family history of PID diagnoses. One of the patients, PID08, had a sibling with a 
similar clinical presentation who had died in infancy. Another patient, PID16, had a history of 
severe TB on the paternal side of the family. Some of the participants had household TB contacts 
from an early age, although most had no known TB contacts in their home environment.  
There was no predominant gender bias amongst the participants, 9 (53%) were male and 8 (47%) 
were female. The participants were ethnically diverse, with 14 patients self-identifying as mixed-
race, and the other 3 were white. Most of the patients had similar socio-economic backgrounds. 
Only 2 of the participants, PID04 and PID09 were referred to TBH Immunology clinic from private 
health care facilities, while the others were all in the public healthcare system. 
QFT-plus was performed for 8 (47%) of the total patients of which 4 (50%) had a negative result 
(PID03, PID08, PID09, and PID12). Three of the 4 patients that had negative QFT-plus results 
have had at least one culture confirmed TB episode, which contradicted the QFT-plus results (TB 
was not successfully cultured for the fourth patient, PID09, who has suspected disseminated 
BCG infection). 
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The clinical presentation and relevant routine laboratory results for all the patients are 
summarised in Table 4.1. 
4.1.2. Genetic Findings 
Plausible disease-causing variants were identified for 11 of the total 17 patients (65%). This 
equates to 11 of  the 12 patients (92%) who were sequenced (either WES plus Sanger or Sanger 
alone). WES identified mutations in 9 patients, whereas Sanger sequencing alone identified 
mutations in 2 patients. Targeted Sanger sequencing alone was only used in cases where a 
variant in a specific gene was highly suspected prior to genetic analysis, such as the IFNGR1 
variant in PID01 and the CYBB variant in PID09, due to it being more cost-effective than WES. 
All variants identified by WES were in turn confirmed by Sanger sequencing. There was one 
patient, PID12, that underwent WES and for whom no plausible disease-causing variant could 
be identified. At the time of conclusion of this study, WES had not yet been performed on 5 of 
the original 17 patients due to funding constraints. 
Variants in known MSMD-associated genes were found in 8 of the 12 sequenced participants 
(67%). This includes variants in IFNGR1, identified for 3 patients (c.G1009A, c.C864G, and 
c.818del4), IL12RB1, in 2 patients (c.G684C and c.G863C), IL12B, in 2 patients (c.A320G and 
c.G863C), and CYBB (c.A302G) in 1 patient. Only 1 of these variants, IFNGR1 c.818del4, has 
been previously described (Al-Muhsen and Casanova 2008; Dorman and Holland 2000), the 
others represent novel variants. The genetic findings and clinical presentation of PID01 (IFNGR1 
c.818del4) has been published (Glanzmann et al. 2018a), although none of the functional 
immune assays in this study have previously been performed. 
Other genetic variants, which are currently not known or described as associated with MSMD but 
could still potentially explain the phenotype, were detected in the other participants. These 
include IKZF1 (c.G1009A), NOD2 (c.C374T), IRAK1 (c.C1939T), IKBKB (c.G2257A), and 
NFKB2 (c.C2042T). 
The genetic findings of each patient are detailed in Table 4.2. 
Functional work was also performed on 2, clinically unaffected, closely related family members. 
One of these was the child of patient PID01, the other was the father of PID02. Both of these 
individuals shared the genetic variant identified in the respective patient to whom they are related. 
. 
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Table 4.1: Clinical information for participants 
Patient Sex Clinical Presentation 
QFT-plus 
result 
Age at first  
presentation Family History? 
Routine Lab results  
(Igs, Compl, Nburst, FBCs & Diff) 
PID01 F 
Concurrent pulmonary TB, TB lymphadenitis and 
recurrent disseminated M.avium infection 
Not performed 6 months No relevant PID history Routine Immunological workup normal 
PID02 F 
Diagnosed with pulmonary TB and TBM (Stage III) at 
age 9.  
Not performed 9 years 
TB exposed (mom). Younger 
sib also developed TBM. 
Routine Immunological workup not done in full. 
All investigations done were normal. 
PID03 F 
Recurrent pulmonary TB (3 episodes), including MDR 
TB, as well as TB lymphadenitis 
Not performed 5 years 
No relevant PID history. 
Household TB contacts (mom) 
High IgA and High IgM (raised less than 2 SD) 
PID04 M 
Chronic mucoid diarrhoea since 3 weeks of age. 
Recurrent Salmonella type C infections. 
Not performed 3 weeks 
No relevant PID history. No 
known household TB contacts. 
Autoimmune investigation normal, and no 
identifiable atopy/food intolerance. All routine lab 
investigations normal. 
PID05 M 
Recurrent pulmonary TB - 4 culture confirmed cases, 
each more than 1 year apart. Previously diagnosed with 
Goldberg-Shprintzen Syndrome. 
Positive 9 months No relevant PID history 
Routine Immunological workup not done in full. 
All investigations done were normal. 
PID06 M 
Unusual extrapulmonary TB with spine and liver 
involvement.  
Not performed 11 years 
No relevant PID history. 
Household TB contacts. 
Anaemia, raised IgG and IgA, raised CD19 cells, 
normal neutrophil burst 
PID07 M 
Recurrent TB lymphadenitis requiring prolonged 
duration of treatment. 
Positive 3 years No relevant PID history 
Routine Immunological workup not done in full. 
All investigations done were normal. 
PID08 F Miliary TB and TB lymphadenitis. Negative 1 year 
Sibling died early in childhood, 
with similar clinical 
presentation 
Anaemia. Routine Immunological workup not 
done in full. All investigations done were normal. 
PID09 M 
Disseminated Mycobacterium complex disease, 
suspected to be BCG.  
Negative 6 months No relevant PID history 
Non-responsive neutrophil burst, compatible with 
CGD diagnosis. CYBB gene Sanger Sequenced. 
All other routine immunological workup normal.  
PID10 F 
Recurrent TB of the liver (6+ episodes). Shortly after 
end of treatment, TB reactivates, and patient needs to 
restart treatment. The most recent TB episode was 
MDR TB. 
Not performed 
1 year 
No relevant PID history. MDR 
TB household contact. 
Routine Immunological workup normal 
PID11 M 
Recurrent TB. First episode was miliary TB and 6 
months after end of treatment presented with TBM. 
Second TBM episode (Stage II) 8 months after 
completion of TB treatment for previous episode. 
Not performed 3 months No relevant PID history Routine Immunological workup normal 
PID12 F 
This patient had a new-born that was diagnosed with 
TB. Upon investigation it was revealed that she (the 
mother) has had 6 suspected, although 4 confirmed, 
and treated episodes of pulmonary TB. 
Negative 15 years No relevant PID history Routine Immunological workup normal 
PID13 M Recurrent TB abscess of anterior chest wall Positive 2 years 
No relevant PID history. 
Household TB contacts 
Routine Immunological workup normal 
PID14 M 
Septic arthritis and miliary TB, which progressed to 
TBM and eventual MDR TB regime 
Not performed 
11 months No relevant PID history Anaemia. Routine Immunological workup normal 
PID15 F Unusual TBM diagnosis in 9-year-old Not performed 9 years No relevant PID history Routine Immunological workup normal 
PID16 F Recurrent TB, with hip involvement, and MDR TB. Positive unknown No relevant PID history Routine Immunological workup normal 
PID17 M Recurrent TB (4 episodes), including MDR TB. Positive 6 months 
History of severe& recurrent 
TB on paternal side 
Routine Immunological workup normal 
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Table 4.2: Genetic results for suspected MSMD patients.  
Patient 
WES 
performed? 
WES Result- Gene(s) & Variant(s) Zygosity Sanger Confirmed/ Sanger Only? 
In silico predicted effect 
of identified variant 
PID01 No IFNGR1 (c.818del4) Heterozygous Sanger only Pathogenic 
PID02 Yes IFNGR1 (c.C864G p.I288M) Heterozygous Sanger confirmed Pathogenic 
  NOD2 (c.C374T p.P125L) Heterozygous Sanger confirmed Pathogenic 
PID03 Yes IKZF1 (c.G1009A p.G337S) Homozygous Sanger confirmed Pathogenic 
  IFNGR1 (c.698C>T p.G233A) Heterozygous Sanger confirmed Pathogenic 
PID04 Yes IL12RB1 (c.G684C p.R213Q) Homozygous Sanger confirmed Pathogenic 
PID05 Yes IL12RB1 (c.C139T p.P47S) Homozygous Sanger confirmed Likely pathogenic 
PID06 Yes IL12B (c.A320G p.K107R) Heterozygous Sanger confirmed Pathogenic 
  NFKB2 (c.C2042T p.P681L) Heterozygous Sanger confirmed Likely pathogenic 
PID07 Yes IL12B (c.G863C p.R288T) Homozygous Sanger confirmed Pathogenic 
PID08 Yes IFNGR2 (c.A708T p.E236D) Homozygous Sanger confirmed Pathogenic 
PID09 No CYBB (c. A302G p.H101R) Hemizygous Sanger only Pathogenic 
PID10 Yes IKBKB (c.G2257A p.A753T) Homozygous Sanger confirmed Likely pathogenic 
  NFKB2 (c.C2042T p.P681L) Heterozygous Sanger confirmed Likely pathogenic 
PID11 Yes IRAK1 (c.C1939T p.L647P) Homozygous Sanger confirmed Pathogenic 
PID12 Yes No result N/A N/A N/A 
PID13 No N/A N/A N/A N/A 
PID14 No N/A N/A N/A N/A 
PID15 No N/A N/A N/A N/A 
PID16 No N/A N/A N/A N/A 
PID17 No N/A N/A N/A N/A 
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4.2. Optimisation of the flow cytometry assays 
4.2.1. Receptor Panel 
PHA stimulation and its effect on CD212 (IL-12Rβ2) and CD119 (IFN-γR1) expression 
PHA (5 µg/mL) stimulation for 24 hours prior to staining, increased CD212 receptor expression on 
the surfaces of all lymphocyte subsets (Figure 4.1). Longer, 48-hour PHA stimulation only minimally 
further increased CD212 expression compared to 24-hour stimulation. CD119 expression on 
monocytes, on the other hand, decreased after 24 and 48-hour PHA stimulation prior to staining. A 
substantial reduction in CD119 detection was observed in 24-hour PHA stimulation, which 
moderated slightly after 48-hour stimulation. Therefore, in subsequent experiments, PBMCs were 
pre-stimulated for 24 hours with 5 µg/mL PHA prior to assessment of CD212 expression while 
CD119 expression was only assessed on unstimulated PBMCs.  
  
Figure 4.1: The effect of PHA stimulation on CD212 and CD119 expression. Expression of CD212 is 
upregulated with PHA (5 µg/mL) stimulation. 48-hour PHA stimulation does not appear to significantly 
enhance CD212 expression compared to 24-hour stimulation. CD119 detection is greater in unstimulated 
samples compared to 24 and 48-hour PHA stimulation. CD212 expression on CD56+ (NK) cells show a 1.43-
fold increase in expression (MFIstim / MFIunstim) with 24-hour PHA stimulation (with other lymphocyte 
subsets showing similar trends), whilst CD119 expression on CD14+ monocytes showed a 2.36-fold decrease 
in expression with 24-hour PHA stimulation. 
Stellenbosch University  https://scholar.sun.ac.za
57 
 
4.2.2. Phosflow Panel 
Permeabilisation buffers 
Both BD Biosciences Perm III and Perm IV (1X) reduced the signal-to-noise ratio for each of the 
surface antibodies compared to a regular staining procedure without fixation or permeabilisation 
steps. Histogram overlays in Figure 4.2 illustrate the loss-of-signal effect that the permeabilisation 
buffers had on the detection of surface markers compared to regular staining. Overall, Perm III 
resulted in a greater loss of signal than Perm IV.  
 
Figure 4.2: Effect of permeabilisation buffers on the detection of surface markers. Both Perm III and 
Perm IV resulted in decreased detection of surface markers compared to regular surface staining without 
fixation or permeabilisation. Only CD3-FITC, CD4-APC, CD8-PE, and CD14-PE-Cy7 are shown here, 
although the same trend was observed in other cell subsets. Perm IV resulted in a less dramatic loss-of-signal 
for all the surface markers. 
 
Stellenbosch University  https://scholar.sun.ac.za
58 
 
In PBMCs stimulated with 100ng/mL of IL-12 and IFN-γ, the fold change in pSTAT detection 
(
MFI of stimulated sample
MFI of unstimulated sample
) was similar overall for both permeabilisation buffers, although Perm IV had 
a slightly higher pSTAT fold change than Perm III (Figure 4.3). pSTAT1 detection was slightly better 
with Perm IV than Perm III. With Perm IV, there was better shift in pSTAT1 detection in the cytokine-
stimulated sample from the unstimulated sample compared to Perm III (i.e. fold change in pSTAT1 
was higher for Perm IV). Fold change in pSTAT4 was also higher with Perm IV as compared to 
Perm III. 
 
Figure 4.3: Effect of permeabilisation buffers on pSTAT detection. Both pSTAT1 and pSTAT4 fold 
changes were higher for Perm IV (1X) than Perm III, indicating that Perm IV was the superior buffer for the 
detection of pSTATs. Fold change in pSTAT = 
𝑀𝐹𝐼 𝑜𝑓 𝑠𝑡𝑖𝑚𝑢𝑙𝑎𝑡𝑒𝑑 𝑠𝑎𝑚𝑝𝑙𝑒
𝑀𝐹𝐼 𝑜𝑓 𝑢𝑛𝑠𝑡𝑖𝑚𝑢𝑙𝑎𝑡𝑒𝑑 𝑠𝑎𝑚𝑝𝑙𝑒
. 
 
Perm IV, rather than Perm III, was used as permeabilisation buffer for all subsequent experiments 
due to the less dramatic impact on surface marker fluorescence and superior detection of pSTATs. 
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Cytokine dosage effect of pSTAT detection 
There was not much variation in pSTAT1 and pSTAT4 fold changes for the varying concentrations 
of cytokine stimuli used (Figure 4.4).  
 
Figure 4.4: Cytokine dosage effect on pSTAT detection. PBMC were stimulated with either 10, 50, 100, 
150, and 200 ng/mL IFN-γ for pSTAT1 detection in lymphocytes or with 10, 50, 100, 150, and 200 ng/mL IL-12 
for the detection of pSTAT4 in lymphocytes. Data shown for CD14+ monocytes (pSTAT1) and CD56+ (NK) 
cells (pSTAT4); Similar effects were observed in other cell subsets.  
Fold change in pSTAT = 
𝑀𝐹𝐼 𝑜𝑓 𝑠𝑡𝑖𝑚𝑢𝑙𝑎𝑡𝑒𝑑 𝑠𝑎𝑚𝑝𝑙𝑒
𝑀𝐹𝐼 𝑜𝑓 𝑢𝑛𝑠𝑡𝑖𝑚𝑢𝑙𝑎𝑡𝑒𝑑 𝑠𝑎𝑚𝑝𝑙𝑒
  (pSTAT1 stimulus = IFN-γ, pSTAT4 stimulus = IL-12). 
 
Due to there not being any significant differences in pSTAT detection with the varying concentrations 
used for stimulation, the intermediate concentration (100 ng/mL) was used for both IL-12 and IFN-γ 
stimulation in subsequent experiments. 
 
PHA stimulation and pSTAT4 detection 
Stimulation of PBMCs with PHA (5 µg/mL) for 24 hours prior to the Phosflow protocol increased 
pSTAT4 detection in lymphocytes after IL-12 stimulation compared to PBMCs that were not pre-
stimulated with PHA. There was little to no pSTAT4 signal in the cells that were not pre-stimulated 
with PHA and there was a more prominent shift in pSTAT4 signal for PHA pre-stimulated PBMCs 
as can be seen in Figure 4.5. This experiment was only performed using Perm IV as the 
permeabilisation buffer, due to it being the ‘better’ buffer for pSTAT detection, with minimal loss of 
surface marker detection, as determined in the previous experiments. 
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Figure 4.5: pSTAT4 detection without vs. with PHA pre-stimulation. pSTAT4 detection was enhanced in 
lymphocytes [CD56+ (NK) cells and CD4-CD8- T cells (γδ T cells) cells shown here, although the same trend 
was observed in other subsets] that were pre-stimulated with PHA for 24 hours. There is a second, distinctly 
positive peak for pSTAT4 in the IL-12 (100 ng/mL) stimulated sample for the PHA stimulated cells. Fold 
change in pSTAT = 
𝑀𝐹𝐼 𝑜𝑓 𝑠𝑡𝑖𝑚𝑢𝑙𝑎𝑡𝑒𝑑 𝑠𝑎𝑚𝑝𝑙𝑒
𝑀𝐹𝐼 𝑜𝑓 𝑢𝑛𝑠𝑡𝑖𝑚𝑢𝑙𝑎𝑡𝑒𝑑 𝑠𝑎𝑚𝑝𝑙𝑒
  (pSTAT1 stimulus = IFN-γ, pSTAT4 stimulus = IL-12). 
4.3. Implementation of the assays 
4.3.1. Establishment of normal expression range in control non-PID 
donor samples 
PBMCs for 10, reportedly healthy, non-PID adult laboratory volunteers were used for each of the 
assays.  
For all subsequent data, CD212 (IL-12Rβ1) data is from PHA pre-stimulated PBMCs whereas 
CD119 (IFN-γR1) data is from unstimulated PBMCs. 
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Receptor Panel 
CD119 expression was highest on CD14+ monocytes and CD19+ (B) cells, with median percentage 
positive cells of 77.2% (IQR: 56.75-83.15%) and 76.75% (IQR: 68.23-80.83%) respectively. The 
IFNγR1 receptor density per cell, i.e. CD119 MFI, for CD14+ monocytes and CD19+ (B) 
lymphocytes had IQRs of 625-790 (median 723) and 98-130 (median 118), respectively. CD119 
had overall lower percentage expression on non-B lymphocyte subsets, such as CD3+ (T) cells and 
CD56+ (NK) cells, with medians ranging between 20.30% and 45.75%. IFNγR1 receptor density 
(MFI) was lower on lymphocyte subsets compared to monocytes, for instance CD56+ (NK) cells and 
CD3+ CD4-CD8- (primarily γδ T cells; Bluestone et al. 1988) had CD119 MFI IQRs of 51-66 (median 
58) and 59-98 (median 74) respectively. According to Dunn’s multiple comparison, the percentage 
CD119 expression on both CD14+ monocytes and CD19+ B cells were significantly higher than T 
lymphocytes, i.e. Total CD3+ (p<0.0001), CD4+ (p<0.0001), CD8+ (p<0.0001), CD4-CD8- (p<0.01). 
High CD212 expression was consistently observed across all lymphocyte subsets. CD56+ (NK), 
CD3+CD56+ (NKT), CD8+ T cells and CD4-CD8- (γδ) T cells had the highest percentage of CD212 
positive cells with medians of 91.6% (IQR: 89.53-95.30%), 87.00% (IQR: 83.83-92.18%), 88.35% 
(IQR: 77.88-91.55%), and 86.10% (IQR: 82.13-91.15%), respectively. A lower percentage of 
monocytes (CD14+) were CD212 positive, as compared to the lymphocyte subsets (median: 51.90; 
IQR: 23.88-60.25%). As with CD119 expression on lymphocyte subsets, CD212 expression levels 
appear to be well-conserved in lymphocytes and they generally had a smaller range of variance 
than monocytes (as seen in standard deviations). Despite lower percentage expression, the 
IL12Rβ1 receptor density per cell was higher for CD14+ monocytes (IQR 1281-1763) compared to 
all lymphocyte subsets (CD56+ IQR: 595-786; CD3+CD56+ IQR: 465-661; CD8+ IQR: 284-474; 
CD4-CD8- IQR: 333-485). According to Dunn’s multiple comparison, percentage CD212 
expression, compared to CD14+ monocytes, was significantly higher for CD56+ NK (p<0.0001), 
CD3+CD56+ NKT (p=0.0008), CD8+ (p=0.0029) and CD4-CD8- cells (p=0.0036). 
Descriptive statistics for CD119 and CD212 expression for controls on various cell subsets can be 
found in Table 4.3. Box-and-whiskers graphs in Figures 4.6 and 4.7 show the distribution of the 
receptor percentage expression data from the controls. CD119 expression was assessed on 
unstimulated cells, while CD212 expression was measured after 24 hours stimulation with PHA 
(5 µg/mL), as described in section 3.2.5. 
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Table 4.3: Descriptive statistics for CD119 (IFNγR1) and CD212 (IL12Rβ1) percentage expression and 
receptor density (MFI) for controls on various cell subsets. The IQR of the control data was used as the 
‘normal’ range against which patient data could be compared. 
 Percentage CD119 
expression 
Median (IQR) 
CD119 MFI 
Median (IQR) 
Percentage CD212 
expression 
Median (IQR) 
CD212 MFI 
Median (IQR) 
FSC/SSC Monocytes 47.80 (40.8 – 62.60) 376 (310 – 474) 40.20 (28.78 – 52.03) 1465 (1281 – 1763) 
CD14+ Monocytes 77.20 (56.75 – 83.15) 723 (625 – 790) 51.90 (23.88 – 60.25) 2153 (1446 – 2450) 
FSC/SSC 
Lymphocytes 
29.90 (26.03 – 35.08) 82 (71 – 87) 83.30 (72.50 – 86.55) 344 (239 – 427) 
CD56+ (NK) Cells 45.75 (39.33 – 49.90) 58 (51 – 66) 91.60 (89.53 – 95.30) 669 (595 – 786) 
CD3+CD56+ (NKT) 
Cells 
38.00 (30.98 – 47.18) 112 (96 – 119) 87.00 (83.83 – 92.18) 560 (465 – 661) 
CD3+ (T) Cells 22.55 (24.25 – 27.13) 84 (72 – 88) 83.70 (70.53 – 86.28) 324 (202 – 391) 
CD4+ T Cells 
(Helper T cells) 
20.30 (19.23 – 24.58) 75 (67 – 79) 78.60 (62.70 – 81.53) 277 (168 – 361) 
CD8+ T Cells 
(Cytotoxic T cells) 
23.35 (20.78 – 27.73) 109 (103 – 120) 88.35 (77.88 – 91.55) 424 (284 – 474) 
CD4-CD8- T Cells 
(primarily γδ T cells) 
28.75 (24.50 – 41.98) 74 (59 – 98) 86.10 (82.13 – 91.15) 417 (333 – 485) 
CD19+ (B) Cells 76.75 (68.23 – 80.83) 118 (98 – 130) 82.70 (72.58 – 86.98) 273 (183 – 354) 
 
 
Figure 4.6: Box-and-whisker plot showing the distribution of CD119 (IFNγR1) expression on various 
cell subsets for controls (n = 10). CD119 expression was highest on CD14+ monocytes and CD19+ (B) 
lymphocytes. CD119 expression was measured on unstimulated PBMCs. The box-and-whisker plot shows 
the 10th to 90th percentile of the data. The rectangular part of the box-plot represents the IQR of the data, with 
the line in the middle representing the median. Outliers are shown as dots. 
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Figure 4.7: Box-and-whiskers plot showing the distribution of CD212 (IL12Rβ1) expression on various 
cell subsets for controls (n=10). CD56+ (NK), CD3+CD56+ (NKT), CD8+ T cells and CD4-CD8- (γδ) T cells 
had the highest percentage of CD212 positive cells. Monocytes had much lower levels of expression 
compared to the lymphocyte subsets, which all had median CD212 expression levels of 78.60% or higher. 
CD212 expression was measured on PHA pre-stimulated PBMCs. The box-and-whisker plot shows the 10th 
to 90th percentile of the data. The rectangular part of the box-plot represents the IQR of the data, with the line 
in the middle representing the median. Outliers are shown as dots. 
 
Signalling Panel 
The fold change in pSTAT1 (i.e. 
𝑝𝑆𝑇𝐴𝑇1 𝑀𝐹𝐼 𝐼𝐹𝑁−𝛾 𝑠𝑡𝑖𝑚𝑢𝑙𝑎𝑡𝑒𝑑 
𝑝𝑆𝑇𝐴𝑇1 𝑀𝐹𝐼 𝑢𝑛𝑠𝑡𝑖𝑚𝑢𝑙𝑎𝑡𝑒𝑑
) was highest for CD14+ monocytes and 
CD20+ (B) cells, with medians of 1.60 (IQR: 1.39-2.05) and 1.63 (IQR: 1.28-1.81) respectively. The 
pSTAT1 fold change was lowest in CD56+ (NK) cells (1.16). CD56+ (NK) cells, CD8+ T cells, and 
CD4-CD8- (γδ) T cells had the highest fold change in pSTAT4 (i.e. 
𝑝𝑆𝑇𝐴𝑇4 𝑀𝐹𝐼 𝐼𝐿−12 𝑠𝑡𝑖𝑚𝑢𝑙𝑎𝑡𝑒𝑑 
𝑝𝑆𝑇𝐴𝑇4 𝑀𝐹𝐼 𝑢𝑛𝑠𝑡𝑖𝑚𝑢𝑙𝑎𝑡𝑒𝑑
), with 
medians of 2.31 (IQR: 2.04-2.75), 1.71 (IQR: 1.33-2.19) and 1.95 (IQR: 1.41-2.74) respectively. 
According to Dunn’s multiple comparisons, fold changes in pSTAT1 did not differ significantly 
between the various cell subsets (p>0.05). Fold changes in pSTAT4 also showed no significant 
differences between the monocyte and lymphocyte subsets, although the fold change in CD56+ NK 
cells were significantly higher compared to CD4+ T cells (p=0.0047) and CD20+ B cells (p=0.0011). 
Descriptive statistics for fold changes in pSTAT1 and pSTAT4 for controls in various cell subsets 
can be found in Table 4.4. Box-and-whisker plots in Figures 4.8 and 4.9 show the distribution of the 
receptor expression data from the controls for CD119 and CD212 respectively. PBMCs were 
stimulated with IFN-γ (100 ng/mL) prior to pSTAT1 detection. For the detection of pSTAT4, PBMCs 
were pre-stimulated for 16-18 hours with PHA (5 µg/mL), followed by stimulation with IL-12 
(100 ng/mL), as described in section 3.2.5. 
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Table 4.4: Descriptive statistics of fold changes in pSTAT1 (i.e. IFN-γ signalling) and pSTAT4 (i.e. IL-12 
signalling) for controls on various cell subsets. Fold change in pSTAT = 
 𝑀𝐹𝐼 𝑐𝑦𝑡𝑜𝑘𝑖𝑛𝑒 𝑠𝑡𝑖𝑚𝑢𝑙𝑎𝑡𝑒𝑑 
𝑀𝐹𝐼 𝑢𝑛𝑠𝑡𝑖𝑚𝑢𝑙𝑎𝑡𝑒𝑑
. The IQR of 
the control data was used as the ‘normal’ range against which patient data could be compared. 
 Fold change in pSTAT1 
Median (IQR) 
Fold change in pSTAT4 
Median (IQR) 
FSC vs. SSC Monocytes 1.29 (0.97 – 1.75) 1.81 (1.53 – 2.07) 
CD14+ Monocytes 1.60 (1.39 – 2.05) 1.94 (1.38 – 2.12) 
FSC vs. SSC 
Lymphocytes 
1.58 (1.16 – 1.86) 1.51 (1.19 – 1.58) 
CD56+ (NK) cells 1.16 (0.89 – 1.34) 2.31 (2.04 – 2.75) 
CD3+CD56+ (NKT) cells 1.51 (1.17 – 1.83) 1.52 (1.23 – 1.73) 
CD3 (T) Cells 1.60 (1.20 – 1.98) 1.47 (1.20 – 1.65) 
CD4+ T cells 
(Helper T cells) 
1.53 (1.23 – 2.10) 1.36 (1.18 – 1.46) 
CD8+ T cells 
(Cytotoxic T cells) 
1.55 (1.17 – 1.82) 1.71 (1.33 – 2.19) 
CD4-CD8- T cells 
(primarily γδ T cells) 
1.42 (0.96 – 2.33) 1.95 (1.41 – 2.74) 
CD20+ (B) cells 1.63 (1.28 – 1.81) 1.24 (0.98 – 1.53) 
 
 
Figure 4.8: Box-and-whiskers plot showing the distribution of fold changes in pSTAT1 (i.e. IFN-γ 
signalling) in various cell subsets for controls (n=10). Fold change in pSTAT1 was highest for CD14+ 
monocytes and CD20+ (B) cells, although it was not much lower for other lymphocyte subsets. The box-and-
whisker plot shows the 10th to 90th percentile of the data. The rectangular part of the box-plot represents the 
IQR of the data, with the line in the middle representing the median. Outliers are shown as dots. 
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Figure 4.9: Box-and-whiskers plot showing the distribution of fold changes in pSTAT4 (i.e. IL-12 
signalling) in various cell subsets for controls (n=10). Fold change in pSTAT4 was highest in CD56+ (NK), 
CD8+ T cells and CD4-CD8- (γδ) T cells. The box-and-whisker plot shows the 10th to 90th percentile of the 
data. The rectangular part of the box-plot represents the IQR of the data, with the line in the middle 
representing the median. Outliers are shown as dots. 
Correlation between cytokine receptor expression and phosphorylation of the receptor-
associated signalling molecule  
There was a significant positive correlation between IL12Rβ1 expression and fold changes in 
pSTAT4 (p=0.0097; r = 0.3048). There was, however, no correlation between IFN-γR1 expression 
levels and fold changes in pSTAT1 (p=0.4; r=0.08108). Figure 4.10A and 4.10B show the correlation 
of receptor expression and signalling. 
 
Figure 4.10: Scatter plots showing correlations of receptor expression and fold change in pSTAT. A. 
IL12Rβ1 expression levels correlated with fold changes in pSTAT4 detection (p=0.0079; r=0.3048). The red 
line through the plot is a linear regression line with error bars (dotted lines). B. There was no correlation 
between IFNGR1 expression and fold changes in pSTAT1 detection (p=0.4; r=0.8108). 
Cytokine Release Assay 
Cytokine-induced cytokine production 
Stimulation of PBMCs with PHA only resulted in IFN-γ production (median: 167.50 pg/mL per 105 
cells; IQR: 57.03-658.20 pg/mL), with very little to no IL-12 production (median: 0.26 pg/mL per 105 
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cells; IQR: 0.13-1.69 pg/mL). Co-stimulation with IL-12 resulted in significantly higher levels of IFN-γ 
production (median: 506.00 pg/mL per 105 cells; IQR: 454.40-692.90 pg/mL; p=0.0004; Figure 
4.11A) and similarly, co-stimulation with IFN-γ significantly enhanced IL-12 production (median: 
17.79 pg/mL per 105 cells; IQR: 11.22-19.42 pg/mL; p<0.0001; Figure 4.11B). Descriptive statistics 
for the induced-cytokine production assays can be found in Table 4.5. 
Table 4.5: Descriptive statistics for the cytokine-induced cytokine production assays for the controls. 
The IQR of the control data was used as the ‘normal’ range against which patient data could be compared. 
IFN-γ production assay: IL-12 production assay: 
 
IFN-γ production (pg/mL) 
Median (IQR)  
IL-12 production (pg/mL) 
Median (IQR) 
PHA 167.50 (57.03 – 658.20) PHA 0.26 (0.13 – 1.69) 
PHA + IL-12 506.00 (454.40 – 692.90) PHA + IFN-γ 17.79 (11.22 – 19.42) 
Net IL-12-induced IFN-γ 
production 
390.00 (176.10 – 443.60) 
Net IFN-γ-induced IL-12 
production 
17.06 (11.08 – 18.02) 
 
 
Figure 4.11: Box-and-whisker plot showing the distribution of the data for the cytokine production 
assays for the controls (n=10). A. IFN-γ production following stimulation with PHA or PHA and IL-12. IL-12 
co-stimulation significantly increased IFN-γ production (p=0.0004); B.IL-12 production following stimulation 
with PHA or PHA and IFN-γ. IFN-γ significantly enhanced IL-12 production (p<0.0001). The box-and-whisker 
plot shows the 10th to 90th percentile of the data. The rectangular part of the box-plot represents the IQR of 
the data, with the line in the middle representing the median. Outliers are shown as dots. 
 
Baseline IFN-γ levels  
The baseline IFN-γ levels present in the blood plasma of controls were all below the minimum 
detectable concentration of 15.6 pg/mL. Therefore, any detectable IFN-γ in plasma of patient 
samples could be considered abnormal. 
 
4.3.2. Patient assay results 
Although a wide range of plausible disease-causing variants were found in the patient group, all 
suspected MSMD patients’ functional data was grouped and compared to the control group in order 
to determine whether any generalized differences could be observed. 
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When assessing the full cohort of suspected MSMD patients as a group (n = 19; 17 patients plus 2 
family members) as compared to controls (n = 10), CD119 expression was essentially similar, 
however the patients had larger ranges of expression (Figure 4.12A). As with CD119, CD212 
expression was similar overall for controls and patients, with patients again showing larger ranges 
for expression (Figure 4.12B). Dunn’s multiple comparison tests revealed that there were no 
significant differences between patient and control receptor expression on any of the various cell 
subsets assessed (with p≥0.5 for most subsets). The difference in CD212 percentage expression 
between patients and controls on the CD4-CD8- (γδ) T lymphocyte subset was approaching 
significance (p=0.0753). 
Fold changes in pSTATs were similar overall for patients and controls, although the patient group 
had much larger ranges. Dunn’s multiple comparison tests revealed that there was no difference 
between the controls and patients for both pSTAT1 and pSTAT4 fold changes in any of the various 
cell subsets. Box-and-whiskers plots comparing the fold change in pSTAT in controls and patients 
can be found in Figure 4.13. 
There were no significant differences in IL-12-induced IFN-γ production or IFN-γ-induced IL-12 
production between controls and patients (p = 0.7950 and p = 0.5087 respectively). There are, 
however, several patients that fall outside of the ‘normal’ IQR of the controls, which can be clearly 
observed in Figure 4.14. There appears to be clustering of high and low IL-12 producing sub-groups 
in the patient cohort. 
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Figure 4.12: Comparison of distribution of cytokine receptor expression levels for controls and 
patients. A. CD119, i.e. IFN-γR1, percentage expression on unstimulated PBMCs for controls and patients 
on various cell subsets; B. CD212, i.e. IL-12Rβ1, percentage expression on PHA pre-stimulated PBMCs for 
controls and patients on various cell subsets. The box-and-whisker plot shows the 10th to 90th percentile of 
the data. The rectangular part of the box-plot represents the IQR of the data, with the line in the middle 
representing the median. Outliers are shown as dots. 
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Figure 4.13: Comparison of distribution of fold changes in pSTATs for controls and patients. A. Fold 
change in pSTAT1, i.e. IFN-γ signalling, for controls and patients in various cell subsets. pSTAT1 was 
measured for both unstimulated and IFN-γ (100ng/mL) stimulated PBMCs; B. Fold change in pSTAT4, i.e. 
IL-12 signalling, for controls and patients in various cell subsets. pSTAT4 was measured on PHA pre-
stimulated PBMCs that were then either left unstimulated or stimulated with IL-12 (100 ng/mL). The box-and-
whisker plot shows the 10th to 90th percentile of the data. The rectangular part of the box-plot represents the 
IQR of the data, with the line in the middle representing the median. Outliers are shown as dots. 
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Figure 4.14: Comparison of distribution of cytokine-induced cytokine production for controls and 
patients. A. IL-12-induced IFN-γ production. The patient group has a larger range, with several patients falling 
outside the IQR of the control group; B. IFN-γ-induced IL-12 production. Several patients fall outside the 
control IQR, with an apparent clustering of high and low IL-12 producers. The box-and-whisker plot shows the 
10th to 90th percentile of the data. The rectangular part of the box-plot represents the IQR of the data, with the 
line in the middle representing the median. Outliers are shown as dots. 
 
Case-by-case results 
Composite data sets for IFN-γR1 and IL-12Rβ1 percentage positive and receptor density (MFI) 
expression, fold changes in pSTAT1 and pSTAT4 detection, as well as the IL-12-induced IFN-γ and 
IFN-γ-induced IL-12 production results for each patient can be found in Appendix E. A short 
summary of the functional data for the major cell subsets for each patient can be found in Table 4.6 
on page 85. 
 
PID01 - IFNGR1 (c.818del4) 
PID01 had very high levels, above 95.40%, CD119 expression across all cell subsets. IFN-γR1 
density was also very high across all cell subsets, with an MFI of 5451 on CD14+ monocytes and 
an MFI of 707 on CD19+ (B) cells, which is significantly higher than the controls. Contrastingly, fold 
change in pSTAT1 was lower than the normal ranges for CD14+ monocytes, as well as for various 
lymphocyte subsets including CD3+CD56+ (NKT) cells, total CD3+ T cells, CD4+, CD8+, CD4-CD8- 
(γδ) T cells and CD20+ (B) cells. This enhanced expression and decreased signalling was also 
observed for the patients’ child. PID01 also had decreased CD212 percentage expression on 
CD56+ (NK), CD3+CD56+ (NKT) and CD4-CD8- T cells. Fold change in pSTAT4 was normal for 
most cell subsets although slightly increased on CD20+ (B) cells. PID01’s child also displayed 
similar CD212 expression and signalling. 
PID01 had normal levels of IFN-γ production in response to IL-12 stimulation, although there was 
no IL-12 produced in response to IFN-γ stimulation. The same cytokine responses were observed 
in PID01’s child. A graphical summary of the functional results for PID01 and their child can be found 
in Figure 4.15. 
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Figure 4.15: Summary of functional results for PID01 and their clinically unaffected child. A. Very high 
levels of CD119 expression was observed across all cell subsets for both PID01 and their child (only FSC vs. 
SSC monocytes and CD14+ monocytes shown). Fold change in pSTAT1 was below the normal range for both 
PID01 and their child for CD14+ monocytes; B. There was very little to no IL-12 production induced by IFN-γ 
stimulation in both individuals. 
 
PID02 - IFNGR1 (c.C864G) & NOD2 (c.C374T) 
PID02 had normal levels of CD119 and CD212 percentage expression for most cell subsets. CD119 
was slightly below normal on CD56+ (NK) cells and slightly above the normal range on CD4+T cells 
and CD19+ (B) cells. Although PID02 had normal CD119 percentage expression on CD14+ 
monocytes, the receptor density was much higher than the controls (CD119 MFI: 1175).  In contrast, 
the parent of PID02 with the same variant in IFNGR1 had lower percentage CD119 expression on 
CD14+ monocytes compared to the patient, although receptor density was within the normal range 
(CD119 MFI: 702). PID02’s fold change in pSTAT1 was below the normal range for CD14+ 
monocytes although it was within normal ranges their unaffected parent. pSTAT1 fold changes were 
higher in the unaffected parent compared to the patient for all cell subsets. 
PID02 and their parent both had normal levels of CD212 expression, although they showed lower 
than normal fold changes in pSTAT4 in CD56+ (NK) cells. 
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PID02 and their unaffected parent both produced higher than normal levels of IFN-γ in response to 
IL-12 stimulation, with PID02’s IFN-γ production being approximately 2.5 times higher than their 
unaffected parent (1451.80 pg/mL per 105 IFN-γ produced by PID02 vs 538.96 pg/mL per 105 IFN-γ 
produced by unaffected parent). IL-12 production in response to IFN-γ stimulation was within normal 
ranges. A graphical summary of the functional results for PID02 and their unaffected parent can be 
found in Figure 4.16. 
 
 
Figure 4.16: Summary of functional results for PID02 and their clinically unaffected parent. A. CD119 
expression and fold changes in pSTAT1 for CD14+ monocytes were within the normal ranges, although there 
was a difference between parent and child for both receptor expression (CD119 expression is lower in the 
unaffected parent) and signalling (fold change in pSTAT1 is higher for the unaffected parent). B. CD212 
expression was normal for both PID02 and their parent, and fold changes in pSTAT4 was below normal in 
CD56+ (NK) cells for both individuals. C. IFN-γ overproduction in response to IL-12 stimulation was observed 
for both PID02 and their parent. IL-12 production was normal. 
PID03 - IKZF1 (c.G1009A) & IFNGR1 (c.C698T) 
PID03 had lower than normal CD119 percentage expression on CD14+ Monocytes (51.5%), 
although the receptor density was higher than normal on the same subset (CD119 MFI: 588). Fold 
changes in pSTAT1 was within the normal range for all cell subsets.  
CD212 expression for PID03 was low on CD14+ monocytes (23.2%; MFI: 1198), CD56+ (NK) cells 
(84.1%; MFI: 448), CD3+CD56+ (NKT) cells (83.0%; MFI: 373), and CD4-CD8- T cells (78.3%; 
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MFI:  252). Fold changes in pSTAT4 were lower than the normal ranges for all subsets except for 
CD8+ T cells and CD20+ (B) cells, which was normal.  
PID03 produced higher than normal concentrations of levels of IL-12 in response to PHA stimulation 
and the net IFN-γ-induced IL-12 production levels were also elevated. IFN-γ production in response 
to IL-12 stimulation was slightly lower than the normal control ranges. A graphical summary of the 
functional results for PID03 can be found in Figure 4.17. 
 
Figure 4.17: Summary of functional results for PID03. A. CD119 expression was lower than normal on 
CD14+ monocytes, although the fold change in pSTAT1 was within the normal range; B. CD212 expression 
was low on CD56+ (NK) cells and CD3+CD56+ (NKT) cells, and pSTAT4 fold changes were also below the 
normal range for both subsets; C. Higher than normal levels of and IL-12 was produced upon PHA stimulation 
and IFN-γ co-stimulation. The net IL-12-induced IFN-γ production was slightly below the normal range. 
 
PID04 - IL12RB1 (c.G684C) 
PID04 had normal levels of CD119 percentage expression on most cell subsets, although the 
receptor density was very high on CD14+ monocytes (CD119 MFI: 917). Fold changes in pSTAT1 
were much higher than normal for CD14+ monocytes, CD56+ (NK) cells and CD20+ (B) cells. 
PID04 had decreased expression of CD212 on all lymphocyte subsets, except for CD4+ T cells, 
which was normal. IL12Rβ1 receptor density was also decreased for all lymphocyte subsets but 
CD4+ T cells. In contrast to the reduced CD212 expression, fold changes in pSTAT4 were very high 
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for all lymphocyte subsets. pSTAT4 fold changes were highest in CD56+ (NK) cells (9.21), CD8+ T 
cells (4.95), CD4-CD8- T cells (3.62), and CD20+ (B) cells (14.14). 
PID04 had higher than normal levels of IL-12-induced IFN-γ production (546.91 pg/mL per 105 cells) 
and IFN-γ-induced IL-12 production (35.06 pg/mL per 105 cells). IFN-γ production in response to 
PHA stimulation was below the normal range (15.85 pg/mL per 105 cells). A graphical summary of 
the functional results for PID04 can be found in Figure 4.18. 
 
Figure 4.18: Summary of functional results for PID04. A. Percentage CD119 expression was normal on 
CD14+ monocytes, although CD119 density (MFI) was higher than for the controls. Fold change in pSTAT1 
was much higher than normal in CD14+ monocytes; B. CD212 expression was decreased on CD56+ (NK) 
and CD4-CD8- (γδ) T cells, although contrastingly, pSTAT4 fold changes were much higher than normal; 
C. IFN-γ production in response to PHA only was lower than normal, however, IL-12-induced IFN-γ production 
was higher than normal. IFN-γ-induced IL-12 production was also higher than normal. 
 
PID05 - IL12RB1 (c.C139T) 
PID05 had decreased percentage CD119 expression on CD14+ monocytes (46.9%), CD56+ (NK) 
cells (30.9%), CD3+CD56+ (NKT) cells (27.1%), total CD3+ (19.5%), CD4+ (17.8%) and CD8+ T 
cells (17.6%), however, the overall receptor density was higher than the normal controls (CD119 
MFI: 704, 67, 146, 122, 103, and 151 respectively). Fold changes in pSTAT1 were slightly elevated 
in CD56+ (NK) cells, total CD3+, CD4+ and CD8+ T cell subsets compared to the controls.  
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PID05 had very low levels of CD212 percentage expression and receptor density on CD56+ (NK) 
cells (72.5%; MFI: 395), CD3+CD56+ (NKT) cells (66.0%; MFI: 245), CD8+ T cells (70.9%; 
MFI: 195), CD4-CD8- T cells (66.8%; MFI: 171), and CD19+ (B) cells (71.5%; MFI: 182). Fold 
changes in pSTAT4 were decreased in nearly all cell subsets, with the lowest response being in 
CD56+ (NK) cells (1.19), CD3+CD56+ (NKT) cells (0.98), and CD20+ (B) cells (0.82). 
PID05 had very high levels of IFN-γ production in response to IL-12 stimulation (686.56 pg/mL 
per 105 cells) and very little IL-12 production in response to IFN-γ stimulation (2.28 pg/mL per 105 
cells). A graphical summary of the functional results for PID05 can be found in Figure 4.19. 
PID06 - IL12B (c.A320G) & NFKB2 (c.C2042T) 
CD119 percentage expression was normal on all cell subsets for PID06, although the receptor 
density was elevated for most cell subsets (e.g. CD14+ monocytes CD119 MFI: 820). Fold change 
in pSTAT1 was higher than normal for CD20+ (B) cells (2.55), but within the normal range for all 
other subsets. PID06 had lower than normal levels of CD212 percentage expression and receptor 
density on CD56+ (NK) cells (84.1%; MFI: 471), CD3+CD56+ (NKT) cells (78.0%; MFI: 362), CD4-
CD8- T cells (72.9%; MFI: 228), and CD19+ (B) cells (71.3%; MFI: 195). pSTAT4 fold changes were 
normal for all cell subsets. 
PID06 had lower than normal IFN-γ production in response to IL-12 stimulation (48.56 pg/mL per 
105 cells), as well as essentially no IL-12 produced in response to IFN-γ stimulation (1.07 pg/mL per 
105 cells). Interestingly, PID06 had higher than normal IFN-γ levels (11.54 pg/mL per 105 cells) in 
the unstimulated well of the cytokine assay, although there was no IFN-γ detected in the blood 
plasma indicating in vitro culture-induced production. 
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Figure 4.19: Summary of functional results for PID05. A. CD212 expression was lower than normal on 
CD56+ (NK), CD3+CD56+ (NKT) and CD19+ (B) cells. Fold changes in pSTAT4 were also below the normal 
ranges for these subsets. B. IFN-γ production in response to IL-12 stimulation was higher than normal, and 
IFN-γ-induced IL-12 production was lower than normal. 
 
PID07 - IL12B (c.G863C) 
PID07 had lower than normal levels of CD119 percentage expression, with variable receptor density 
on CD56+ (NK) cells (31.5%; MFI: 39.4), CD3+CD56+ (NKT) cells (28.6%; MFI: 117), CD8+ T cells 
(19.0%; MFI: 128) and CD19+ (B) cells (60.5%; MFI: 94.10). Fold change in pSTAT1 was only 
slightly higher than the normal ranges in CD14+ monocytes (2.19) and CD3+CD56+ (NKT) cells 
(1.96). Additionally, PID07 also had decreased levels of CD212 percentage expression, but normal 
receptor densities on CD56+ (NK) cells (86.6%), CD3+CD56+ (NKT) cells (82.4%), CD4-CD8- T 
cells (80.4%), and CD19+ (B) cells (71.8%). Fold changes in pSTAT4 were elevated in CD14+ 
monocytes (2.35), CD4+ T cells (1.53), and CD4-CD8- T cells (5.02). 
PID07 produced normal levels of IFN-γ in response to IL-12 stimulation (294.42 pg/mL per 105 cells), 
although the IFN-γ produced in response to PHA stimulation alone was below the normal range 
(5.49 pg/mL per 105 cells). There was very little IL-12 production induced upon IFN-γ stimulation 
(4.61 pg/mL per 105 cells). A graphical summary of the functional results for PID07 can be found in 
Figure 4.20. 
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Figure 4.20: Summary of functional results for PID07. A. CD119 expression was normal on CD14+ 
monocytes, although fold change in pSTAT1 was slightly elevated; B. CD212 percentage expression was 
slightly decreased on CD4-CD8- T cells, and the fold changes in pSTAT4 were higher than the controls; C. 
IFN-γ production in response to IL-12 stimulation was within the normal range, while IFN-γ-induced IL-12 
production was lower than normal. 
 
PID08 - IFNGR2 (c.A708T) 
Although the detection of IFN-γR2 (as opposed to IFN-γR1) was not part of the current study, CD119 
(IFN-γR1) expression was found to be decreased on CD14+ monocytes (56.5%; MFI: 536) and 
CD3+CD56+ (NKT) cells (25.8%; MFI: 144). CD119 receptor density was elevated on all lymphocyte 
subsets. CD119 percentage expression was slightly elevated only on CD56+ and CD19+ (B) cells 
in this patient, and normal on other subsets. Fold changes in pSTAT1 was low for CD14+ monocytes 
(1.03). PID08 had decreased CD212 expression on CD56+ (NK) cells (80.0%; MFI: 430), 
CD3+CD56+ (NKT) cells (83.3%; MFI: 423), and CD19+ (B) cells (72.0%; MFI: 186). Decreased 
fold changes in pSTAT4 detection was observed on CD56+ (NK) cells (1.51) and CD3+CD56+ 
(NKT) cells (1.12) compared to the controls.  
PID08 had very low levels of IFN-γ production in response to IL-12 stimulation (25.55 pg/mL per 105 
cells), as well as very little IL-12 production in response to IFN-γ stimulation (3.44 pg/mL per 105 
cells). PID08 was the only patient that had detectable levels of IFN-γ present in their blood plasma 
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(18.59 pg/mL) which relates to the high baseline IFN-γ production seen in the unstimulated well for 
the cytokine assay (10.31 pg/mL per 105 cells). A graphical summary of the functional results for 
PID08 can be found in Figure 4.21. 
 
 
Figure 4.21: Summary of functional results for PID08. A. CD119 expression was decreased on CD14+ 
monocytes, and the fold change in pSTAT1 was also below the normal range; B. CD212 expression on 
CD3+CD56+ (NKT) cells was decreased, and the fold change in pSTAT4 was also lower than normal; 
C. IL-12-induced IFN-γ production was lower than normal. There was also very little IL-12 production upon 
IFN-γ stimulation. PID08 was the only participant that had detectable levels of IFN-γ present in their blood 
plasma. 
PID09 - CYBB (c. A302G) 
PID09 had normal CD119 expression levels on most cell subsets, although it was slightly higher 
than normal on total CD3+ T cells (27.4%; MFI: 86.4), CD4+ T cells (25.1%; MFI: 82.1), and CD8+ 
T cells (29.1%; MFI: 115). Fold changes in pSTAT1 was also normal on all subsets except for CD20+ 
(B) cells, which was higher than normal (2.23). CD212 expression was slightly decreased on 
CD3+CD56+ (NKT) cells (80.4%; MFI: 395) and CD4-CD8- T cells (78.9%; MFI: 301) for PID09. 
Fold changes in pSTAT4 were decreased in all cell subsets except for CD20+ (B) cells.  
PID09 produced higher than normal levels of both IFN-γ (646.85 pg/mL per 105 cells) and IL-12 
(47.19 pg/mL per 105 cells) in response to IL-12 and IFN-γ stimulation, respectively. IFN-γ 
production in the unstimulated (NIL) well was also high (47.72 pg/mL per 105 cells), although no 
IFN-γ was detected in the blood plasma. 
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PID10 - IKBKB (c.G2257A) & NFKB2 (c.C2042T) 
PID10 had higher expression levels of CD119 on CD14+ monocytes (84.7%; MFI: 827), and 
pSTAT1 fold change was also higher than normal for this subset (2.19) as well as in CD20+ (B) cells 
(2.00). PID10 had decreased CD212 expression on CD56+ (NK) cells (83.1%; MFI: 470), 
CD3+CD56+ (NKT) cells (80.0%; MFI: 401), CD4-CD8- T cells (77.0%: MFI: 285), and CD19+ (B) 
cells (68.1%; MFI: 170). Fold changes in pSTAT4 was lower than normal for CD56+ (NK) cells 
(1.43), CD3+CD56+ (NKT) cells (1.15), and CD4-CD8- T cells (1.22). 
PID10 produced normal levels of IFN-γ (379.97 pg/mL per 105 cells) in response to IL-12 stimulation, 
although the IFN-γ production in response to PHA only was lower than the normal range 
(19.57 pg/mL per 105 cells). There was very little to no IL-12 production (1.54 pg/mL per 105 cells) 
in response to IFN-γ stimulation. 
 
PID11 - IRAK1 (c.C1939T) 
PID11 had slightly lower CD119 percentage expression on CD56+ (NK) cells (37.9%), CD3+CD56+ 
(NKT) cells (25.4%), total CD3+ T cells (20.5 %), CD8+ T cells (18.7%), and CD19+ (B) cells 
(63.7%), although CD119 receptor densities on these cell subsets were within the normal ranges. 
Fold changes in pSTAT1 were moderately increased on CD14+ monocytes (2.30), CD3+CD56+ 
(NKT) cells (2.22), total CD3+ T cells (2.25), CD4+ T cells (2.30), and CD8+ T cells (2.34). PID11 
had slightly increased CD212 expression on CD14+ monocytes (86.2%; MFI: 3000), but slightly 
decreased expression on CD4-CD8- T cells (81.0%; MFI: 302) and CD19+ (B) cells (68.30%; 
MFI: 136). Fold changes in pSTAT4 were normal for all cell subsets. PID11 had normal IFN-γ 
production (229.16 pg/mL per 105 cells) in response to IL-12 stimulation. IL-12 production 
(10.12 pg/mL per 105 cells) in response to IFN-γ stimulation was, however,  slightly below normal 
levels. 
 
PID12 - No result from WES 
CD119 expression was higher than normal on total CD3+ T cells (27.2%; MFI: 120) and CD19+ (B) 
cells (87.4%; MFI: 168) for PID12, and CD119 receptor density was decreased on CD14+ 
monocytes (MFI: 519). Fold change in pSTAT1 was higher than normal in CD20+ (B) cells (1.92), 
although normal in all other cell subsets. PID12 had decreased CD212 expression on CD56+ (NK) 
cells (86.8%; MFI: 544), CD3+CD56+ (NKT) cells (82.7%; MFI: 417), and CD4-CD8- T cells (79.5%; 
MFI: 262).  Fold changes in pSTAT4 were decreased in CD14+ monocytes (1.02), CD3+CD56+ 
(NKT) cells (0.95), total CD3+ (0.83), CD4+ (0.84), CD8+ (0.82), and CD4-CD8- T cells (0.85). 
PID12 had lower than normal IFN-γ production (103.39 pg/mL per 105 cells) in response to IL-12 
stimulation. The IL-12 production (29.26 pg/mL per 105 cells) in response to IFN-γ stimulation was 
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higher than normal. A graphical summary of the functional results for PID12 can be found in Figure 
4.22. 
 
 
Figure 4.22: Summary of functional results for PID12. A. CD212 expression was lower than normal on 
CD3+CD56+ (NKT) and CD4-CD8- (γδ) T cells. Fold changes in pSTAT4 was below the normal ranges for 
CD3+CD56+ (NKT) and CD4-CD8- (γδ) T cells; B. IL-12-induced IFN-γ production was lower than normal, 
and IFN-γ-induced IL-12 production was higher than normal. 
 
PID13 - WES not performed 
For PID13, CD119 expression was low on CD14+ monocytes (32.6%; MFI: 394), CD56+ (NK) cells 
(37.6%; MFI: 46.8), and CD19+ (B) cells (59.1%; MFI: 84.4). Fold changes in pSTAT1 were normal 
for all cell subsets. CD212 expression was low on CD56+ (NK) cells (81.7%; MFI: 459), CD3+CD56+ 
(NKT) cells (69.2%; MFI:282), CD8+ T cells (69.9%; MFI:190), CD4-CD8- T cells (67.0%; MFI:190), 
and CD19+ (B) cells (64.4%; MFI:153). Fold changes in pSTAT4 were decreased in CD56+ (NK) 
cells (1.53), but normal in other cell subsets. 
PID13 had slightly higher than normal levels of both IL-12-induced IFN-γ production (485.86 pg/mL 
per 105 cells) and IFN-γ-induced IL-12 production (23.61 pg/mL per 105 cells). 
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PID14 - WES not performed 
PID14 had decreased CD119 expression on CD14+ monocytes (48.8%; MFI: 563) and CD56+ (NK) 
cells (35.6%; MFI: 40.60), although fold changes in pSTAT1 were normal for all cell subsets. PID14 
had low levels of CD212 expression on nearly all cell subsets, including CD14+ monocytes (10.6%; 
MFI: 943), CD56+ (NK) cells (75.7%; MFI: 445), CD3+CD56+ (NKT) cells (72.0%; MFI: 296), CD8+ 
(70.5%; MFI: 203), CD4-CD8- T cells (66.8%; MFI: 184) and CD19+ (B) cells (65.8%; MFI: 154). 
Fold changes in pSTAT4 were decreased for all non-B lymphocyte subsets, i.e. CD56+ (NK) cells 
(1.88), CD3+CD56+ (NKT) cells (0.82), total CD3+ (0.69), CD4+ (0.68), CD8+(0.69), and CD4-CD8- 
T cells (0.83). Fold changes in pSTAT4 were normal for monocytes and CD20+ (B) cells 
PID14 had normal IFN-γ production (203.47 pg/mL per 105 cells) in response to IL-12 stimulation. 
There was very little IL-12 production (2.75 pg/mL per 105 cells) in response to IFN-γ stimulation. A 
graphical summary of the functional results for PID14 can be found in Figure 4.23. 
 
Figure 4.23: Summary of functional results for PID14. A. CD119 expression was decreased on CD14+ 
monocytes, although the fold change in pSTAT1 was within the normal range. B. CD212 expression was 
decreased on CD3+CD56+ (NKT) cells and CD4-CD8- (γδ) T cells and the fold changes in pSTAT4 for these 
subsets were also below the normal ranges. C. IL-12-induced IFN-γ production was within the normal range, 
although there was very little IL-12 production in response to IFN-γ stimulation.  
 
Stellenbosch University  https://scholar.sun.ac.za
82 
 
PID15 - WES not performed 
PID15 had lower than normal levels of CD119 percentage expression on CD56+ (NK) cells (33.2%), 
CD3+ (19.9%), CD8+ (18.9%) and CD4-CD8- T cells (17.2%), although the receptor densities were 
normal on these cells. The CD119 receptor density was higher than normal on CD14+ monocytes 
(MFI: 917) even though the percentage of CD119 positive monocytes were within the normal range. 
The fold changes in pSTAT1 were higher than normal in CD14+ monocytes (2.84), CD3+CD56+ 
(NKT) cells (1.93), total CD3+ (2.65), CD4+ (2.86), and CD8+ cells (2.46).  
CD212 expression was lower than normal on CD56+ (NK) cells (75.2%; MFI: 479), CD4-CD8- T 
cells (67.0%; MFI: 217) and CD19+ (B) cells (62.5%; MFI: 165). Fold changes in pSTAT4 were 
decreased in CD14+ monocytes (0.97) and CD56+ (NK) cells (1.56) although it was increased in 
CD4-CD8- T cells (3.63). 
PID15 produced higher than normal levels of IFN-γ (873.90 pg/mL per 105 cells) in response to IL-12 
stimulation even though the IFN-γ production in response to PHA only was below the normal ranges 
(27.92 pg/mL per 105 cells). IL-12 production (16.92 pg/mL per 105 cells) in response to IFN-γ 
stimulation was normal. 
 
PID16 - WES not performed 
PID16 had below normal percentage expression of CD119 on CD56+ (NK) cells (19.3%) and CD3+ 
(17.8%), CD4+ (16.9%), CD8+ (17.0%) and CD4-CD8- (17.5%) T cells, although fold changes in 
pSTAT1 were normal for all these subsets. The fold change in pSTAT1 for CD14+ monocytes (1.14) 
was lower than the normal range. Expression of CD212 was slightly elevated on CD14+ monocytes 
(68.5%; MFI: 2200) and CD8+ T cells (92.1%; MFI: 516). Fold changes in pSTAT4 were below 
normal for all cell subsets (see Appendix E). 
IFN-γ production (402.02 pg/mL per 105 cells) in response to IL-12 stimulation was normal for PID16, 
however, IL-12 production (28.77 pg/mL per 105 cells) in response to IFN-γ stimulation was higher 
than normal. A graphical summary of the functional results for PID16 can be found in Figure 4.24. 
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Figure 4.24: Summary of functional results for PID16. A. CD212 expression was normal for all cell subsets, 
however, the fold changes in pSTAT1 detection was below normal for nearly all subsets [CD56+ (NK) cells, 
CD3+CD56+ (NKT) cells and CD4-CD8- (γδ) T cells shown]; B. IFN-γ production was normal, however IFN-γ-
induced IL-12 production was higher than normal.  
 
PID17 - WES not performed 
CD119 expression was slightly lower than control ranges on CD3+CD56+ (NKT) cells (23.8%; 
MFI: 77.8) and CD19+ (B) cells (60.1%; MFI: 85.4) for PID17. Fold changes in pSTAT1 were slightly 
lower than normal in CD3+CD56+ (NKT) cells (0.97) but elevated in CD14+ monocytes (2.65) and 
CD4-CD8- T cells (5.86). CD212 percentage expression was low in all lymphocyte subsets except 
CD4+ T cells. CD212 receptor densities were also lower than the normal ranges for all lymphocyte 
subsets. Fold changes in pSTAT4 were decreased in CD14+ monocytes (1.23), CD56+ (NK) cells 
(1.43), CD3+CD56+ (NKT) cells (0.51), CD4+ T cells (1.09), and CD4-CD8- T cells (0.57). 
PID17 had normal IFN-γ production (288.80 pg/mL per 105 cells) in response to IL-12, although 
IL-12 production (8.74 pg/mL per 105 cells) in response to IFN-γ stimulation was lower than normal. 
A graphical summary of the functional results for PID17 can be found in Figure 4.25. 
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Figure 4.25: Summary of functional results for PID17. A. CD212 expression was decreased on CD56+ 
(NK) and CD3+CD56+ (NKT) cells, and the fold changes in pSTAT4 detection were also below the normal 
ranges in these cell subsets; B. IL-12-induced IFN-γ production was normal, however, IFN-γ-induced IL-12 
production below the normal range for PID17. 
  
Stellenbosch University  https://scholar.sun.ac.za
85 
 
Table 4.6: Basic summary of functional results for all 17 patients.  
Patient 
ID 
Genetic 
Variant(s) 
IFN-γR1 
IFN-γ 
signalling 
IFN-γ-induced 
IL-12 
production 
IL-12Rβ1 
IL-12 
signalling 
IL-12-induced 
IFN-γ 
production 
Baseline 
IFN-γ 
PID01 IFNGR1 +++ - - - - - - + + ND 
Child of 
PID01 
IFNGR1 +++ - - - - - + - ND 
PID02 
IFNGR1 / 
NOD2 
+ - ++ + - +++ ND 
Parent 
of 
PID02 
IFNGR1 + + - + - +++ ND 
PID03 
IFNGR1 / 
IKZF1 
- + ++ - - - - ND 
PID04 IL12RB1 +++ +++ ++ - - +++ +++ ND 
PID05 IL12RB1 - - + - - - - - - +++ ND 
PID06 
IL12B / 
NFKB 
+ + - - - - + - ND 
PID07 IL12B + ++ - - - + + ND 
PID08 IFNGR2 - - - - - - + - +++ 
PID09 CYBB + + +++ + - +++ ND 
PID10 
IKBKB / 
NFKB2 
+++ ++ - - - - - + ND 
PID11 IRAK1 + ++ - - + + ND 
PID12 No result + + +++ - - - ND 
PID13 WES NP - - + ++ - - - ++ ND 
PID14 WES NP - - + - - - - - + ND 
PID15 WES NP + ++ + - - + +++ ND 
PID16 WES NP + - +++ + - - + ND 
PID17 WES NP + ++ - - - - - - + ND 
 
This is an overall representation of the functional results for the 
major cell subsets. Results for IFN-γR1 expression and IFN-γ 
signalling in the table represent the CD14+ monocyte subset, 
while the CD56+ (NK) cells and CD4-CD8- (γδ) T cells are used 
as representatives for IL-12Rβ1 expression and IL-12 
signalling results. 
 
 
 
WES NP: WES Not Performed; ND: Not Detected 
 
- - 
 
Significantly decreased (Patient values below 10th 
percentile of control values) 
- 
 
Decreased (Patient values fall outside ‘normal’ IQR, but 
above 10th percentile) 
+ 
 
Normal (Patient values within IQR of control data) 
++ 
 
Elevated (Patient values fall outside ‘normal’ IQR, but 
below 90th percentile) 
+++ 
 
Significantly elevated (Patient values above 90th 
percentile of control values) 
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Chapter 5  Discussion 
This chapter is presented in four sections. The first section (5.1) discusses the study participants 
and their genetic results. The second section (5.2) focusses discussion on the optimisation of the 
flow cytometric assays and the third section (5.3) discusses the results obtained for each of the 
respective functional assays. The final section (5.4) is an overarching discussion of the entire study. 
5.1. Participants 
5.1.1. Case Reports and Routine Laboratory Findings 
Recurrent TB was the most common clinical presentation amongst the participants in this study. 
Two of the participants with suspected MSMD had a positive family history suggestive of PID, PID08 
had a sibling that died in infancy and PID16 has a history of severe and recurrent TB on the paternal 
side of the family. 
Most PID studies show a male gender predominance, due to X-linked disorders (Naidoo et al. 2010). 
Although some X-linked MSMD-associated genes have been described, there was no gender 
predominance in the current study, and only one of the patients, PID09, was found to have an X-
linked PID (Bustamante et al. 2011). 
All the participants were BCG vaccinated, but only one presented with likely BCGosis, which is one 
of the most common described presentations of MSMD. To date, BCGosis has not been as common 
in reported South African MSMD cases as compared to those in developed countries (Esser et al. 
2016; Caragol and Casanova 2003). Seeing as various countries vaccinate with different strains of 
BCG, it is possible that the BCG strain (Danish 1331) used in South Africa is more attenuated or 
less virulent than those used in countries where TB is less prevalent. It has been previously 
described that BCG vaccination is not entirely effective at preventing TB infection, although it is still 
used routinely due to its ability to prevent severe TB and disseminated TB in children (World Health 
Organization 2017; Esser et al. 2015; Sasaki et al. 2002). In the current cohort of PID patients, it 
appears that the BCG vaccination had no protective effect as it did not prevent TB disease or even 
severe and disseminated TB in multiple cases. 
Only 2 patients presented with non-tuberculous mycobacterial infections, namely PID01 and PID09. 
PID01 had concurrent pulmonary TB and disseminated M.avium infection, while PID09 had 
disseminated Mycobacterium complex infection, which was suspected to be BCG. Unfortunately, 
the routine laboratories were unable to culture and identify the causative Mycobacterium in PID09. 
Only 1 patient presenting with recurrent Salmonella infection, which is one of the most common 
described presentations in IL12RB1 and IL12B deficiencies, was documented (Robinson 2015).  
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Negative QFT-plus results i.e. lack of IFN-γ production in response to TB antigens, in the 3 
participants that had confirmed TB episodes (PID03, PID08 and PID12) are a clear indication that 
there is a defect related to IFN-γ production (i.e. in the IL-12-IFN-γ pathways) in response to TB 
antigenic stimulation. This shows that the routine QFT-plus TB diagnostic test is a useful tool to 
identify potential PID in patients with known TB.  
5.1.2. Genetic Findings 
WES in the combination with TAPER™ pipeline was very efficient in finding plausible disease-
causing variants, with 8 of the participants having gene variants in known MSMD-associated genes 
identified. All but one of these variants, IFNGR1 (c.818del4), are novel and have not been reported 
before.  
The IFNGR1 (c.818del4) variant is known to be a partial dominant disease-causing variant. Most 
described cases of 818del4 present with BCGosis or with M.avium infection (Wang et al. 2012). 
PID01 is the first patient described with this variant that also presented with ‘regular’ pulmonary TB 
(Glanzmann et al. 2018a). PID01’s daughter was screened for the 818del4 variant when she was 
only 1 month old, and it was revealed that she also had the variant. The child is being closely 
monitored by her mother and physician for any signs of TB or M.avium infection. The early diagnosis 
of the young child may be beneficial in the long-term management of the condition. 
The effect of the other novel variants in MSMD-associated genes are unknown, although they were 
all predicted to be pathogenic or likely pathogenic by various in silico prediction tools. It was 
expected, and to some extent confirmed in this study, that variants in IFNGR1 or IL12RB1 would 
impair the response to IFN-γ or IL-12, and variants in IL12B would lead to lack of IL-12 production 
as well as an overall lack of response to IFN-γ, similar to what has been described in other variants 
within the same genes (Bustamante et al. 2014). PID09 is the first patient with CYBB mutation, 
usually leading to CGD, that presented with mycobacterial disease in South Africa (Glanzmann et 
al. 2018b; Reed and Dolen 2018). 
The other, non-MSMD associated variants identified could potentially also lead to the disease 
phenotype since these genes encode for proteins that are essential for the immune response 
against TB. For instance, IKZF1 encodes for a zinc finger transcription factor, which plays an 
important role in lymphocyte development and differentiation (Boutboul et al. 2018; Cytlak et al. 
2018; Bonilla et al. 2015). Therefore, it is possible that a defect in IKZF1 could impact the ability of 
lymphocytes to respond to IL-12 or to produce IFN-γ. NOD2 encodes for an important pattern 
recognition receptor, which is essential for the recognition M.tb and induction of IL-12 (Mishra et al. 
2017; Naranbhai 2016). IRAK1, is an important part of the NF-κB pathway and is known to interact 
with the protein NEMO, which is a described MSMD-associated variant (Bustamante et al. 2019; 
Ghosh and Dass 2016). The proteins encoded by IKBKB and NFKB2 also interact with NEMO 
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(Boisson-dupuis et al. 2015). It is not known if or how these non-MSMD-associated variants would 
impact on the IL-12-IFN-γ cytokine pathways.  
The genetic results for each patient will be further discussed in section 5.3, along with the respective 
functional data for each patient. 
5.2. Optimisation of flow cytometric assays 
5.2.1. Receptor panel 
PHA stimulation upregulated expression of CD212. The upregulation was similar, although slightly 
to a lesser degree than what has previously been described by Esteve-Solé et al. (2018), Fieschi 
(2004), and Altare et al. (2001), where PBMCs were stimulated with both IL-2 and PHA. Although 
the 24-hour PHA stimulation without IL-2 stimulation in the current study was shorter than the 
stimulation in preciously published methods, it still allowed sufficient expression of CD212 for 
detection by flow cytometry, and also allows for faster processing time.  
The effect of PHA stimulation on CD119 has not previously been described and was assessed in 
this study in order to determine whether both CD119 and CD212 expression on PBMCs could be 
measured simultaneously. PHA pre-stimulation for 24 hours appeared to significantly downregulate 
CD119 expression on monocytes, although expression started to increase again after 48 hours of 
PHA stimulation. PHA is a mitogen that acts on lymphocytes, and it is likely that upon the activation 
of the lymphocytes with PHA these lymphocytes secrete cytokines and other mediators which can 
alter the phenotype and activity of monocytes in vitro. Additionally, culturing of monocytes in vitro 
also leads to their differentiation into macrophages, which have a very different phenotype to 
circulating monocytes (Movafagh et al. 2011). 
Based on the findings of this study, it is not advisable to assess both CD119 and CD212 expression 
simultaneously, due to the effect of PHA on CD119 expression. Therefore, for the optimal detection 
of CD212, PBMCs were pre-stimulated for 24 hours while additional PBMCs were left unstimulated 
for optimal detection of CD119.  
5.2.2. Phosflow panel 
The Phosflow protocol is much harsher on cells compared to regular surface staining protocols and 
this is evident by the loss of surface marker fluorescent signal observed when using either of the 
Perm buffers. Both the fixation and permeabilisation steps result in destruction of surface epitopes, 
which explains the decreased signals of the surface markers. Perm IV resulted in a lower loss-of-
signal of surface markers compared to Perm III. Perm IV is a detergent-based buffer and is less 
harsh on the cells than the alcohol-based Perm III. It was initially assumed that Perm III would allow 
better pSTAT detection, due to its harsher, often more effective, permeabilisation capabilities. 
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However, it was found that Perm IV allows equivalent, if not slightly better, pSTAT1 and pSTAT4 
detection in these conditions.  
All of the cytokine stimulation concentrations tested in this study resulted in a similar signal, which 
differs from what has been described by other studies (Fieschi 2004; Uzel et al. 2001; Fleisher et 
al. 1999). Usually, different concentrations for stimulation results in different degrees of 
phosphorylation of STATs. Different permeabilisation methods and sample types were used in these 
other studies. For instance, both Uzel et al (2001) and Fleisher et al. (1999) used methanol to 
permeablise cells for pSTAT1 or pSTAT4 detection. Uzel et al. (2001) also used PBMC-derived 
PHA/IL-2 blast cells as opposed to regular, untreated PBMCs for pSTAT4 detection.  
Stimulation of PBMCs with PHA prior to the Phosflow protocol allowed much better detection of 
pSTAT4, although once again these results are not equivalent to that of other studies, where PBMCs 
were co-cultured with PHA and IL-2 for 72 hours prior to the cytokine stimulation (Fieschi 2004; Uzel 
et al. 2001). Although the detection of pSTAT4 in this study was not perfectly aligned with that in 
other studies, the overall trends and outcomes of the assays were similar.  
5.3. Implementation of the Assays 
5.3.1. Controls 
Receptor Panel 
CD119 expression was highest on monocytes, which was expected, since these cells are the main 
producers of IL-12 and are they are dependent on IFN-γ for induction of various functions (Lammas 
et al. 2000). CD119 expression was also present on most lymphocytes. IFN-γ is important for 
lymphocyte functions and plays roles in promoting NK cell activity, leukocyte migration and even 
enhances further differentiation of CD4+ T cells into IFN-γ producing Th1 cells (Bhat et al. 2017). 
CD119 percentage expression was high on B cells, similar percentage expression on monocytes, 
although the receptor density (MFI) on B cells were comparable to other lymphocytes. IFN-γR1 
expression on B cells has not been well described before, and the role of IFN-γ in B cell function is 
not as well know but it is likely related to  the induction or regulation of antibody production (Chan 
et al. 2014; Nimmerjahn and Ravetch 2008). 
Percentage CD212, or IL-12Rβ1, expression was very high on all PHA pre-stimulated lymphocytes, 
likely due to the important role that IL-12 plays in lymphocyte differentiation and induction cytotoxic 
activity (Losana et al. 2002; Lammas et al. 2000). Percentage IL-12Rβ1 expression was highest in 
NK, NKT, CD8+ T cells and CD4-CD8- (γδ) T cells, likely to the inducible cytotoxic activity of these 
cells. These cytotoxic lymphocytes are also known to be the main producers of IFN-γ. 
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Signalling Panel 
The fold changes in pSTAT1 was highest in CD14+ monocytes and B cells, which agrees with the 
higher levels of CD119 (IFN-γR1) expression observed in these cells. Likewise, fold changes in 
pSTAT4 was highest in the lymphocytes with higher levels of CD212 (IL-12Rβ1) expression, 
especially NK cells and double negative / γδ T cells. Unlike receptor expression, the differences in 
pSTAT detection did not differ significantly between the various cell subsets. Due to the lack of 
difference in fold changes between the different cell subsets, it appears that a similar degree of 
‘signal’ is transferred through the cytokine receptors, regardless of the levels of receptor expression. 
IFN-γ signalling (fold change in pSTAT1) showed no correlation with the levels of IFN-γR1 
expression. IL-12 signalling (fold change in pSTAT4) showed a positive correlation to the levels of 
IL-12Rβ1 expression, indicating that cells with higher levels of IL-12Rβ1 expression tend to have 
slightly enhanced IL-12 signalling. This could potentially explain why lymphocytes, which are more 
dependent of IL-12 for their function, and not monocytes have relatively high levels of IL-12Rβ1 
expression. 
Cytokine Assay 
Cytokine-induced cytokine production 
As expected, PHA induced a moderate amount of IFN-γ production, while co-stimulation with IL-12 
enhanced the levels of IFN-γ production. Similarly, IL-12 was produced upon PHA and IFN-γ co-
stimulation but not with PHA alone, which confirms the findings described by other authors (Dorman 
and Holland 1998). The results generated by this assay are comparable to other previously 
published experiments where PHA was used to activate PBMCs as well as to the ‘gold standard’ 
cytokine assay developed by Feinberg et al. (2004) for the study of the integrity of the IFN-γ pathway 
which uses BCG to activate the cells.  
This cytokine assay can easily detect complete defects, but it is often difficult to identify partial 
defects in this manner. PHA co-stimulation has previously been shown to be less effective than 
BCG stimulation for the detection of partial deficiencies of IFNGR1 or IL12RB1. This is due to the 
fact that PHA induces a ‘general’ type of immune response (mitogenic “global” T cell stimulation), 
unlike BCG, which induces a mycobacterial pathogen-specific immune response (Esteve-Solé et al. 
2018). 
Unlike the flow cytometry-based methods, the cytokine production is measured for total PBMCs and 
not for each of the relevant cell subsets. IL-12 is produced mainly by monocytes and DCs, which 
make up about 10% of total PBMCs, whereas the main producers of IFN-γ, T cells, make up about 
60-70% of PBMCs. The ratios of IL-12 and IFN-γ producing cells in the PBMCs would be expected 
to impact on the levels of cytokines that were detected. The state of the immune cells, i.e. if anergic 
or exhausted or activated due to underlying conditions or active infections, would also impact on 
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cell responsiveness to stimulation. For future studies it may be beneficial to rather measure 
intracellular cytokine production after stimulation by means of flow cytometry. Alternatively, cell 
subsets can be separated, through fluorescent or magnetic cell sorting prior to stimulation and assay 
readout through ELISA. 
Baseline IFN-γ levels  
In healthy individuals, IFN-γ is undetectable in blood plasma. No IFN-γ was detected in the blood 
plasma of the laboratory volunteers, and for this reason any IFN-γ detected in the plasma in 
succeeding experiments was considered abnormal.  
IFN-γ is usually only increased in patients with active infection or chronic inflammation, such as 
during HIV infection, although elevated IFN-γ in blood plasma has been described in various cases 
of IFN-γR deficiencies (Esteve-Solé et al. 2018; Fieschi et al. 2001). The increased IFN-γ present 
in plasma of patients with IFN-γR deficiencies is due to the accumulation of IFN-γ in the plasma as 
a result of the inability of IFN-γ to bind to its receptor or as a result of IFN-γ overproduction by the 
host’s immune system. This latter phenomenon is an attempt to compensate for either low binding 
affinity of IFN-γ to its receptor or lack of signal transduction though the receptor.  
5.3.2. Patients 
Receptor expression, signalling through the receptor, and downstream cytokine production was not 
significantly different between the control group and the combined patient group. Although there 
were no significant differences, there was a lot more variation in the patient group compared to the 
controls with the patient group showing much larger ranges of receptor expression, signalling and 
cytokine production. In the IL-12 production assay, there appeared to be a clustering of distinct high 
and low IL-12 producers in the patient group, which was absent in the control group. 
 
Case-by-case patient results 
IFNGR1 
A well described heterozygous mutation in IFNGR1 (c.818del4) was identified in PID01 and her 
infant daughter. The functional assays in this study, which revealed very high levels of IFN-γR1 
expression on all cell subsets along with lack of signalling though the receptor as well as a lack of 
IL-12 production upon IFN-γ stimulation, were in agreement with what has previously been 
published on this specific variant. It has been well described that the 818del4 variant in IFNGR1 
results in high levels of non-functional IFN-γR1 expression on the surfaces of immune cells (Esteve-
Solé et al. 2018). The non-functional IFN-γR is capable of binding IFN-γ but no signal is transduced 
through the receptor due to a lack of Janus Kinase (JAK1)/STAT1 binding sites in the intracellular 
domain of the IFN-γR. The 818del4 variant has been associated with M.avium infection but not with 
TB (Wang et al. 2012; Sasaki et al. 2002; Villella et al. 2001; Jouanguy et al. 1999). PID01 is the 
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first person with an 818del4 IFNGR1 variant that presented with both pulmonary TB and M.avium 
infection. PID01 successfully cleared the TB infection on standard treatment, however her M.avium 
infection recurs whenever M.avium treatment is terminated. As a result, the patient has been placed 
on prophylactic treatment permanently. Early identification of this IFN-γR1 defect in PID01’s 
daughter may prove to be beneficial in future management.  
Novel heterozygous variants in both IFNGR1 (c.C864G) and NOD2 (c.C374T) were identified in 
PID02 and PID02’s father had the same variant in IFNGR1. IFN-γ signalling was decreased in PID02 
but not in her father, however IL-12 production was normal for both the patient and her father, 
indicating that the observed defect in IFN-γ signalling is potentially not as harmful as with the 
818del4 variant in PID01. The overproduction of IFN-γ by both PID02 and her father could potentially 
be an immune compensatory mechanism, where the host is overproducing IFN-γ to compensate for 
lack of receptor expression or binding affinity or even signalling through the receptor. The NOD2 
variant, which encodes for a pattern recognition receptor belonging to the NOD-like family of 
receptors, might explain the decreased function in PID01 compared to her father. NOD receptors 
are important for activation of the NF-κB pathway, which in turn plays an important role in T cell 
development, maturation and proliferation (Pellegrini et al. 2018; Mishra et al. 2017; Ghosh and 
Dass 2016). 
Two novel variants were identified in PID03, a heterozygous variant in IFNGR1 (c.C698T) as well 
as a homozygous variant in IKZF1 (c.G1009A). The decreased IFN-γ production observed agrees 
with the negative QFT-plus result that showed lack of IFN-γ production upon stimulation of immune 
cells with TB antigens. The lack of IL-12 receptor expression and signalling could possibly be 
explained by the IKZF1 variant, which encodes for DNA-binding protein Ikaros, also known as Ikaros 
family zinc finger protein 1. IKZF1 plays important roles in lymphocyte development and 
differentiation (Boutboul et al. 2018; Cytlak et al. 2018; Bonilla et al. 2015).  
Variants in the same gene, IFNGR1, were identified in PID01, PID02, and PID03. Although these 
patients all had variants in the same gene, they had very different clinical presentation and functional 
immune profiles. This shows that it is important to always assess immune functionality in vitro, rather 
than assuming that variants within the same gene will lead to similar phenotypes. The novel IFNGR1 
variants in PID02 and PID03 may need to be further investigated in order to determine exactly how 
the variants affect IFN-γR1 expression and functionality. This may include further investigations 
such as ligand affinity binding assays as well as biochemical modelling to assess potential changes 
in protein structure induced by the variants. 
IL12RB1 
Plausible disease-causing mutations were identified in IL12RB1 for both PID04 (c.G684C) and 
PID05 (c.C139T), although they had very different clinical presentations – Inflammatory bowel 
disease (IBD) phenotype and recurrent Salmonella infection in PID04 versus recurrent pulmonary 
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TB in PID05. PID05 had decreased IL-12Rβ1 expression and decreased IL-12 signalling, similar to 
what has been described in other non-complete defects in IL12RB1 (Fieschi 2004). The cytokine 
production assay results for PID05 were contradictory, and not in agreement with previously 
described IL12RB1 variants, with IFN-γ-induced IL-12 production being very low, whilst IL-12-
induced IFN-γ production was higher than controls (Esteve-Solé et al. 2018; Fieschi 2004). The 
contradictory cytokine production results could be due to the fact that the cytokine assays are PBMC 
based rather than immune cell subset based. The results may be unusual if the ratios of cell subsets 
are skewed significantly or if the responder cells are anergic or exhausted due to other underlying 
conditions. A possible confounding factor for PID05 could be the Shprintzen–Goldberg syndrome 
previously diagnosed in this patient. PID05 generally responds well to standard TB treatment 
regimens and is therefore treated in the standard way for each recurring TB episode. 
Recurrent Salmonella infection is common amongst patients with mutations in IL12RB1, with about 
62% of described cases presenting with this clinical phenotype (Haverkamp et al. 2014; Ramirez-
Alejo and Santos-Argumedo 2014; Qu et al. 2011). Unlike previously described IL12RB1 variants, 
the heterozygous variant identified in PID04 (c.G684C) resulted in an immunological phenotype that 
has never been described before. PID04 had lower IL-12Rβ1 expression (percentage positive cells 
as well as receptor density per cell), similar to previously described IL12RB1 variants and PID05; 
however, PID04 had very high levels of IL-12 signalling through the receptor, which resulted in high 
levels of IFN-γ production upon IL-12 stimulation. A gain-of-function variant in IL12RB1 has never 
been described before, even though several case studies of IL12RB1 variants with clinical 
presentation similar to that of PID04 have been published (Göktürk et al. 2016; Robinson 2015; de 
Beaucoudrey et al. 2011). These other case studies, however, only assessed IL-12Rβ1 expression 
levels and not receptor functionality, and therefore it is possible that a gain-of-function mutation may 
have been overlooked. PID04 also had higher levels of IFN-γ signalling as well as IL-12 production 
after IFN-γ stimulation when compared to controls. The higher levels of cytokine signalling as well 
as increased cytokine production may explain the IBD-like presentation that PID04 has had from a 
very young age. It is likely that this possible gain-of-function IL12RB1 variant presents as both 
immunodeficiency, as evidenced by susceptibility to Salmonella (and potentially mycobacteria), and 
autoimmunity. Other PIDs, such as IPEX syndrome and IL10/IL10R deficiencies have previously 
been shown to present with both autoimmunity and immunodeficiencies, and this dual-presentation 
is becoming more commonly recognized as more PIDs relating to immune dysregulation are 
identified (Carneiro-Sampaio and Coutinho 2015). 
After the initial genetics-based diagnosis of IL12RB1, PID04 received a HSCT from a well-matched 
donor at the age of 3 and a half years. This was the first HSCT transplant in South Africa for a 
patient with IL12RB1 diagnosis. Shortly after the transplant, his condition deteriorated, and he 
presented with very high fevers. It was initially assumed to be a sign of rejection, due to the lack of 
any obvious infections. An IL-12/23 blocker, Ustekinumab, was administered and the fever improved 
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after about 10 hours, and he started engrafting host cells. It is now suspected that due the over-
responsiveness of his immune cells to IL-12, as evidenced by the pre-HSCT functional assays, there 
was an increased induction of various inflammatory cytokines resulting in a ‘cytokine storm’ type 
response. He is currently (2 months post-transplant) doing well and recovering at home, however, 
it is unknown whether he will develop a fully competent immune system and is therefore closely 
monitored by various physicians. The potential gain-of-function IL12RB1 variant will be investigated 
further in cell-lines altered by site-directed mutagenesis as well as in animal models.  
Similar to the IFNGR1 variants described earlier, different variants in IL12RB1 resulted in varying 
clinical presentation and immune functionality, once again highlighting the importance of in-depth in 
vitro assessment of immune functionality. 
IL12B 
All reported variants in IL12B, which encodes for the IL-12p40 subunit, are autosomal recessive 
loss-of-function and are characterised by lack of IL-12 production by immune cells (Al-Muhsen and 
Casanova 2008; Picard et al. 2002). Similar to previously reported IL12B variants, both PID06 
[IL12B (c.A320G) and NFKB2 (c.C2042T), both heterozygous] and PID07 [IL12B (c.G863C) 
homozygous] had very low levels of IL-12 production upon IFN-γ stimulation. The slightly higher 
signalling, for both IFN-γ and IL-12, observed in these patients could potentially be an immune 
compensatory mechanism for the lack of IL-12 production by host cells. From the functional assay 
results for PID07, it can be assumed that the c.C863C variant also acts in an autosomal recessive 
manner as previously reported IL12B mutations (Al-Muhsen and Casanova 2008; Picard et al. 
2002). PID06’s immune function results were very similar to PID07’s, although PID06’s IL12B 
variant (c.A320G) is present in heterozygous form – which has never before been reported to be 
associated with MSMD. It is possible that the additional variant in PID06, NFKB2 (c.C2042T), may 
have a compound heterozygous effect on the IL12B variant, which could lead to the clinical disease 
phenotype. PID06 had lower than normal levels of IFN-γ production in response to PHA and IL-12 
co-stimulation, which may potentially also be explained by the compounded effects of the 
heterozygous IL12B and NKFB2 variants. NFKB2 forms a crucial part of the non-canonical NF-κB 
pathway, which is essential for immunity and cell survival. Dysregulation of the NF-κB pathway has 
previously been associated with improper immune development leading to increased susceptibility 
to infections or autoimmune manifestations (Ghosh and Dass 2016; Shi et al. 2016).  
IFNGR2 
Very few IFNGR2 mutations have been described to date, but all these result in phenotypes similar 
to the more commonly observed IFNGR1 mutations (Parvaneh et al. 2015; Kong et al. 2013). 
PID08’s immunological phenotype is very similar to the first reported IFNGR2 mutation, by Dorman 
and Holland (1998), where IFN-γR1 was detectable on immune cells but there was a lack of 
response to IFN-γ, indicating that the IFN-γR is non-functional. PID08 had very high levels of IFN-γ 
Stellenbosch University  https://scholar.sun.ac.za
95 
 
present in blood plasma, similar to what has been observed in various IFN-γR deficiencies (Apt et 
al. 2017), which indicates that there is either a build-up of IFN-γ due to lack of binding to its receptor 
or the host cells are overproducing IFN-γ in an attempt to compensate for lack of signal transduction 
through the IFN-γR. Kotenko et al. (1995) have shown that the association of IFN-γR1 and IFN-γR2, 
to form the IFN-γR complex, is needed for signal transduction and that the IFN-γR2 intracellular 
domain plays an essential role in IFN-γ signalling. Further research on the IFNGR2 variant 
(c.A708T) found in PID08 is needed in order to determine the exact impact of the variant on IFN-γR2 
protein expression and folding, which may contribute to a better understanding of the dependence 
on IFN-γR components for IFN-γ signalling.  
CYBB 
Most CYBB mutations are associated with CGD and approximately 70% of CGD patients harbour 
mutations in CYBB (Ochs and Petroni 2017). There are also other reported cases of CYBB 
mutations, which lead to a defective IFN-γ dependant respiratory burst response in macrophages, 
that has been associated with a selective susceptibility to mycobacterial infections, usually BCGosis 
(Abel et al. 2017; Al-Herz et al. 2015; Wu and Holland 2015). PID09 presented with disseminated 
mycobacterial disease and not the traditional CGD presentation of recurrent staphylococcal or 
fungal infections  , indicating that the CYBB (c.A302G) variant may be associated with MSMD. 
IFN-γR1 and IL-12Rβ1 expression and IFN-γ signalling was mostly normal for PID09, and IL-12 
signalling was slightly decreased, which was expected since the gp91phox protein, encoded by 
CYBB, is not expected to alter cytokine receptor expression and signalling. 
Variants in NF-κB pathway – not previously associated with MSMD 
Variants in two separate genes that are important for the functionality of the NF-κB pathway, IKBKB 
(c.G2257A) homozygous and NFKB2 (c.C2042) heterozygous, were identified in PID10. IKBKB 
encodes for the IKK-β subunit of the IκB kinase, or IKK, an enzyme complex located upstream of 
the NF-κB signalling cascade. Upon binding of IKK to NEMO (NF-κB essential modulator, also 
known as IKK-γ), NF-κB is activated resulting in transcription of various immunological genes 
(Rothwarf et al. 1998). NF-κB deficiencies, brought upon by mutations in NFKB1 or NFKB2, have 
been associated with CVID (Shi et al. 2016; Chen et al. 2013).  
IL-12 production upon IFN-γ stimulation was impaired in PID10, likely due to the IKBKB variant, 
which is involved to some extent in downstream IFN-γ signalling events (Boisson-dupuis et al. 2015). 
The higher expression levels of IFN-γR1 as well as enhanced IFN-γ signalling observed in PID10 
could be a potential immune compensatory mechanism due to defects in the downstream IFN-γ 
signalling cascade. The decreased IL-12Rβ1 expression and IL-12 signalling could be due to the 
additional heterozygous NFKB2 variant, since NF-κB is essential for lymphocyte development and 
functions (Ghosh and Dass 2016; Shi et al. 2016; Chen et al. 2013). Interestingly the NFKB2 variant 
in PID10 was the exact same variant as in PID06, and both patients showed a similar change in 
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lymphocyte phenotypes and cytokine production. The functional assays in this study were not able 
to define the exact effect of NFKB2 variants since the assays are focussed around the IL-12 and 
IFN-γ pathways and not the NF-κB pathway. Further research on this NFKB variant is needed in 
order to determine the extent of the resulting immune deficit. 
IRAK1 encodes for an enzyme that functions downstream of IL-1, and is partially responsible for 
IL-1 induced activation of NF-κB (Bustamante et al. 2019; Ghosh and Dass 2016). IRAK1 associates 
with IKK and in turn with NEMO, and therefore it was expected that the functional phenotype of the 
IRAK variant in PID11 (c.C1939T) would be similar, although to a lesser extent, to the IKBKB variant 
in PID10. PID11 did have slightly lower than normal IFN-γ-induced IL-12 production, although not 
as low as PID10. PID11 also had enhanced IFN-γ signalling, similar to PID10. The results from 
PID11’s functional assays were not as clear-cut as PID10’s, with contradictory up- and down 
regulation of cytokine receptor expression and signalling on the different cell subsets making it 
harder to make a definitive call on the likely effect of this IRAK1 variant on the IL-12-IFN-γ pathway. 
More research is needed on IRAK1, as with IKBKB and NFKB2, to determine the exact 
pathophysiology of associated immune defects. 
Patients without genetic results 
WES and the subsequent bioinformatics pipeline were unable to identify plausible disease-causing 
variants for PID12. Several other variants in a wide array of genes were identified that have never 
been associated with PID, however, re-analysis of the WES data at a later point may be able to 
identify newly described variants associated with PID. It is also possible that a potential PID-causing 
defect in PID12 may not be located in their exome but rather in non-coding regulatory elements of 
the DNA. Defects in non-coding regions of the DNA could potentially lead to alteration(s) in 
expression levels, exporting, or homing of immunological protein(s), and can be assessed by means 
of RNA-sequencing (Naranbhai 2016). PID12 had lower than control levels of IL-12Rβ1 expression, 
as well as decreased IL-12 signalling and IL-12-induced IFN-γ production. The defective IFN-γ 
production revealed by these functional assays support the negative QFT-plus result that this patient 
had, despite several culture-confirmed TB episode. The functional phenotype of PID12 is 
reminiscent of that of a loss-of-function defect in IL12RB1, although no plausible disease-causing 
mutation was found in IL12RB1. It is likely that this patient has a regulatory defect relating to 
IL-12Rβ1 expression and function or perhaps a more complex defect that relates to overall 
lymphocyte function. The over-production of IL-12 upon IFN-γ stimulation, could potentially 
represent an immune compensatory mechanism to counteract the lack of lymphocyte 
responsiveness to IL-12. 
Patients PID13 - PID17 have not yet undergone WES, due to funding constraints however the 
functional assays in this study revealed likely defects in or closely related to the IL-12-IFN-γ 
pathway. 
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In PID13, IL-12Rβ1 expression was low on various lymphocyte subsets, however, IL-12 signalling 
was low only on NK cells, suggesting that he may potential have an immune deficiency relating 
specifically to NK cells development and function. The slightly higher than normal levels of both 
IFN-γ-induced IL-12 production and IL-12-induced IFN-γ production in PID13 cannot be explained 
based solely on the decreased IL-12 responsiveness of NK cells and further investigations may be 
needed to explain the overproduction of these cytokines. 
PID14 had decreased levels of IFN-γR1 expression, although signalling though the receptor was 
within the normal range. Additionally, IFN-γ-induced IL-12 production was lower than normal, which 
is in alignment with the overall functional phenotype seen in some cases of IFNGR1/2 and all IL12B 
mutations (Esteve-Solé et al. 2018). Interestingly, PID14 also had lower than normal levels of 
IL-12Rβ1 expression and IL-12 signalling in nearly all lymphocyte subsets, similar to previously 
reported loss-of-function IL12RB1 mutations, although in this case the IL-12-induced IFN-γ 
production was normal (Robinson 2015). It is likely that PID14 has a defect in IL12B based on the 
similarity of the immune functional readouts to that of PID07, which had a homozygous variant in 
IL12B. Both PID14 and PID17 showed decreased IL-12Rβ1 expression and IL-12 signalling, 
especially in NK cells. Alternatively, PID14 may have a defect in some part of the NF-κB pathway 
or another immune pathway essential for lymphocyte development and function. 
PID15’s clinical phenotype, unusual TBM in a 9-year-old, was very similar to that of PID02 (IFNGR1 
variant) and both of these patients had very high levels of IL-12-induced IFN-γ production. Unlike 
PID02, however, PID15 had higher than normal density of IFN-γR1 expression and IFN-γ signalling 
in monocytes as well as decreased of IL-12Rβ1 expression and IL-12 signalling in NK cells, similar 
to what was observed for PID11, who had variants in both IKBKB and NFKB2. IL-12 production was 
normal for PID15, unlike for PID11 and PID02. It is possible that PID15 has a defect in the NF-κB 
pathway that relates to defective lymphocyte development and function – the enhanced IFN-γ 
production and signalling may be a potential compensatory mechanism of the host immune cells, 
however, further research and genetic investigation is needed in order to confirm the diagnosis. 
Higher than normal levels of IFN-γ-induced IL-12 production as well as the decreased IL-12 
signalling observed in all cell subsets for PID16, is very similar to the immunological phenotypes of  
loss-of-function IL12RB1 mutations (Robinson 2015), however PID16 had contradictory, normal 
IL-12-induced IFN-γ production. Mutations in IL12RB1 are usually associated with BCGosis or non-
tuberculous mycobacterial and Salmonella infections and would therefore not, however, explain the 
severe clinical phenotype of recurrent and disseminated TB infection that was non-responsive to 
treatment which eventually lead to the demise of PID16 (Ramirez-Alejo and Santos-Argumedo 
2014). The functional results suggest that PID16 most likely had an immune defect relating to 
defective lymphocyte responses, although further research, including genetic analysis, is needed in 
order to diagnose the potential PID. 
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PID17 had lower than normal levels of IL-12Rβ1 expression and IL-12 signalling in nearly all 
lymphocyte subsets although IL-12-induced IFN-γ production was normal, similar to PID14. It is 
therefore likely that PID17 has a PID similar to that of PID14, which is likely related to IL12B 
expression or function. 
5.4. Combined Discussion 
WES and the TAPER™ bioinformatics pipeline is a very efficient tool for identifying genetic variants 
associated to PID. Plausible-disease causing variants were identified in all but one of the 
participants that underwent WES. Most of the variants identified though WES were novel and would 
likely have been missed by commercially available gene panels. Several variants that do not fall 
within the conventional IL-12-IFN-γ pathway were also identified. Plausible disease-causing variants 
that fall within the NF-κB pathway were identified in 4 of the 11 patients that underwent WES. This 
indicates that mycobacterial susceptibility may also be associated with defects in the NF-κB 
pathway.  
The combination of the three functional assays for the assessment of the integrity of the IL-12-IFN-γ 
pathway was successful in identifying immune deficits in essentially all of the participants. The 
results generated by the functional assays were variable, and in several cases the functional data 
alone could not fully explain the disease phenotypes, especially in patients for which no plausible 
disease-causing variant(s) were yet identified. The functional assays were easier to interpret if a 
plausible variant/gene had been identified; however, even in the absence of genetic data the 
functional assays provided some clues as to the likely defect.  
The functional assays did not always correlate well with each other, for instance, PID05 had lower 
than normal levels of IL-12Rβ1 expression (percentage positive cells as well as receptor density per 
cell) and IL-12 signalling, however IFN-γ production upon IL-12 stimulation was paradoxically higher 
than normal. In several cases, the cytokine assay did not correlate well to the cytokine receptor and 
signalling readouts. This may be an unexpected but accurate observation of the immune 
functionality of the immune cells in vitro, however, it could also be due to the non-mycobacterial-
specificity of the cytokine assays or the fact that the cytokine production is measured for total 
PBMCs and not for each respective cell subset as with the flow cytometric assays. The percentages 
of constituent cell subsets in the PBMCs of each patient may differ and this may significantly impact 
the final readout of the cytokine assay.  
The clinical and molecular phenotypes of the patients that shared variants in the same genes, for 
instance IFNGR1 and IL12B, were highly variable. Different variants in IFNGR1, identified in patients 
with distinctly different clinical presentations (PID01-PID03), led to variable levels of  IFN-γR1 
expression and functionality (signalling) as well as downstream cytokine production. Similarly, the 
different variants in IL12RB1 (PID04 and PID05) also lead to varying levels of IL-12Rβ1 expression, 
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functionality, and downstream cytokine production in patients with different clinical disease 
presentation. Although both PID04 and PID05 had decreased IL-12Rβ1 expression levels, PID04 
had decreased IL-12 signalling similar to previously reported loss-of-function IL12RB1 mutations, 
whereas PID05 had enhanced IL-12 signalling, suggesting a never-before encountered gain-of-
function variant (Robinson 2015). Due to the variability of the molecular phenotypes associated with 
variants within the same gene, it is important to assess the immune functionality for all likely disease-
causing variants rather than assuming that variants within the same gene would lead to similar 
phenotypes. 
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Chapter 6  Conclusions and Future Perspectives 
Evidence of functional abnormalities is essential in confirming whether a potentially pathogenic 
variant identified by WES manifests as truly pathogenic in vitro. The functional assays implemented 
and optimised in this study were able to identify immune deficits relating to the IL-12-IFN-γ pathway 
for nearly all the participants with suspected MSMD.  
Although functional assays alone could not always provide a clear diagnosis, they do give an 
overview of the integrity of the IL-12-IFN-γ pathway. It would be beneficial to apply these assays 
routinely for patients with suspected PID relating to mycobacterial susceptibility. Abnormalities 
observed in these ‘routine’ functional readouts can be used to pre-select patients for subsequent 
genetic analysis. If the functional readout is similar to well-defined, previously described cases 
associated with certain genetic mutations e.g. IFNGR1 (c.818del4), it may speed up the genetic 
diagnosis of the patient as they can likely be diagnosed by Sanger sequencing or commercial gene 
panels rather than undergoing costly, complex and time-consuming WES. If the functional readouts 
show no abnormalities or abnormalities that do not fit characteristic patterns, it may earmark these 
patients for further investigation through WES or RNA-sequencing.  
Several of the plausible disease-causing variants that were identified in the participants form part of 
the NF-κB signalling pathways, which is essential for T cell development and function (Pellegrini et 
al. 2018; Mishra et al. 2017; Ghosh and Dass 2016; Lee et al. 2011). This suggests that 
mycobacterial susceptibility, especially in a TB endemic area, could also be caused by defects in 
pathways other than the IL-12-IFN-γ pathway. Defects in the NF-κB pathway have previously been 
associated with CVID (Chen et al. 2013), but further research is required to investigate the 
pathophysiology of mycobacterial susceptibility relating to the NF-κB pathway. 
A molecular diagnosis paves the way for better treatment options for the patients, based on a better 
understanding of the molecular mechanism that leads to disease. Molecular diagnoses also allow 
genetic counselling of affected family members, which increases awareness for the specific disorder 
within the family.  
The flow cytometry-based assays implemented in this study differ slightly from previously published 
methods that also assess IL-12 and IFN-γ receptor expression and functionality. The assays 
optimised in this study have much faster turn-around times, although potentially sub-optimal 
stimulation conditions when compared to others.  
Due to problems accessing standardised viable titred stocks of BCG, PHA was used to activate 
PBMCs during the cytokine assays. This has been shown to be less efficient at detecting partial 
defects in the IL-12-IFN-γ pathways. Using BCG instead of PHA would have been preferable, due 
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to the induction of a mycobacterial specific immune activation state. Future studies will incorporate 
BCG stimulation to activate PBMCs. 
The 10 controls used to establish normal ranges for receptor expression, signalling, and cytokine 
production, were not age matched to the participants. For future, larger scale studies, it would be 
better to have more controls that are age-matched to the participants in order to have more reliable 
comparative data. 
PBMCs were isolated from patient blood collected during clinic visits or hospitalisation. The 
activation status of the patients’ PBMCs at the time of collection, due to active diseased state, could 
have potentially affected the functional assay readouts.  
Final Concluding Remarks 
The current study has led to the implementation of functional immune assays which allowed for the 
evaluation of the functional impact of both novel and previously described genetic variants on the 
IL-12-IFN-γ pathways. These functional assays aided in the identification and confirmation of 
immune deficits in all participants in this study. This is the first documented study with such a diverse 
cohort of MSMD patients – in terms of clinical presentation and genetic phenotypes – with readouts 
of immune functionality.  These assays have direct clinical relevance and treatment implications, as 
seen in this study  with patients PID01 and PID04. This IL-12-IFN-γ pathway functional ‘screening’ 
could potentially also be used to pre-select patients for further genetic investigations and might 
provide a much faster and cost-effective approach to diagnosing PIDs associated with 
mycobacterial infections 
This study further emphasises the importance of investigating PID and TB susceptibility in TB 
endemic regions. Most features that have been previously described for MSMD – such as the 
predisposition to unusual mycobacterial infections – resulted from studies done in developed first 
world settings or areas where TB is rare. MSMD and other previously described PIDs relating to TB 
susceptibility may present differently in TB endemic areas such as South Africa. It is therefore 
important to have access to in vitro functional investigations to better understand the functional 
impact of both novel and previously described MSMD variants. The functional definition of novel 
variants associated with mycobacterial susceptibility will also contribute towards the understanding 
of host immune responses to mycobacteria. 
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Appendix A 
PARTICIPANT INFORMATION AND INFORMED CONSENT 
FORM FOR RESEARCH INVOLVING GENETIC STUDIES 
 
 
TITLE OF RESEARCH PROJECT: 
 
Identification of novel candidate genes for susceptibility to tuberculosis by 
identifying disease causing mutations in individuals with Primary 
Immunodeficiencies. 
 
REFERENCE NUMBER: 
 
PRINCIPAL INVESTIGATOR: Dr Craig Kinnear 
 
ADDRESS:  Department of Biomedical Sciences,  
Faculty of Medicine and Health Sciences 
Stellenbosch University 
P.O. Box 19063 
Tygerberg. 
 
CONTACT NUMBER: (021) 938 9695/ 076 094 8957 
 
 
We would like to invite you to participate in a research study that involves genetic analysis 
and possible long-term storage of blood or tissue specimens.  Please take some time to 
read the information presented here which will explain the details of this project.  Please 
ask the study staff or doctor any questions about any part of this project that you do not fully 
understand.  It is very important that you are fully satisfied that you clearly understand what 
this research entails and how you could be involved.  Also, your participation is entirely 
voluntary and you are free to decline to participate.  If you say no, this will not affect you 
negatively in any way whatsoever.  You are also free to withdraw from the study at any 
point, even if you do agree to take part initially.  
 
This research study has been approved by the ethics Health Research Ethics Committee 
at Stellenbosch University and it will be conducted according to international and locally 
accepted ethical guidelines for research, namely the Declaration of Helsinki, and the SA 
Department of Health’s 2004 Guidelines: Ethics in Health Research: Principles, Structures 
and Processes. 
 
What is Genetic research? 
Genetic material, also called DNA or RNA, is usually obtained from a small blood sample.  
Occasionally genetic material is obtained from other sources such as saliva or biopsy 
specimens. (A biopsy is a tiny piece of tissue that is cut out e.g. from the skin or from a 
lump, to help your doctor make a diagnosis.)   Genes are found in every cell in the human 
body.  The genes are the instructions that tell the body how to grow and function. The genes 
determine what we look like and sometimes what kind of diseases we may be susceptible 
to.  Worldwide, researchers in the field of genetics are continuously discovering new 
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information that may be of great benefit to future generations and also that may benefit 
people today, who suffer from particular diseases or conditions. 
 
 
What does this particular research study involve? 
 
➢ The immune system refers to the body cells that fight infection. A person with a 
faulty immune system will get infections much more easily than other people. This 
person has an ‘immune deficiency’. There are many causes of immune deficiency, 
and we still don’t know all the possible causes. Some immune deficiencies are 
caused by ‘faulty genes’ as described below. 
➢ The genes are instructions that are passed on from parent to child in the egg cell 
and sperm cell. Some of these instructions are for how the immune system will 
work, and each gene tells a specific part of the immune system how to work.  
➢ If there is a fault (mutation) in one of these genes, the person will have an immune 
deficiency.  
➢ Currently we do not know all of the genes and gene faults that cause immune 
deficiency. Therefore, we are aiming to find out more about: 
• The genes that cause immune deficiency. 
• The gene fault(s) causing immune deficiency in your family.  
➢ We will do genetic testing to try and identify the cause of immune deficiency in 
each affected person who participates in the study. The type of genetic test will 
vary in different people.  
• In some people the test might target certain known genes in the immune 
system.  
• In other people we will do a much broader screen for gene faults 
(mutations), to see if we can identify the cause of the immune deficiency. 
This test is called ‘exome sequencing’. Exome sequencing screens all or 
most of the known genes in the body, because we don’t yet know the 
functions of all these genes. This allows us to test for a lot more gene faults 
to see if these are causing the immune deficiency. However, exome 
sequencing may also detect faults in genes that can cause a different 
disease.  
 
 
Why have you been invited to participate? 
 
➢ Your child has an immune deficiency that might be caused by a gene fault. 
However, we do not know what this gene fault is. 
➢ We would like to do genetic tests to try and identify the gene fault (mutation). 
 
 
What procedures will be involved in this research? 
 
➢ A doctor or nurse will draw 5ml (one teaspoon) of blood from your child so that we 
can extract the DNA. We will then do all our genetic tests on your child’s DNA.  
➢ In some cases we may also draw 5-10ml (one to two teaspoons) of blood at a later 
stage from you (the available parents of the child) for comparison purposes. 
 
Are there any risks involved in genetic research? 
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➢ If exome sequencing is conducted, there is a small chance that we will detect a 
gene fault that shows susceptibility to another condition (e.g. for developing 
cancer). Some of these conditions may only be expected to develop in adulthood 
and may therefore have no immediate importance to a child with 
immunodeficiency. However the same fault may be present in a parent and 
perhaps other family members.  
➢ It may therefore be beneficial for you to know about such gene faults, especially if 
they can cause a condition that can be prevented or treated. However, knowledge 
of such gene faults can sometimes have negative effects: 
• It may cause anxiety or other negative feelings.  
• There is chance that a person who carries such a gene fault may be 
stigmatised in some way, e.g. within the family. 
• This can apply to the child or to adults found to have gene faults.  
➢ We therefore ask you to decide in advance whether you want us to inform you, if 
we detect such other (incidental) gene faults.  
➢ Results will be made known only if they indicate: 
• A definite risk for developing a particular disorder. 
• Require genetic counselling. 
➢ In addition, if we do genetic tests on the parents as well as the child, there is a 
chance that it will give us unexpected information about the family, e.g. that the 
father is not the biological of the child. We do not specifically report this 
information, but there is a chance it will be apparent from genetic information we 
report back regarding gene faults detected in the family.  
➢ We further request your consent to enter your information onto the South African 
PID and linked international databases. The database will contain information 
about you and your attending doctors as well as laboratory results, relative clinical 
findings and treatment used. This will be followed up at 6 or 12 monthly intervals. If 
you agree and if the genetic mutations (changes in the normal inheritance pattern) 
causing you/your child’s medical condition are known, they can be stored 
anonymously in a European database for the documentation and analysis of 
mutations involved in immunodeficiencies. This database is hosted by the Institute 
of Medical Technology at the University of Tampere, Finland (http://bioinf.uta.fi/idr/) 
with the aim of collecting immunodeficiency data to improve the understanding of 
PID and ultimately improve the treatment of these diseases. Mutation data is 
transferred anonymously to this database through a secure connection from the 
ESID (European Society for Immunodeficiency Diseases) database. For the South 
African database the data will be entered with patient name and residential 
address but for international registries such as the ESID or African Society for 
Immunodeficiencies (ASID), patient information will be anonymous without the 
name or address given.  Your/ your child’s data will only be made available on 
request for research purposes with the permission of the Registry panel. If you 
decide not to agree to have your/ your child’s information stored in these 
databases, it will not affect you negatively and you/your child will still be able to 
take part in the study. 
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 Tick the options you choose: 
 
I AGREE that my/my child’s information be stored in the databases as explained 
above           
 
 OR 
 
I  DO NOT AGREE that my/my child’s information be stored in the databases as 
explained above         
 
 
Are there any benefits to your taking part in this study and will you get told your 
results? 
 
➢ We will inform you if we detect the gene faults causing immune deficiency in your 
child. If we do detect a specific gene fault, this knowledge: 
• May or may not make a difference to the treatment we offer your child. 
• May allow us to offer genetic testing in the family (e.g. for prenatal diagnosis 
of future pregnancies).  
➢ Please note that we cannot guarantee that we will get any results which we can 
feed back, or how long it will take.  
➢ We will inform you of coincidental gene faults we detect that may cause other 
conditions - if you have indicated that you want to be informed.  
➢ Please note that if we do not detect any gene faults, this does not guarantee that 
none are present, because not all gene faults can be detected by current methods.  
➢ Any results reported back to you will be discussed with you by a genetic 
counselling professional (genetic counsellor/clinical geneticist), who will also inform 
you about any implications for the family. 
➢ Findings from this study may benefit people with immune deficiencies in the future.  
 
 
How long will your blood be stored and where will it be stored? 
 
➢ DNA will be stored at the University of Stellenbosch until we have detected the 
gene faults causing immune deficiency in your family.  
➢ Afterwards it may continue to be stored and used to help establish tests for other 
people with immune deficiencies. If you do not wish your blood specimen to be 
stored after this research study is completed you will have an opportunity to 
request that it be discarded when you sign the consent form. 
➢ We work together with colleagues in South Africa and overseas. Your DNA 
samples may be sent to such colleagues for further testing. 
 
 
If your blood is to be stored is there a chance that it will be used for other research? 
 
Your and your child’s blood will only be used for genetic research that is directly related to 
immune deficiency.   
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How will your confidentiality be protected? 
 
➢ We will keep your genetic information private. DNA samples are identified only by a 
study number. This is linked to your personal information on a database that is kept 
private and protected by a password.  
➢ If your sample is sent to any other colleagues, they will have access to your study 
number, and to details of the condition we are looking for, but not to your personal 
details.  
➢ If we do find any gene faults we will do our best to contact you using the contact 
details you supply us. Please contact us with any change in your contact details 
using the contact details on this form. 
 
Will you or the researchers benefit financially from this research? 
 
You will not be paid to take part in this study.  
 
Important information: In the unlikely event that this research leads to the 
development of a commercial application or patent, you or your family will not 
receive any profits or royalties 
 
 
Is there anything else that you should know or do? 
➢ You should inform your family practitioner or usual doctor that you are taking part in 
a research study.  (Include if applicable) 
➢ You should also inform your medical insurance company that you are participating 
in a research study.  
➢ While you are not required to inform any current insurance company about any 
incidental findings, you would be required to inform any future insurance company 
about any incidental findings that may increase your risk of developing pathological 
conditions. 
➢ You can contact Dr Craig Kinnear at tel (021) 938 9695, Dr Monika Esser at 021-
938-5995, Dr Mike Urban at 021-938-9807 or Mardelle Schoeman at 021-938-9807 
if you have any further queries or encounter any problems. 
➢ You can contact the Health Research Ethics Committee at 021-938 9207 if you 
have any concerns or complaints that have not been adequately addressed by your 
study doctor. 
➢ You will receive a copy of this information and consent form for your own records. 
 
 
 
 
 
 
Declaration by participant 
 
By signing below, I …………………………………..…………. agree to take part in a genetic 
research study entitled (Identification of novel candidate genes for susceptibility to 
tuberculosis by identifying disease causing mutations in individuals with Primary 
Immunodeficiencies). 
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I declare that: 
 
• I have read or had read to me this information and consent form and it is written 
in a language with which I am fluent and comfortable. 
• I have had a chance to ask questions and all my questions have been 
adequately answered. 
• I understand that taking part in this study is voluntary and I have not been 
pressurised to take part. 
• I have received a signed duplicate copy of this consent form for my records. 
 
 
Tick the options you choose: 
 
 I agree that blood or tissue samples can be stored on my child 
.............................................................. / myself  indefinitely / stored for     
………years, but I can choose to request at any time that my stored sample be 
destroyed. My sample will be identified with a special study number that will 
remain linked to my name and contact details. I have the right to receive 
confirmation that my request has been carried out.   
     By choosing this option I indicate that I wish to receive results regarding the gene 
fault detected that may be causing the immune deficiency in my family. 
     In addition I choose: 
           To receive other coincidentally detected results 
           Not to receive other coincidentally detected results 
 
OR 
I agree that blood or tissue sample can be stored on my child 
……………………………………….. / myself indefinitely / stored for     
………years after the project is completed but that it is anonymised with all 
possible links to my identity removed, and that the researchers may then use it 
for additional research in this or a related field. Once my sample is anonymised, 
my rights to that sample are waivered. My sample may be shipped to another 
laboratory in SA or abroad to be used in other research projects in this or a 
related field 
 
OR 
 Please destroy my blood sample as soon as the current research project has 
been completed.   
 
 
Signed at (place)  ...............................................  on (date)  ............................................  
 
 
 
 ..............................................................   ............................................................  
Signature of participant Signature of witness 
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Declaration by investigator 
 
I (name) ………………………………………………… declare that: 
 
• I explained the information in this document to …………………..……………... 
• I encouraged him/her to ask questions and took adequate time to answer them. 
• I am satisfied that he/she adequately understands all aspects of the research 
as discussed above. 
• I did/did not use a interpreter.  (If a interpreter is used then the interpreter must 
sign the declaration below. 
 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. . 
 
 
 
 ..............................................................   ............................................................  
Signature of investigator Signature of witness 
 
 
Declaration By Interpreter 
 
I (name) ………………………………………………… declare that: 
 
• I assisted the investigator (name) …………………………. to explain the 
information in this document to (name of participant) …………………………….. 
using the language medium of Afrikaans/Xhosa. 
• We encouraged him/her to ask questions and took adequate time to answer 
them. 
• I conveyed a factually correct version of what was related to me. 
• I am satisfied that the participant fully understands the content of this informed 
consent document and has had all his/her question satisfactorily answered. 
 
 
Signed at (place) ......................…........…………….. on (date) …………....………... 
 
 
 
 ..............................................................   ............................................................  
Signature of interpreter Signature of witness 
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Appendix B 
PARTICIPANT INFORMATION AND INFORMED CONSENT 
FORM FOR RESEARCH INVOLVING IMMUNE FUNCTION 
STUDIES 
 
TITLE OF RESEARCH PROJECT: 
 
Identification of novel candidate genes for susceptibility to tuberculosis by identifying disease 
causing mutations in individuals with primary Immunodeficiencies – Functional Studies 
 
REFERENCE NUMBER: N13/05/075 
 
We would like to invite you to participate in a research study that involves functional immune analysis 
of blood specimens.  Please take some time to read the information presented here which will 
explain the details of this project.  Please ask the study staff or doctor any questions about any part 
of this project that you do not fully understand.  It is very important that you are fully satisfied that 
you clearly understand what this research entails and how you could be involved.  Also, your 
participation is entirely voluntary, and you are free to decline to participate.  If you say no, this will 
not affect you negatively in any way whatsoever.  You are also free to withdraw from the study at 
any point, even if you do agree to take part initially.  
 
This research study has been approved by the ethics Committee for Human Research at 
Stellenbosch University and it will be conducted according to international and locally accepted 
ethical guidelines for research, namely the Declaration of Helsinki, and the SA Department of 
Health’s 2004 Guidelines: Ethics in Health Research: Principles, Structures and Processes. 
 
What does this particular research study involve? 
➢ The immune system refers to the body cells that fight infection. A person with a faulty 
immune system will get infections much more easily than other people. This person 
has an ‘immune deficiency’. There are many causes of immune deficiency, and we 
still don’t know all the possible causes. Some immune deficiencies are caused by 
‘faulty genes’ as described below. 
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➢ The genes are instructions that are passed on from parent to child in the egg cell 
and sperm cell. Some of these instructions are for how the immune system will work, 
and each gene tells a specific part of the immune system how to work.  
➢ If there is a fault (mutation) in one of these genes, the person will have an immune 
deficiency.  
➢ Currently we do not know all of the genes and gene faults that cause immune 
deficiency. Therefore, we are aiming to find out more about: 
• The genes that cause immune deficiency. 
• The gene fault(s) causing immune deficiency in your family.  
➢ We will do genetic testing to try and identify the cause of immune deficiency in each 
affected person who participates in the study. The type of genetic test will vary in 
different people.  
• In some people the test might target certain known genes in the immune 
system.  
• In other people we will do a much broader screen for gene faults (mutations), 
to see if we can identify the cause of the immune deficiency. This test is called 
‘exome sequencing’. Exome sequencing screens all or most of the known 
genes in the body, because we don’t yet know the functions of all these genes. 
This allows us to test for a lot more gene faults to see if these are causing the 
immune deficiency. However, exome sequencing may also detect faults in 
genes that can cause a different disease. 
➢ When a genetic mutation is found, further research is done in order to describe the 
effect of the mutation on immune function.  
 
Why have you been invited to participate? 
 
You are a healthy volunteer, and you are therefore the ideal person to participate in this study as a 
‘healthy control’. Approximately 6-15 healthy controls will participate in this particular project. 
 
What procedures will be involved in this research? 
 
For getting the blood samples, a sterile needle will be used to draw blood from a vein in the arm. 
The amount of blood drawn will be 5-15ml, depending on age and body weight. This is not an 
amount that poses any dangers to a healthy adult.  
White blood cells, or peripheral blood mononuclear cells (PBMCs), will be extracted from the blood 
for immune functional investigation. 
 
Are there any risks involved in this research? 
 
You may experience minor pain and/or bruising at the site where blood is taken. Any related 
injury, which is highly unlikely, will be managed by the nurse or doctor taking the blood. 
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Some insurance companies may mistakenly assume that taking part in genetic research indicates 
a higher risk for disease.  Thus, no information about you or your family will be shared with such 
companies. 
 
Controls for functional studies are NOT genetically analysed, therefore risks associated with genetic 
studies does not apply. 
 
Are there any benefits to your taking part in this study and will you get told your 
results? 
 
While the research project may not be directly beneficial to you, the results of the research will help 
us to understand how the immune system functions and this information may help us in the future 
to diagnose patients with immune defects related to TB susceptibility.  
 
Your personal results will be made known to you only if they indicate that you may: 
• Have a definite risk for developing a particular disorder. 
• Have a condition or predisposition to developing a condition that is treatable or avoidable 
e.g. by a lifestyle modification. 
• Need genetic counselling. 
 
How long will your blood be stored and is there a chance that it will be used for other 
research? 
 
PBMCs may be stored to be tested at a later date, however ALL remaining control samples will be 
destroyed upon completion of functional studies.  
Your blood will not be used in any other studies. 
 
How will your confidentiality be protected? 
 
All personal information obtained from this study will be strictly confidential. Only the Principal 
Investigators at Stellenbosch University and the nursing sister who takes consent from you will have 
access to the information that links the blood samples to the nominal data (names and addresses). 
Confidentiality will be protected by the Health Professionals Council of South Africa’s guidelines. 
The results of the study will be published in medical or science journals, but without mentioning the 
name of any person on whom blood was taken. Research Ethics Committee members may need to 
inspect research records. This committee can be contacted at 021 938 9207. 
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Will you or the researchers benefit financially from this research? 
You will not be paid to take part in this study. 
 
Important information: In the unlikely event that this research leads to the development of a 
commercial application or patent, you or your family will not receive any profits or royalties 
Declaration by participant 
 
By signing below, I …………………………………..…………. agree to take part in a genetic research 
study entitled:  
 
Identification of novel candidate genes for susceptibility to tuberculosis by identifying 
disease causing mutations in individuals with primary Immunodeficiencies – Functional 
Studies 
 
I declare that: 
 
• I have read or had read to me this information and consent form and it is written in a 
language with which I am fluent and comfortable. 
• I have had a chance to ask questions and all my questions have been adequately 
answered. 
• I understand that taking part in this study is voluntary and I have not been pressurised 
to take part. 
• I have received a signed duplicate copy of this consent form for my records. 
 
 
Signed at (place)  ................................................... on (date)  ............................................... 
 
 
 
 ..............................................................   ............................................................  
Signature of participant Signature of witness 
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Declaration by investigator 
 
I (name) ………………………………………………… declare that: 
 
• I explained the information in this document to …………………..……………... 
• I encouraged him/her to ask questions and took adequate time to answer them. 
• I am satisfied that he/she adequately understands all aspects of the research as 
discussed above. 
• I did/did not use a interpreter.  (If an interpreter is used then the interpreter must sign 
the declaration below. 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. 2005. 
 
 
 ..............................................................   ............................................................  
Signature of investigator Signature of witness 
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Appendix C 
In-silico prediction tools for characterising genetic variants 
Table C.1: Description of each of the in-silico prediction tools used in this study to determine 
pathogenicity of identified variants 
SIFT The Sorting Intolerant from Tolerant, or SIFT, tool predicts the functional 
importance of amino acid substitution based on the alignment of paralogous and/or 
orthologous protein sequences  
PolyPhen Polymorphism Phenotyping, or PolyPhen, tool can predict the functional 
importance of an amino acid substitution by considering evolutionary conservation, 
physiochemical differences and proximity of substitution to predicted functional or 
structural domains 
MutationTaster2 MutationTaster can predict the functional consequences of not only amino acid 
substitutions but also intronic and synonymous alterations, short insertions and/or 
deletion (indel) mutations and variants that span intron-exon borders. 
CADD Score The Combined Annotation-Dependent Depletion (CADD) method integrates many 
diverse annotations of genetic variations into a single measurement, a CADD score, 
for each variant. CADD scores correlate with allelic diversity, pathogenicity, disease 
severity, etc. 
  
ACMG Criteria The American College of Medical Genetics and Genomics (ACMG) criteria provides 
guidance for the interpretation of sequence variants. The ACMG criteria describes 
genetic variants as “pathogenic”, “likely pathogenic”, “uncertain significance”, “likely 
benign”, and “benign” based on five different categories of evidence: functional 
data, population data, computational data and segregation data. 
Sherloc Criteria Sherloc (semiquantitative, hierarchical evidence-based rules for locus 
interpretation) is a variant classification framework that is essentially a refinement 
of the ACMG criteria. 
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Figure C.1: Scoring thresholds and evidence categories used for assessment of genetic variants. (a) 
Thresholds for scoring variants as pathogenic, likely pathogenic, uncertain significance, likely benign, and 
benign. (b) Evidence, in the order that they are evaluated, that is used to score genetic variants (Nykamp et 
al. 2017) 
 
Figure C.2: Hierarchical approach to efficient variant research, as suggested by Nykamp et al. (2017). 
Evaluation of evidence for pathogenicity prediction usually goes from the simplest type (i.e. population data 
and variant type) to the more complex type evidence (i.e. clinical data and functional data). 
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Appendix D 
Primers used for Sanger Sequencing 
IFNGR1  PID01 
 Start Stop Length Tm GC% 
Forward 
CCTAACTTCTGCTTCCTTCAGT (Sense)  
64 86 22 62 45.5 
Reverse 
GCAGGTGACATCTTGTTGAATATC (AntiSense)  
426 450 24 62 41.7 
 
NOD2  PID02 
 Start Stop Length Tm GC% 
Forward 
CTGGACACCGTCTGGAATAAG (Sense)  
323 344 21 62 52.4 
Reverse 
TTTCCTGCCAAGAGTCAAGAG (AntiSense)  
744 765 21 62 47.6 
 
IFNGR1  PID02 
 Start Stop Length Tm GC% 
Forward 
CCCATAGATCTCTGTGGTAAGAAG (Sense) 
75 99 24 62 45.8 
Reverse 
GGTGAAGAACTCTCTCTCTCTATTG (AntiSense) 
338 363 25 62 44 
 
IKZF1  PID03 
 Start Stop Length Tm GC% 
Forward 
GCTACGAGAAGGAGAACGAAAT (Sense)  
209 231 22 62 45.5 
Reverse 
CTGCTCCTCGTTGTTGCT (AntiSense)  
520 538 18 62 55.6 
 
IFNGR1  PID03 
 Start Stop Length Tm GC% 
Forward 
ATACTCACGCAGAAGGAAGATG (Sense) 
239 261 22 62 45.5 
Reverse 
CCATCACATGGCTTTCCAAATTA (AntiSense) 
607 630 23 62 39.1 
 
IL12RB1  PID04 
 
IL12RB1  PID05 
 
 Start Stop Length Tm GC% 
Forward 
GCCAAGTCCTGGACAATTCTTA (Sense) 
136 158 22 62 45.5 
Reverse 
ACTCCTGACCTCAAGTGATCT (AntiSense) 
553 574 21 62 47.6 
 Start Stop Length Tm GC% 
Forward 
GAAACAGCCAAACACAGACAC (Sense)  
36 57 21 62 47.6 
Reverse 
TTCCAGGCCATTACCCATTC (AntiSense)  
341 361 20 62 50 
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IL12B  PID06 
 Start Stop Length Tm GC% 
Forward 
 ACCAGAGCAGTGAGGTCTTA (Sense) 
285 305 20 62 50 
Reverse 
 GTTGATAACCCAAAGGGTCCA (AntiSense) 
627 648 21 62 47.6 
 
NFKB2  PID06 & PID10 
 Start Stop Length Tm GC% 
Forward 
CTCCAGGCTGGGCAATAAG (Sense) 
17 36 19 62 57.9 
Reverse 
GTGGGTCAGGGCTAGGT (AntiSense) 
378 395 17 62 64.7 
 
IL12B  PID07 
 Start Stop Length Tm GC% 
Forward 
CTCAGCTTACCCTGTGACTATG (Sense)  
179 201 22 62 50 
Reverse 
TTCCTGCAATATCCCTGTGG (AntiSense)  
564 584 20 62 50 
 
IFNGR2  PID08 
 
CYBB  PID09 
 Start Stop Length Tm GC% 
Forward 
 GATGACTGCATCTCTCTGAACC (Sense) 
44 66 22 62 50 
Reverse 
 CAACATATCCAACCACCACTTAATC (AntiSense) 
389 414 25 62 40 
 
IKBKB  PID10 
 Start Stop Length Tm GC% 
Forward 
 TTGTCCTGATTTCCTCCTGAAG (Sense) 
55 77 22 62 45.5 
Reverse 
 CTGCACAAGGCCTGCTAT (AntiSense) 
242 260 18 62 55.6 
 
IRAK1  PID11 
 
 
 
 Start Stop Length Tm GC% 
Forward 
CCTTTCAGAAGCAACTCCATTTC (Sense) 
174  197 23 62 43.5 
Reverse 
TGCAGTTCAGCACTCTTCTC (AntiSense) 
436 456 20 62 50 
 Start Stop Length Tm GC% 
Forward 
 CTGCCCTTGGACTTCTCTG (Sense) 
12 31 19 62 57.9 
Reverse 
 CAGCTTCTGGACCATCTTCT (AntiSense) 
193 213 20 61 50 
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Appendix E 
Table E.1: CD119/IFN-γR1 expression levels (%) and receptor densities (MFI) for each of the cell subsets. Values in blue or red are either below or above 
the respective normal ranges.  
 
 
 
FSC vs. SSC 
Monocytes CD14+ 
FSC vs. SSC 
Lymphocytes CD56+ CD3+CD56+ CD3+ CD4+ CD8+ CD4-CD8- CD19+ 
%CD119
+ 
IQR:  
41-63 
CD119 
MFI 
IQR: 
310-474 
%CD119
+ 
IQR:  
57-83 
CD119 
MFI 
IQR: 
625-790  
%CD119
+ 
IQR: 
26-35 
CD119 
MFI 
IQR: 
71-87 
%CD119
+ 
IQR: 
39-50 
CD119 
MFI 
IQR: 
51-66 
%CD119
+ 
IQR: 
31-47 
CD119 
MFI 
IQR: 
96-119 
%CD119
+ 
IQR: 
24-27 
CD119 
MFI 
IQR: 
72-88 
%CD119
+ 
IQR: 
19-25 
CD119 
MFI 
IQR: 
67-79 
%CD119
+ 
IQR: 
21-28 
CD119 
MFI 
IQR: 
103-120 
%CD119
+ 
IQR: 
25-42 
CD119 
MFI 
IQR: 
59-98 
%CD119
+ 
IQR: 
68-81 
CD119 
MFI 
IQR: 
98-130 
PID01 97.20 2646 99.30 5451 98.70 506 97.50 328 99.20 515 99.30 511 99.40 482 99.90 557 95.40 375 99.40 707 
Child of 
PID01 
91.10 2649 97.10 4261 95.40 380 87.40 253 97.70 397 98.30 397 98.60 395 99.70 423 90.60 297 91.60 226 
PID02 49.00 447 81.20 1175 34.40 106 34.40 45 44.00 168 29.40 126 29.60 108 25.20 173 28.70 83 80.40 164 
Parent of 
PID02 
44.30 363 62.60 702 38.00 118 41.60 61 40.50 151 33.60 120 33.30 108 31.40 154 22.10 70 88.20 171 
PID03 29.00 282 51.50 588 30.40 99 33.50 51 32.00 122 25.10 101 24.50 94 21.80 137 25.10 73 69.70 112 
PID04 57.60 454 83.80 917 33.30 97 55.20 76 27.50 105 24.80 98 23.70 92 21.90 123 30.90 71 63.90 96 
PID05 42.90 523 46.90 704 33.40 122 30.90 67 27.10 146 19.50 122 17.80 103 17.60 151 31.00 143 64.90 134 
PID06 52.50 423 71.80 820 33.70 130 51.80 77 35.90 150 27.10 130 26.60 119 25.20 157 27.90 82 76.40 132 
PID07 39.10 275 65.80 759 28.00 100 31.50 39 28.60 117 22.50 105 22.20 100 19.00 128 26.20 67 60.50 94 
PID08 60.10 423 56.50 536 46.90 134 59.40 100 25.80 144 25.10 110 24.80 99 21.00 193 25.00 116 89.70 211 
PID09 44.10 305 77.10 698 36.20 91 48.30 65 40.20 108 27.40 86 25.10 82 29.10 115 25.70 60 69.90 113 
PID10 63.60 519 84.70 827 32.00 78 41.00 47 35.40 100 25.70 75 24.10 66 22.80 106 36.60 69 69.40 108 
PID11 49.00 449 66.00 855 29.00 79 37.90 63 25.40 85 20.50 77 19.20 68 18.70 97 32.30 80 63.70 104 
PID12 56.00 382 57.00 519 31.10 122 43.40 56 38.40 151 27.20 120 26.60 109 23.40 152 33.10 92 87.40 168 
PID13 35.10 272 32.60 394 29.20 98 37.60 47 30.30 119 23.00 103 21.70 97 20.40 129 31.60 92 59.10 85 
PID14 32.20 275 48.80 563 30.60 100 35.60 41 25.10 107 24.80 100 25.70 96 23.00 118 21.80 70 74.60 128 
PID15 66.30 655 82.10 917 28.80 80 33.20 45 34.90 107 19.90 79 19.40 76 18.90 106 17.20 36 72.30 110 
PID16 42.40 401 59.00 745 24.00 87 19.30 30 39.90 129 17.80 95 16.90 90 17.00 125 17.50 70 69.30 119 
PID17 62.20 500 67.00 704 30.10 73 39.40 56 23.80 78 21.80 72 20.70 65 19.60 91 25.70 66 60.10 85 
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Table E.2: CD212/IL-12Rβ1 expression levels (%) and receptor densities (MFI) for each of the cell subsets. Values in blue or red are either below or above 
the respective normal ranges 
 
FSC vs. SSC 
Monocytes CD14+ 
FSC vs. SSC 
Lymphocytes CD56+ CD3+CD56+ CD3+ CD4+ CD8+ CD4-CD8- CD19+ 
%CD212
+ 
IQR: 
29-52 
CD212 
MFI 
IQR: 
1281-
1763 
%CD212
+ 
IQR: 
24-60 
CD212 
MFI 
IQR: 
1446-
2450 
%CD212
+ 
IQR: 
73-87 
CD212 
MFI 
IQR: 
239-427 
%CD212
+ 
IQR: 
90-95 
CD212 
MFI 
IQR: 
595-786 
%CD212
+ 
IQR: 
84-92 
CD212 
MFI 
IQR: 
465-661 
%CD212
+ 
IQR: 
71-86 
CD212 
MFI 
IQR: 
202-391 
%CD212
+ 
IQR: 
63-82 
CD212 
MFI 
IQR: 
168-361 
%CD212
+ 
IQR: 
78-92 
CD212 
MFI 
IQR: 
284-474 
%CD212
+ 
IQR: 
82-91 
CD212 
MFI 
IQR: 
333-485 
%CD212
+ 
IQR: 
73-87 
CD212 
MFI 
IQR: 
183-354 
PID01 29.80 1257 35.00 1331 78.60 272 82.90 423 77.90 346 80.10 258 74.90 234 80.80 284 75.00 247 80.90 269 
Child of 
PID01 
32.30 1291 32.00 1289 84.60 316 88.60 549 82.50 589 87.20 316 86.20 322 89.30 382 78.40 241 75.60 201 
PID02 32.70 1365 63.20 2088 85.20 357 91.80 532 88.10 457 82.80 264 78.30 238 83.90 295 81.00 291 81.30 259 
Parent of 
PID02 
35.70 1376 50.30 1751 86.70 377 95.20 616 88.30 457 85.30 309 81.50 279 86.50 355 83.20 292 84.50 290 
PID03 9.91 921 23.20 1198 81.40 278 84.10 448 83.00 373 82.20 256 79.40 251 81.70 268 78.30 252 83.90 264 
PID04 39.40 1402 71.80 2382 70.60 191 77.80 409 69.50 274 73.30 185 68.90 174 76.10 226 78.20 249 68.60 165 
PID05 19.70 969 39.80 1445 70.60 198 72.50 395 66.00 245 72.10 180 68.30 171 70.90 195 66.80 171 71.50 182 
PID06 51.60 1745 66.10 2355 75.00 245 84.10 471 78.00 362 76.30 227 71.20 202 80.20 284 72.90 228 71.30 195 
PID07 31.60 1270 56.80 1952 78.50 261 86.60 558 82.40 411 81.10 261 77.50 242 84.50 321 80.40 289 71.80 192 
PID08 55.90 1949 63.90 2230 76.70 257 80.00 430 83.30 423 78.80 244 70.20 191 90.10 363 85.60 291 72.00 186 
PID09 36.10 1379 47.80 1663 79.90 292 91.10 611 80.40 395 80.70 277 78.10 265 83.00 328 78.90 301 76.10 228 
PID10 15.80 1016 13.70 1069 75.60 231 83.10 470 80.00 401 78.80 235 75.20 221 79.70 265 77.00 285 68.10 170 
PID11 60.90 1939 86.20 3000 76.00 228 88.80 616 81.80 532 77.20 205 71.90 175 80.40 257 81.00 302 68.30 136 
PID12 20.30 1096 25.40 1207 77.30 247 86.80 544 82.70 417 77.80 217 71.90 194 80.50 259 79.50 262 80.10 242 
PID13 21.90 991 26.80 1088 71.00 202 81.70 459 69.20 282 72.80 184 69.40 178 69.90 190 67.00 190 64.40 153 
PID14 9.82 754 10.60 943 68.40 184 75.70 445 72.00 296 70.80 175 66.30 161 70.50 203 66.80 184 65.80 154 
PID15 30.80 1320 39.50 1519 52.80 112 75.20 479 84.40 521 73.30 255 69.50 244 76.70 301 67.00 217 62.50 165 
PID16 45.00 1616 68.50 2200 85.00 395 91.10 625 89.40 581 84.40 352 81.10 329 92.10 516 81.90 320 85.60 316 
PID17 42.40 1527 51.30 1801 69.00 171 78.00 438 76.00 407 70.30 155 65.00 137 71.80 190 71.40 195 66.60 134 
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Table E.3: Fold change in pSTAT1 for each of the cell subsets. Values in blue or red are either below or above the respective normal ranges 
Patient ID 
  
FSC vs. SSC 
Monocytes 
IQR: 0.97-1.75 
CD14+ 
IQR: 1.39-
2.05 
FSC vs. SSC 
Lymphocytes 
IQR: 1.16-1.86 
CD56+ cells 
 
IQR: 0.89-1.34 
CD3+CD56+ 
cells 
IQR: 1.17-1.83 
CD3+ 
 
IQR: 1.20-1.98 
CD4+ 
 
IQR: 1.23-2.10 
CD8+ 
 
IQR: 1.17-1.82 
CD4-CD8- 
 
IQR: 0.96-2.33 
CD20+ 
 
IQR: 1.28-1.81 
PID01 0.50 0.80 1.17 1.02 1.03 1.13 1.10 0.72 1.01 1.05 
Child of PID01 1.07 1.20 1.18 1.04 1.02 0.86 1.13 1.10 0.86 1.18 
PID02 1.11 1.31 1.34 1.11 1.16 1.42 1.44 1.45 1.22 1.59 
Parent of PID02 1.54 1.82 1.63 1.24 1.37 1.70 1.71 1.76 1.26 2.14 
PID03 1.41 1.74 1.27 1.15 1.21 1.30 1.33 1.27 1.13 1.51 
PID04 3.57 4.23 2.14 2.00 2.23 1.95 1.88 2.32 1.92 4.24 
PID05 1.65 1.84 2.02 1.40 1.82 2.18 2.23 2.13 1.74 1.97 
PID06 1.48 1.64 1.54 1.36 1.57 1.51 1.51 1.47 1.45 2.55 
PID07 1.67 2.19 1.77 1.18 1.96 1.83 1.97 1.47 2.26 1.64 
PID08 0.86 1.03 1.23 0.92 0.92 1.20 1.29 0.95 0.89 1.66 
PID09 1.55 1.95 1.53 1.24 1.60 1.50 1.53 1.41 1.65 2.23 
PID10 1.61 2.19 1.33 1.14 1.37 1.33 1.34 1.32 1.24 2.00 
PID11 2.79 2.30 2.21 1.51 2.22 2.25 2.30 2.34 1.44 1.74 
PID12 1.46 1.71 1.69 1.19 1.48 1.73 1.81 1.65 1.39 1.92 
PID13 1.39 1.56 1.50 1.00 1.50 1.62 1.72 1.53 1.64 1.58 
PID14 1.18 1.94 1.29 1.14 1.57 1.29 1.32 1.21 0.98 1.34 
PID15 2.24 2.84 2.44 1.15 1.93 2.65 2.86 2.46 1.94 1.69 
PID16 0.44 1.14 1.44 0.99 1.52 1.49 1.64 1.26 0.98 1.54 
PID17 3.74 2.65 1.37 1.00 0.97 1.31 1.27 1.17 5.86 1.33 
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Table E.4: Fold change in pSTAT4 for each of the cell subsets. Values in blue or red are either below or above the respective normal ranges 
Patient ID  
  
FSC vs. SSC 
Monocytes 
IQR: 1.53-2.07 
CD14+ 
 
IQR: 1.38-2.12 
FSC vs. SSC 
Lymphocytes 
IQR: 1.19-1.58 
NK cells 
 
IQR: 2.04-2.75 
NKT cells 
 
IQR: 1.23-1.73 
CD3+ 
 
IQR: 1.20-1.65 
CD4+ 
 
IQR: 1.18-1.46 
CD8+ 
 
IQR: 1.33-2.19 
CD4-CD8- 
 
IQR: 1.41-2.74 
CD20+ 
 
IQR: 0.98-1.53 
PID01 1.58 1.58 1.45 1.83 1.55 1.39 1.32 1.48 1.74 2.15 
Child of PID01 1.76 1.50 1.22 2.61 1.30 1.17 1.10 1.76 1.02 1.00 
PID02 1.47 1.20 1.48 1.32 1.48 1.57 1.44 1.93 1.20 1.35 
Parent of PID02 0.99 0.82 1.21 1.03 1.13 1.26 1.21 1.33 1.21 1.03 
PID03 1.51 1.25 1.10 1.07 0.95 1.10 1.07 1.25 1.07 1.15 
PID04 3.92 2.41 3.49 9.21 2.34 3.06 2.68 4.95 3.62 14.14 
PID05 1.26 1.01 1.07 1.19 0.98 1.13 1.04 1.25 1.53 0.82 
PID06 1.84 1.75 1.38 2.33 1.33 1.36 1.27 1.50 1.38 1.31 
PID07 2.48 2.35 1.79 1.50 1.28 1.71 1.53 1.74 5.02 1.42 
PID08 1.32 1.35 1.33 1.51 1.12 1.32 1.33 1.24 1.81 1.17 
PID09 1.40 1.32 1.15 1.78 1.16 1.13 1.09 1.33 1.13 1.16 
PID10 1.57 1.40 1.32 1.43 1.15 1.38 1.30 1.67 1.22 1.18 
PID11 0.91 0.93 1.66 2.17 1.62 1.58 1.68 1.85 1.58 1.52 
PID12 1.06 1.02 0.88 2.26 0.95 0.83 0.84 0.82 0.85 1.00 
PID13 2.05 2.13 1.60 1.53 1.50 1.61 1.56 1.76 1.75 1.43 
PID14 1.53 1.68 0.75 1.88 0.82 0.69 0.68 0.69 0.83 1.10 
PID15 0.94 0.97 1.63 1.56 1.24 1.54 1.32 1.79 3.63 1.36 
PID16 1.13 1.04 0.96 1.18 1.05 0.94 0.92 1.07 0.88 0.98 
PID17 1.11 1.23 1.44 1.43 0.51 1.28 1.09 1.64 0.57 1.20 
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Table E.5: Cytokine-induced cytokine production values for all participants. Values in blue or red are either below or above the respective normal ranges 
Patient ID 
 
 
IFN-γ production assay IL-12 production assay 
NIL (pg/mL) 
 
IQR: 0-0 
PHA (pg/mL) 
 
IQR: 57-658 
PHA+IL-12 
(pg/mL) 
IQR: 545-692 
Net IL-12-induced IFN-γ 
 production (pg/mL) 
IQR: 176-443 
NIL (pg/mL) 
 
IQR: 0-0 
PHA (pg/mL) 
 
IQR: 0.13-1.69 
PHA+IFN-γ 
(pg/mL) 
IQR: 11-19 
Net IFN-γ-induced  
IL-12 production (pg/mL) 
IQR: 11-19 
PID01 0.00 70.00 425.40 355.40 0.00 0.26 0.69 0.43 
Child of PID01 0.00 197.98 343.70 145.73 0.00 0.27 2.06 1.79 
PID02 0.00 57.49 1512.29 1454.80 0.00 0.90 22.14 21.24 
Parent of PID02 0.00 57.18 596.14 538.96 0.00 0.38 9.95 9.57 
PID03 0.00 480.56 620.00 139.43 0.00 18.63 38.83 20.20 
PID04 0.00 15.85 562.76 546.91 0.00 1.84 36.90 35.06 
PID05 0.00 68.75 755.31 686.56 0.00 0.19 2.47 2.28 
PID06 11.54 25.67 74.23 48.56 0.00 0.05 1.12 1.07 
PID07 0.00 5.49 299.91 294.42 0.00 0.21 4.81 4.61 
PID08 10.31 -6.68 25.55 32.23 0.00 0.27 3.72 3.44 
PID09 47.72 82.88 729.73 646.85 0.00 1.07 48.26 47.19 
PID10 0.00 19.57 399.54 379.97 0.00 0.11 1.64 1.54 
PID11 0.00 566.17 795.34 229.16 0.00 0.82 10.94 10.12 
PID12 0.00 2.09 106.01 103.93 0.00 0.87 30.49 29.62 
PID13 0.00 279.06 764.92 485.86 0.00 1.86 25.48 23.61 
PID14 0.00 12.32 215.79 203.47 0.00 0.04 2.79 2.75 
PID15 0.00 27.92 901.82 873.90 0.00 0.46 17.38 16.92 
PID16 0.00 23.09 425.11 402.02 0.00 0.41 29.18 28.77 
PID17 0.00 24.03 312.83 288.80 0.00 0.24 8.98 8.74 
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